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Abstract 
Breast cancer is a malignant neoplasm that results from innate and/or acquired 
genetic predisposition from somatic mutations in breast tissue and their interaction 
with hormonal exposure and other risk factors. MicroRNAs might be important for 
the pathogenesis of breast cancer since they have been described as important 
epigenetic regulators of gene expression present in all the molecular pathways 
involved in cancer biology. Previous research has shown that mutations present in 
miRNA sequences could result in the changes in miRNA synthesis and function seen 
in cancer biology and single nucleotide polymorphisms (SNPS) are the most 
common type of variation present in miRNA genes. Only a small fraction of the total 
of microRNA SNPs (miR-SNPs) identified to date, have been studied in relation to 
breast cancer. Findings are still somewhat controversial and this is probably the 
result of limitations in terms of the populations examined, experimental design and 
methods used for analysis. To address this gap in the literature the present study aims 
to achieve the following aims: i) establish a large sized and well characterised 
prospective DNA biobank to be used as a replication cohort to the one previously 
available in our facility, using the most appropriate DNA extraction protocol in a 
time-efficient and cost-effective manner; and ii) identify miR-SNPs associated with 
breast cancer risk in both Australian Caucasian populations using genotype and 
haplotype association analysis.   
 
Chapter One explores the scientific problem and aims of this study. Chapter 
Two and Three provide a comprehensive literature review of the background in this 
field of work and the methodology used to conduct our research. We aimed to 
establish a prospective genomic DNA (gDNA) biobank extracted from whole blood 
samples obtained from 929 breast cancer patients in Queensland recruited in 
collaboration with the Cancer Council Queensland. In order to determine the best 
possible method to perform DNA extraction from the ones available at our facility, 
Chapter Four presents our in-house evaluation study conducted to determine the most 
cost effective and time efficient method to perform genomic DNA (gDNA) 
extraction from whole blood samples. We compared the modified salting-out 
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protocol described by Nasiri et al, against a traditional salting out method and a 
commercially available DNA extraction kit and we performed gDNA extraction from 
whole blood samples. We evaluated the performance of each method in terms of the 
quality and quantity of DNA obtained, as well as time requirements and costs for 
each technique.  Our results highlighted the modified salting out method to be the 
most cost-effective and time-efficient technique to isolate genomic DNA from whole 
blood samples. The modified salting out method has consistently proved to be an 
appropriate technique based on the quality and quantity of DNA obtained from blood 
samples extracted at our facility and these samples have also been shown to perform 
well in downstream applications used for the genotyping studies included in this 
thesis. Some of the limitations of this study included the small number of samples 
used to test our chosen DNA extraction methods and that we also failed to include a 
more comprehensive range of techniques that were unavailable at the time at our 
facility. 
 
We also decided to review current knowledge of genomic DNA extraction 
from whole blood methods. Our study (Chapter Five) reviews the history of DNA 
extraction techniques, the main categories of the methods most commonly used in 
facilities around the world, as well as the available literature on evaluation studies 
comparing different extraction techniques to highlight their strengths and 
weaknesses.  This review evidenced the limited scientific evidence available in 
regards to the best choice for gDNA extraction and it also highlighted the need to 
conduct our own validation study to determine the most appropriate technique to be 
used in the establishment of our new case control cohort.  
  
The following study (Chapter Six) validated previous findings in relation to the 
miR-SNP rs2910164 present in MIR146A that has shown conflicting results in 
previous studies because it had not been properly analysed in purely sporadic or 
purely Caucasian breast cancer populations. We genotyped this variant using high 
resolution melt (HRM) analysis and were able to determine that presence of the 
mutant allele in this gene is significantly associated with breast cancer risk in both 
our primary and replicate populations (p = 0.03 and p = 0.00013). However we 
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acknowledge that we were limited by the small number of samples included in our 
replication population (GU-CCQ BB population), as this was still under 
development. To the best of our knowledge this is the first study to identify 
association between this rs2910164 and breast cancer risk in a purely sporadic breast 
cancer bearing Caucasian population. 
 
Chapter Seven presents the results of a large scale genotyping study using both 
of our previously established cohorts. In this study, we developed a selection 
algorithm to choose miR-SNPs to be included in this and other studies, which 
allowed the selection of a large panel of miR-SNPs (24 miR-SNPs in total present in 
9 miRNA genes) to be analysed using multiplex PCR and chip-based matrix assisted 
laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). 
Results from our study showed 6 of the miR-SNPs (rs73798217, rs112394324, 
rs35301225, rs1547354, rs7050391 and rs3851812) not to be polymorphic in our 
populations, providing initial validation of the rare presence of these miR-SNPs in 
Caucasian populations. We were also most importantly, able to show significant 
association to breast cancer risk for one of our selected variants present in MIR145. 
We determined that miR-SNP rs353291 in the MIR145 gene had significant 
differences in allele frequencies between cases and controls in both of our tested 
populations (p = 0.041 and p = 0.023) and to the best of our knowledge this is the 
first report of an association to breast cancer risk for this variant. Our study provided 
initial validation of our findings using two independent populations, but further 
validation of these results in larger cohorts or populations of both similar and 
different ethnic background is required to strengthen their significance. If we take 
into account multiple testing correction of our results, our findings are not 
statistically significant, but since they were validated in two independent populations 
they are still very interesting and worthy of further research.  
 
Our last study (Chapter Eight) presents the results of our genotype and 
haplotype analysis of 6 miR-SNPs present in the microRNA 17-92 cluster host gene 
(MIR17HG) conducted in our two Australian Caucasian breast cancer cohorts. We 
decided to study polymorphisms in MIR17HG because of its importance in cancer 
development, which has been shown in previous studies. It was the first cluster host 
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gene to be found to play a role in cancer biology and it has also been linked to the 
pathogenesis of breast cancer targeting important genes in breast biology, like 
NCOA3, CCDN1 and ESR1. To the best of our knowledge there are no previous 
studies evaluating the role of miR-SNPs for this particular cluster host gene, making 
it an ideal candidate for research. We selected 6 miR-SNPs located in the cluster 
gene region or in close proximity to it providing good coverage for this miRNA 
cluster gene, and they included a polymorphism located inside the mature sequence 
for MIR92A1 (rs9589207). We genotyped these miR-SNPs using multiplex PCR and 
chip-based MALDI-TOF MS analysis in our two independent Australian Caucasian 
breast cancer case-control cohorts. Our results showed significant differences 
between cases and control for miR-SNP rs4284505 in both of our tested populations 
(p = 0.01 and p = 0.03) and for rs7336610 only in our initial population (p = 0.03) for 
the genotypic analysis. Furthermore haplotypic analysis on the combined results 
from both populations identified these two miR-SNPs (rs4284505/rs7336610) to be 
in linkage disequilibrium and part of a haplotype block (D’ score = 0.98). Chi-square 
analysis of the haplotypes contained in this block showed a lower frequency for 
haplotype AC in cases compared to controls and our analysis showed it to be 
significantly associated with breast cancer (p = 5x10-4). Odds ratio (OR) for this 
haplotype suggests that individuals that carry the AC haplotype had a reduced risk of 
developing breast cancer (about 25%) in comparison to other haplotype carriers (OR: 
0.75; 95% CI: 0.60 to 0.94; p = 0.012). To the best of our knowledge this is the first 
report of a significant association between these polymorphisms and breast cancer 
risk.  
    
Taken together, these data indicate that the presence of specific miR-SNPs may 
play a role in breast cancer development and the results presented in Chapters Six to 
Eight of this document are only the initial step required to determine their effect on 
breast cancer pathogenesis. Further research that includes functional assays will be 
required for these findings to be translated into strategies that impact breast cancer 
diagnosis, treatment and prognosis. Further validation of our positive findings 
through genotyping of larger populations or populations of different ethnic 
backgrounds as well as functional validation using cell culture or animal models are 
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also required to proceed with translational studies and these would allow a better 
understanding of the detailed mechanisms occurring in breast cancer biology. 
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Chapter 1: Introduction 
 
1.1 A DESCRIPTION OF THE SCIENTIFIC PROBLEM INVESTIGATED 
 
Breast Cancer is the second most common type of cancer in the world and it is 
the most common type of cancer diagnosed in women in Australia. It is a major 
concern for Australian public health, because more and more cases are being 
diagnosed every day, with Australia’s breast cancer incidence being the third highest 
in the world. Furthermore, it is the second most common cause of death for women 
in this country (AIHW, 2009, 2012; AIHW & AACR, 2010, 2012; Ferlay et al., 
2010; Ferlay et al., 2013; Robbins, Kumar, & Cotran, 2010). 
 
Genetic information stored within the cells in breast tissue governs cellular fate 
from cellular genesis to their death. Breast cancer is a complex disease, which arises 
as a result of cumulative and permanent DNA damage to cells within tissues in the 
breast and their interaction with many other risk factors (Robbins et al., 2010; 
Strachan & Read, 2011; Weinberg, 2007). Therefore, genetics plays a key role in 
understanding, preventing and managing this life threatening disease. Many different 
genetic markers have been identified and are being used to refine early diagnosis and 
prevention, to classify cases and to make more accurate treatment decisions and to 
predict response to treatment and other outcomes in breast cancer patients. However, 
none of the current genetic markers have proven to be a sufficient and highly 
accurate way of addressing any of these important disease features (Ben Zhang, 
Beeghly-Fadiel, Long, & Zheng, 2011), therefore more research is needed to identify 
molecular markers of disease development and progression.  
 
Study of MicroRNA genes is an emerging field of study in relation to cancer 
and they could be useful to understand the complexity of the molecular and cellular 
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 mechanisms involved in breast cancer carcinogenesis and progression. They have 
been shown to be involved in many different types of cancer because they regulate 
complex gene networks required for cell growth, differentiation and cell survival 
(Farazi, Spitzer, Morozov, & Tuschl, 2011; Robbins et al., 2010; Westholm & Lai, 
2011; Zuoren Yu et al., 2010). Different types of cancer have been seen to exhibit 
up-regulation and down-regulation of specific miRNA genes. However, we still lack 
knowledge of the mechanisms that result in changes in miRNA expression in cancer, 
in particular for breast cancer. Polymorphisms present in the functional and 
regulatory regions of specific miRNA genes could change the expression of the 
miRNA genes and studying these would be an initial way to address the current gap 
in knowledge for their role in the pathogenesis of breast cancer (Gong et al., 2012; 
H.-C. Lee, Yang, Chen, & Au, 2011; Mishra, Banerjee, & Bertino, 2008). To 
successfully characterise microRNA single nucleotide polymorphisms (miR-SNPs) 
we are required to conduct genotyping studies in well-characterized, large case 
control cohorts. Therefore in our study we also aimed to establish a larger population 
of DNA samples from breast cancer patients and matched controls that could serve as 
a replicate population to our previously existing cohort. We determined the most 
appropriate method for DNA extraction from whole blood samples that would yield a 
good quality and good quantity of genomic DNA to use in our miR-SNP genotyping 
analysis. We identified microRNAs previously implicated in breast cancer 
development and we selected polymorphisms within those genes to genotype in our 
two Australian Caucasian breast cancer cohorts. 
 
1.2 THE OVERALL OBJECTIVE OF THE STUDY 
 
The overall objective of the work described in this thesis is to contribute to the 
general knowledge of microRNA polymorphisms and their potential association with 
breast cancer risk. 
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1.3 THE SPECIFIC AIMS OF THE STUDY 
 
1. To create and establish a significant sized prospective DNA biobank from 
blood samples collected from newly diagnosed breast cancer patients and 
control volunteers in Queensland. 
 
2. To determine the most cost-effective and time-efficient technique to 
isolate DNA from whole blood samples that improves our genotyping 
results. 
 
3. To conduct association analysis of single nucleotide polymorphisms 
present in previously identified microRNA genes using high resolution 
melting (HRM) and multiplex PCR and matrix assisted laser desorption 
ionization time-of-flight (MALDI-TOF)  in both our previously 
established  and newly developed Australian Caucasian case-control 
populations. 
. 
1.4 AN ACCOUNT OF SCIENTIFIC PROGRESS LINKING THE SCIENTIFIC 
PAPERS 
 
The five papers presented as part of this thesis are directly linked to the topic of 
genetic association analysis of miRNA polymorphisms and breast cancer risk in 
Australian Caucasian populations. 
 
Chapter Four presents an evaluation study that was performed to choose a 
suitable technique to extract genomic DNA from whole blood samples for the GU-
CCQ BB population. It highlights the modified salting-out method developed by 
Nasiri et al to be both a cost-effective and time-efficient technique. The work 
presented in this chapter was published in the journal “Molecular Biology Reports”.   
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Chapter Five presents a review of most commonly used laboratory techniques 
used to extract genomic DNA from whole blood samples. This literature review was 
undertaken to try to identify current findings in terms of cost-effective and time 
efficient methods for DNA extraction to determine the most suitable technique to use 
for our large sized DNA biobank: The Griffith University-Cancer Council 
Queensland Breast Cancer Biobank (GU-CCQ BB). The work presented in this 
chapter was published in the “Journal of Biorepository Science for Applied 
Medicine”. 
 
Chapter Six describes our initial genotyping study for a single nucleotide 
polymorphism (SNP) present in MIR146A in our Australian Caucasian breast cancer 
case-control cohorts; the Genomics Research Centre Breast Cancer (GRC-BC) 
population and the GU-CCQ Biobank. This study is the first to identify rs2910164 to 
be associated with breast cancer risk in an Australian Caucasian population. The 
work presented in this chapter has been submitted to the journal “Gene”. 
 
Chapter Seven presents our large scale genetic association analysis of a 
significant number of microRNA single nucleotide polymorphisms (miR-SNPs) 
present in 10 miRNA genes in both of our Australian Caucasian breast cancer 
populations. This work is the first to analyse the 24 selected miR-SNPs in 10 miRNA 
genes in relation to breast cancer risk. It is also the first study to identify association 
of rs353291 (MIR145) with risk of developing breast cancer in Australian Caucasian 
females. The work presented in this chapter has been submitted the “BMC Medical 
Genetics”. 
  
Chapter Eight describes our large scale genotype and haplotype analysis of six 
miR-SNPs present in the microRNA 17-92 cluster host gene (MIR17HG) conducted 
in both Australian Caucasian breast cancer case-control populations. This is the first 
association study for MIR17HG SNPs conducted in Australian Caucasian 
individuals. It is also the first to identify association with breast cancer risk with both 
rs4284505 and haplotype for rs4284505/rs7336610 in Australian Caucasian 
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populations. The work presented in this chapter has been accepted for publication in 
the journal “Tumor Biology”. 
 
 Chapter Nine provides a comprehensive discussion of the main findings of this 
study and highlights the outcome of the research. 
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 Chapter 2: Literature Review 
 
2.1 BREAST CANCER EPIDEMIOLOGY 
 
Cancer represents a significant burden of disease worldwide. In 2007, cancer 
accounted for 12.7 million new cases and 7.6 million deaths around the world 
according to the International Agency for Research on Cancer (IARC). By 2011 it 
had reached 14.1 million new cases and 8.2 million deaths which represented an 
increase of about 11% in world incidence and about 8% in world mortality (See 
Table 2-1) (Ferlay et al., 2010; Ferlay et al., 2013). This percentage increase in 
cancer incidence is particularly remarkable since it is double the increase in world 
population for the same period of time, which was only about 5.5% according to the 
figures reported by the Population Reference Bureau (6,625 million people in 2007 
and 6,987 million people in 2011) (PRB, 2007, 2011).   
 
Cancer in Australia is also a major cause for concern, since incidence increased 
about 13% from 2007 to 2011 with 108,368 and 122,031 new cancer cases diagnosed 
in each year respectively. In 2011 52,361 cancer cases in Australia were diagnosed in 
women, 43% of all diagnosed cancer cases. Similarly, cancer deaths in Australia are 
rising with 39,884 people reported as dying from cancer in 2007 and 43,403 in 2011. 
44% of all Australian cancer related deaths were women, with about 17,000 women 
reported to die from cancer in 2007 and about 19,000 women in 2011 (AIHW & 
AACR, 2010, 2012). The Australian population increased from 21,180,600 to 
22485300 people in the 2007-2011 period according to the Australian Bureau of 
Statistics, which corresponds to a 6.2% increment (ABS, 2007, 2011). Based on 
these figures, we observe a similar pattern both in Australia and worldwide statistics 
with growth of cancer incidence doubling the reported percent population increase. 
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Table 2-1 Cancer incidence and mortality in the world in 2007 and 2011 according to the International 
Agency for Research on Cancer (Ferlay et al., 2010; Ferlay et al., 2013). 
  World Mortality World Incidence   
Year 2007 2011 Increase 2007 2011 Increase 
All cancers 7,6000,000 8,200,000 8.2% 12,700,000 14,100,000 11% 
Breast 
cancer 
458,000 522,000 14% 1,380,000 1,700,000 23% 
 
Breast cancer is a particularly concerning type of cancer since 1.38 and 1.7 
million new breast cancer cases were reported in 2007 and 2011, respectively, 
showing an increase of about 23% in 4 years. In 2007 458,000 deaths in the world 
were related to breast cancer, accounting for about 6% of all cancer related deaths, 
and they increased to about 14% in 2011 with 522,000 deaths (See Table 2-1). Breast 
malignancies are also the most common type of cancer in women in Australia and 
worldwide, and it is estimated that they will be diagnosed in one in eight women 
living to the age of 90 (Ferlay et al., 2010; Ferlay et al., 2013; Robbins et al., 2010). 
Breast cancer has the highest rates for 5 year prevalence for any cancer for women 
both in Australia and around the world  and it is also the first cause of cancer related 
deaths for women worldwide, while being the second cause of cancer death in 
Australian women (see Table 2-2) (AIHW, 2009, 2012).  
   
Table 2-2 Incidence, mortality and 5 year prevalence of breast cancer in women in Australia and the 
world in 2011 according to the International Agency for Research on Cancer (Ferlay et al., 2013). 
  World Australia 
  No Cases % Ranking No Cases % Ranking 
 Incidence 1,676,633 25.2 1st  14,710 28.1 1st  
Mortality 521,817 14.7 1st  2,968 15.7 2nd  
5 year prevalence 6,255,391 36.4 1st  59,584 37.5 1st  
 
There are a number of epidemiological risk factors associated with breast cancer and 
they include age; reproductive factors such as age at menarche, menopause and first 
pregnancy, oral contraceptives and hormone replace therapy; lifestyle factors like 
diet, weight, alcohol intake, smoking and ionizing radiation and chemical exposure. 
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 Breast cancer incidence is low in women under 25 years of age and it doubles about 
every 10 years until menopause, when the rate of increase slows considerably. 
However, this phenomenon seems to be dependent on geographical location, in some 
countries like Japan and Colombia there is a flattening of the incidence curve after 
menopause, while in US and Sweden risk keeps on increasing until 75 years of age 
(Dumitrescu & Cotarla, 2005; McPherson, Steel, & Dixon, 2000). 
 
Reproductive factors also seem to affect breast cancer incidence. Early age of 
menarche and late menopause increase the risk of developing breast cancer by about 
20%. On the other hand, women who undergo bilateral oophorectomy before 35 
years of age have only 40% of the risk of breast cancer of women experiencing 
natural menopause. Nulliparity and late age at first birth increase risk of breast 
cancer. Furthermore, women giving their first birth after the age of 35 have a higher 
risk than nulliparous women. Finally both use of oral contraceptives  and hormonal 
replacement therapy seem to be associated with a small increase in the risk of 
developing breast cancer, but further studies are still required (relative risk (1.07) 
(Dumitrescu & Cotarla, 2005; Hulka & Moorman, 2001; McPherson et al., 2000).  
 
Although there seems to be a correlation between the incidence of breast cancer and 
dietary fat intake, however epidemiological evidence available up to date is not 
particularly consistent or strong. Obesity in postmenopausal women is associated 
with a twofold increase in the risk of developing breast cancer. Conversely, obesity is 
associated with a reduced incidence of breast cancer in premenopausal women. 
Results from studies evaluating the role of other dietary components such as soy 
protein, vitamins A, C, E and D have been inconclusive and further research is 
required (Dumitrescu & Cotarla, 2005; Hulka & Moorman, 2001; McPherson et al., 
2000). 
 
Alcohol consumption and smoking have been linked to many types of cancer and 
there is evidence that suggests that alcohol consumption of one to two drinks on 
average per day increases the risk of developing breast cancer (relative risk of 1.2 to 
1.4). On the other hand, current evidence shows that smoking has a little overall 
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effect on breast cancer risk (Dumitrescu & Cotarla, 2005; Hulka & Moorman, 2001; 
McPherson et al., 2000).  
 
Finally, studies on chemical compounds including the pesticide bis(4-chlorophenyl)-
1,1,1-trichloroethane (DDT) and its metabolite bis(4-chlorophenyl)-1,1-
dichloroethene (DDE) and polychlorinated biphenyls (PCBs) have shown no 
association to breast cancer risk. Exposure to ionising radiation doubled the risk of 
breast cancer for teenage girls exposed to radiation during the Second World War 
(Hulka & Moorman, 2001; McPherson et al., 2000; Wolff, Collman, Barrett, & Huff, 
1996).  
 
2.2 ANATOMY OF THE MAMARY GLAND 
 
Female mammary glands (or breasts) are skin-covered modified 
sebaceous/sweat glands located in the superficial fascia on the ventral wall of the 
thorax, anterior to the pectoral muscles. They stretch from the second rib to about the 
seventh intercostal cartilage and from the lateral edge of the sternum to the 
midaxillary line. Breasts are part of the female reproductive system and they become 
functional after pregnancy finishes, producing milk to nurse the newborn baby. They 
are markedly undeveloped during childhood and they start acquiring their round 
conical adult shape after puberty. 
 
On the exterior surface, mammary glands have a central ring of pigmented skin 
known as the areola. It surrounds a protruding conical structure of about 12mm in 
diameter called the nipple, commonly located at about the level of the fourth 
intercostal space in young women.  Lying underneath the skin, there are between 15 
to 20 lobes that open through their individual excretory duct to the surface of the 
nipple. Lobes are formed by smaller structures called lobules, which contain multiple 
glandular alveoli (or acini) able to produce milk during lactation. Acini are connected 
through a network of lactiferous ducts that merge into the lactiferous sinus, a dilated 
structure leading to the excretory duct, where milk accumulates throughout nursing. 
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 Glandular tissue, lactiferous ducts and lactiferous sinuses are surrounded by fatty 
connective tissue. These structures are connected to the skin and the muscular layer 
underneath by fibrous bands of the superficial fascia, which form the suspensory 
ligament of Cooper on the upper part of the breasts (Ellis, 2010; Love & Barsky, 
2004; Marieb, 2010; Morehead, 1982) (See Figure 2-1). 
 
 
Figure 2-1 Anatomical structure of mammary glands. Anterolateral disection and 
sagital section (Reproduced from , Netter, F. H. (2011). Atlas of human 
anatomy. Copyright © 2011 by permission of Elsevier, Inc.). 
 
Blood supply to the mammary gland is provided by three main sources: 
Internal thoracic artery, axillary artery and intercostal arteries. Internal thoracic 
artery arises from the subclavian artery and it provides the largest arterial vessels 
reaching the breasts. Axillary artery is the second major source of blood, which is 
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supplied through 4 main branches: Superior thoracic, pectoral branch, lateral thoracic 
and subscapular arteries. Venous drainage follows the pathway of the 
aforementioned arteries and it ends in two major vessels: Axillary vein or the internal 
thoracic vein. 
 
There are two main sites for lymphatic drainage from mammary glands and 
they are the axillary lymph nodes and the internal thoracic lymph nodes (Figure 2-2). 
Axillary lymph nodes are divided into 5 groups and they receive approximately 75% 
of all drainage, which explains why early metastases for most breast cancer patients 
are located in the axilla. (Morehead, 1982; Netter, 2011). 
 
 
Figure 2-2 Lymphatic drainage of the breast ((Reprinted from , Netter, F. H. (2011). 
Atlas of human anatomy. Copyright © 2011 by permission of Elsevier, Inc.). 
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 2.3 BREAST CANCER DEFINITION AND AETIOLOGY 
 
Malignant neoplasm or cancer is the term to define a new growth that invades 
local tissue and/or distant places within the human body. It is a complex disease in 
which cells proliferate with no control and with no physiological purpose. Cancer is 
the result of genetic alteration to a cell or a group of cells that modifies normal 
growth pattern (Neighbors & Tannehill-Jones, 2006). Robert Weinberg defined it as 
“a disease of chaos, a breakdown of existing biological order within the body” 
(Weinberg, 2007), whereas Strachan and Read referred to it as “the natural end of a 
multi cellular organism” (Strachan & Read, 2011). It is a medical condition that 
requires at least six successive somatic mutations within a cell, or a number of 
different cells in a tissue, to allow uncontrolled cellular division. Malignant 
proliferation of cells can be accomplished through seven main cellular capabilities: 
 
1. Autonomy from external growth signals. 
2. Freedom from external anti-growth signals. 
3. Ability to avoid apoptosis (programmed cell-death). 
4. Faculty to replicate indefinitely. 
5. Competence to trigger angiogenesis. 
6. Ability to invade tissues and establish secondary tumours (metastasis). 
7. Failure in DNA repair 
 
Hanahan and Weinberg described these features as the hallmarks of cancer in 
2000 and they have been a fundamental principle in our understanding of the 
pathogenesis of cancer (Hanahan & Weinberg, 2000). These features are 
accomplished in cancers by two basic means: Mutations that increase cell 
proliferation and mutations that affect stability of the entire genome increasing 
mutation rate (Robbins et al., 2010; Strachan & Read, 2011; Weinberg, 2007). 
Research into the molecular mechanisms underlying neoplastic disease has also 
identified two additional hallmarks: reprogramming of energy metabolism and 
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evading immune destruction. These hallmarks are achieved through the activation 
and/or silencing of complex intracellular pathways which are out of the scope of the 
present review. However, neoplasms are not the result of isolated cancer cells. 
Malignant tumours have also been recognised as organs because they require the 
interplay of specialised cell types and the tumour microenvironment that they 
develop during the progression of the disease. Cancer cells, cancer stem cells, 
endothelial cells, pericytes, immune inflammatory cells, cancer-associated fibroblast 
and stem and progenitor cells of the tumour stroma are key players of the tumour 
microenvironment. Cancer progression is achieved through very complex signalling 
networks that are established amongst all specialised cells previously mentioned. To 
date, many of these networks remain to be fully identified and they are also the focus 
of current research studies into targeted cancer therapies (Hanahan & Weinberg, 
2011). 
 
Although there is no definitive cause to the genetic alteration to most cancers, 
one or many contributing risk factors have been identified, including race/ethnicity, 
exposure to chemical carcinogens, hormones, radiation exposure, viruses, genetic 
predisposition or familial history and other personal circumstances such as alcohol 
use, nutritional habits and smoking (Martin & Weber, 2000; Neighbors & Tannehill-
Jones, 2006).  
 
Breast cancer is a malignant neoplasm arising from the epithelial cells that line 
the terminal duct lobular unit. Out of all the risk factors previously mentioned, 
hormonal factors and genetic factors are the two mainly involved in the development 
of carcinoma of the breast in women. As a result, pathologists usually divide breast 
cancer into those related to hormonal exposure or sporadic cases and the ones 
featuring germline mutations or hereditary cases (Copstead & Banasik, 2010; 
Robbins et al., 2010; Sainsbury, Anderson, & Morgan, 2000).  
 
Genes and germline mutations involved in the aetiology of breast cancer will 
be further discussed in this chapter, however they account only for a small fraction of 
all diagnosed breast cancer patients. Sporadic cases are primarily associated with 
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 hormone exposure and its main effects on women, mediated through factors such as 
age at menarche and menopause, reproductive history, breastfeeding and use of 
exogenous oestrogen (Martin & Weber, 2000). Oestrogen is a key hormone in the 
development of normal breast epithelium, but it also seems to have an effect on 
breast cancer development by increasing the number of malignant target cells 
through breast growth stimulation. DNA damage may also occur through mutations 
caused by hormonal metabolites or production of free radicals and due to their effect 
on gene variants related to oestrogen synthesis and metabolism. It binds to two 
specific receptors, oestrogen receptor alpha (ERα) and oestrogen receptor beta 
(ERβ), which act as nuclear transcription factors. ERα is the receptor most 
commonly associated with breast cancer since it is the one mainly expressed in breast 
tissue (Abeloff, Armitage, & Niederhuber, 2008; Robbins et al., 2010). 
 
Of the hormonal related pathways for malignant development, two of the most 
clinically important ones are the ones related to oestrogen receptor (ER): ER-positive 
and ER-negative pathways. The majority of breast cancers are ER-positive, about 
70%, and they most probably develop initially in the epithelium of the glandular 
ducts, mainly in the luminal cells expressing oestrogen receptor. ER-negative 
carcinomas have no clear precursor cells but they might be derived from ER-negative 
myoepithelial cells or from ER-positive cells that lose ER expression. ER- positive 
carcinomas tend to have better differentiation and a slowly growing pattern. Almost 
half of breast carcinomas in young women who develop breast cancer are ER-
negative or human epidermal growth factor receptor 2 (HER2/neu) positive, while 
these markers are only positive in less than a third of women over 40 years of age, 
contributing to a more aggressive phenotype seen in breast cancers arising earlier in 
life. Most lobular carcinoma in situ (LCIS) are ER-negative, they usually tend to 
over express HER2/neu and to lose expression of E-cadherin (Abeloff et al., 2008; 
Copstead & Banasik, 2010; Robbins et al., 2010). HER2/neu will be discussed in 
section 2.5.1 referring to genes and breast cancer further ahead in this chapter and 
LCIS will be described as part of section 2.4.1, which deals with the classification of 
breast cancer (Abeloff et al., 2008; Robbins et al., 2010). 
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Progesterone receptor (PR) is an oestrogen regulated gene. There are two 
isoforms of this receptor PR-A and PR-B, the last one being more specific to breast 
cancer. Polymorphisms in the PR gene promoter seem to increase risk of endometrial 
and breast cancer. The relationship of PR with ER seems to have an effect on tumour 
biology.  Tumours which are ER/PR-positive seem to be less aggressive, they usually 
do not extend to surrounding lymph nodes and they have a better response to anti-
oestrogen therapy. On the other hand, ER-positive/PR-negative carcinomas are more 
frequently found in women over 50 years of age and they associate with abnormal 
chromosomal count and nodal involvement. Furthermore, they have a poor clinical 
response to anti-oestrogen therapy (Abeloff et al., 2008; De Vivo et al., 2002).  
 
Breast cancer is a complex disease and there is no robust association between a 
single genetic marker and sporadic breast cancer development. However, there is 
clear evidence about the role genetics play in the development of cancer. There are 
many different molecular pathways described and they seem to interact with each 
other creating very complex signalling networks. Therefore, it is more likely that 
several genes play a role in carcinogenesis. These genes are the target for genetic 
damage during carcinogenesis, a process aided by many other environmental factors 
previously mentioned.  Although inherited predisposition is very rare for most types 
of breast cancer, recognition of genes contributing to such predisposition has had a 
major impact in our understanding of carcinogenesis. Genes associated with cancers 
with a strong hereditary component seem to also be involved in the sporadic forms. 
Genetic predisposition to breast cancer is found within two categories: Autosomal 
dominant inherited cancer syndromes and familial cancers, which are summarized in 
Table 2-5, which will be discussed section 2.5.1 of this review, which covers 
genetics and breast cancer due to their importance for both familial and sporadic 
forms of the disease (Robbins et al., 2010; Weinberg, 2007; Ben Zhang et al., 2011). 
 
2.4 BREAST CANCER CLASSIFICATION 
 
Many different classifications of breast carcinomas have been created over the 
years in an attempt to group tumours according to morphologic patterns and clinical 
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 behaviour (Bloom & Richardson, 1957; Meyer et al., 2005; Sainsbury et al., 2000). 
We will focus on some of the most commonly used by pathologist and clinicians: the 
histological classification, Bloom and Richardson grading system and the American 
Joint Committee on Cancer (AJCC) staging system. However, the molecular 
classification of breast cancer will be covered further ahead in section 2.5.1.2 
discussing genetics and breast cancer because it relates to gene expression signatures 
used in clinical settings to determine treatment and predict outcome.  
 
2.4.1 Histological Classification 
 
Adenocarcinomas are the main type of breast cancer and they can be further 
grouped as in situ carcinomas and invasive carcinomas. A neoplastic tumour within 
ducts and lobules limited by the basement membrane is called carcinoma in situ, 
whereas the invasive form crosses the basement membrane and invades the stroma. 
The latter form can potentially extend to vasculature and reach regional lymph nodes 
and distant anatomical locations. Previously, ductal carcinoma was a general term 
initially used to designate neoplastic proliferation within the ducts and lobular 
carcinoma was the one used for malignant tumours within the lobules. However as 
classification evolved, these terms are now used to designate differences in tumour 
cell biology, based on particular patterns of growth and cellular morphology and 
specific markers. Histological classification of breast cancer is summarised in Table 
2-3 (Robbins et al., 2010; Sainsbury et al., 2000). 
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Table 2-3 Histological Classification of Breast Cancer (Robbins et al., 2010). 
CARCINOMA IN SITU 
Type Subtype 
Ductal Carcinoma in Situ (DCIS) 
Comedocarcinoma   
Non-comedo DCIS 
Solid 
Cribriform 
Papillary 
Micropapillary 
Paget's Disease   
Lobular Carcinoma in Situ (LCIS) 
 
INVASIVE (INFILTRATING) CARCINOMA 
Type Subtype 
Invasive Carcinoma No Special Type (NST; 
Invasive Ductal Carcinoma) 
    
Invasive Lobular Carcinoma Special Type 
Tubular 
Cribriform 
Mucinous 
Papillary 
Medullary 
Classic Lobular 
 
In general, in situ carcinomas have a better outcome overall compared to 
invasive carcinomas but their overall incidence is lower, about 30% of total cases. 
Ductal carcinoma in situ (DCIS) is the second most common type of carcinoma (12 
to 24% of cases) and it is further classified into 5 architectural subtypes which are 
present in the majority of DCIS tumours. It can have infiltrating edges and when it 
becomes invasive it usually spreads to the surrounding normal breast tissue. 
Following this it disseminates into the lymphatic system, initially to the lymph 
system of the axilla and from here to other distant sites such as lung, liver and bone. 
In its initial stages, it can be cured in about 95% of patients through mastectomy and 
DCIS recurrences or deaths after surgery are rare. Most lobular carcinoma in situ 
(LCIS) are found incidentally and they account for about 3 to 6% of total cases. They 
are very hard to detect through mammography and they affect primarily young 
women (up to 90% of cases are identified before menopause). Treatments for LCIS 
tend to be more aggressive and they include bilateral prophylactic mastectomy 
(Abeloff et al., 2008; Robbins et al., 2010).  
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 On the other hand, invasive carcinomas constitute the majority of breast cancer 
cases (70 to 85% of all cases). Invasive carcinomas of no special type (NST), also 
known as invasive ductal carcinomas, are the most common subtype and they are 
about 55 to 67% of all cases. Molecular classification of invasive ductal carcinomas 
is clinically important to determine prognosis and response to therapy and will be 
discussed in detail in section 2.5.1.2. As a general rule, neoplasms classified as 
special type carcinoma tend to have a better prognosis compared to the no special 
type. Invasive lobular carcinoma of special type can be divided in 6 main subtypes: 
Classic lobular carcinoma, cribriform, mucinous, papillary, tubular and medullary 
carcinoma (Page, 2003). Classic lobular carcinoma account for about 7 to 8.5% of 
total cases and they are hard to detect on physical examination and mammography. 
Invasive lobular carcinoma is usually graded using grading scales and staging 
systems, further described in section 2.4.2 and they have a different pattern of 
metastasis, usually spreading to the abdominal and pelvic cavities (peritoneum, 
retroperitoneum, gastrointestinal tract, ovaries and uterus). Medullary and mucinous 
carcinomas together make up about 1.7% of all cases. Medullary carcinomas are very 
common in the sixth decade and usually poorly differentiated. Mucinous carcinomas, 
also known as colloid carcinomas, occur after the seventh decade and have a slow 
growing rate. Both of these subtypes rarely involve lymph node metastases and have 
a slightly better prognosis than no specific type carcinomas. Finally, tubular 
carcinomas range from 4 to 5% of total cases and are commonly present in the fourth 
decade. They are usually detected by mammography and overall they tend to have an 
excellent clinical prognosis (Abeloff et al., 2008; Robbins et al., 2010). 
 
2.4.2 Bloom and Richardson grading system 
 
Bloom and Richardson grading, also known as Scarff, Bloom and Richardson 
grading, is an histological grading scale developed to obtain prognostic information 
especially for invasive carcinoma of no special type. Tumours are graded on three 
main factors: Degree of glandular formation, nuclear pleomorphism and frequency of 
mitoses. Each one of these factors is scored from 1 to 3 and these results combined 
would allocate a tumour into one of three groups: Grade I (Scores 3 to 5), grade II 
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(scores 6-7) and grade III (8-9). Lower scores for each factor, leading to lower 
grades, would give a better prognosis for both disease free and overall survival, as it 
has been shown that most deaths occur within the first 10 years after diagnosis for 
grade III patients  (Bloom & Richardson, 1957; Robbins et al., 2010; Sainsbury et al., 
2000).  
 
2.4.3 The American Joint Committee on Cancer (AJCC) staging system. 
 
The American Joint Committee on Cancer (AJCC) developed a staging system 
in 2002, which relies on the pathological examination of the primary tumour as well 
as the axillary lymph nodes to establish prognosis. This staging system is very 
complex and it defines various different categories to classify tumours and lymph 
nodes. The main features of the AJCC staging system, which divides patients into 5 
different stages associated with different survival rates are summarized in Table 2-4. 
Breast cancers classified in the lower grades show a better outcome compared to the 
higher grades, starting with 92% survival for local, non-invasive carcinomas in grade 
0 and lowering down to 13% for invasive carcinomas classified as grade IV. (F. 
Greene, Balch, Haller, & Morrow, 2002; Robbins et al., 2010; Sainsbury et al., 
2000). 
 
Table 2-4 American Joint Committee on Cancer Staging System (Adapted from AJCC Staging 
Manual 2002) 
Stage T: Primary Cancer Lymph Nodes (LNs) M: Distant Metastasis 
5-Year 
Survival 
(%) 
0 DCIS or LCIS No metastases Absent 92 
I Invasive Carcinoma ≤ 2 cm No metastases Absent 87 
II Invasive Carcinoma > 2 cm No metastases Absent 75 
Invasive Carcinoma < 5 cm 1-3 positive LNs Absent 
III Invasive Carcinoma >  5 cm 1-3 positive LNs Absent 46 
Any size invasive carcinoma ≥ 4 positive LNs Absent 
Invasive carcinoma with skin or 
chest wall involvement or 
inflammatory carcinoma 
0 to > 10 positive 
LNs 
Absent 
IV Any size invasive carcinoma Negative or positive 
LNs 
Present 13 
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 Current available classifications for breast cancer, including molecular 
profiling discussed in section 2.5.1.2, still fail to provide accurate patient prognosis, 
response to treatment and prediction of disease relapse. Molecular diversity overlaps 
with histopathology, therefore changes to these classifications are currently under 
work. Reviews and studies are being conducted to include validated genetic profiling 
in an effort to strengthen our understanding of breast cancer and to provide better 
treatment rationale and disease outcome. (Singletary et al., 2003; Singletary & 
Connolly, 2006). 
 
2.5 GENETICS AND BREAST CANCER 
 
Four main types of regulatory genes are involved in the development and 
progression of breast cancer: growth promoting proto-oncogenes, growth-inhibiting 
tumour suppressor genes, genes regulating apoptosis and genes participating in DNA 
repair (Robbins et al., 2010; Strachan & Read, 2011; Weinberg, 2007). 
 
Oncogenes are genes that promote self-sufficient cell growth in cancer cells. 
They derive from proto-oncogenes and they are transcribed and translated to produce 
oncoproteins, required for the continued, autonomous replication of cells even in the 
absence of growth factors or other external signals. Proto-oncogenes, under normal 
conditions, are involved in physiological processes like cellular growth and 
proliferation and they transform into oncogenes when DNA damage occurs within 
them. Activation or transformation of proto-oncogenes can be achieved through 3 
main mechanisms: amplification, point mutation and chromosomal translocation. 
Each of these results in overproduction of the product of the gene, or an altered 
product with increased signalling capacity. Oncoproteins, the final product of 
oncogenes, can be classified as one of four main categories: growth factors, growth 
factor receptors, signal transduction proteins and nuclear-regulatory proteins 
(Robbins et al., 2010; Strachan & Read, 2011; Weinberg, 2007).  
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Tumour suppressor genes have a counteracting function to that of oncogenes. 
They inhibit cell proliferation by restraining inadequate cell division, maintaining 
DNA integrity or driving cells to apoptosis. They are able to achieve these functions 
through different final protein products which include categories like transcription 
factors, cell cycle inhibitors, signal transduction molecules, cell surface receptors and 
regulators of cellular responses to DNA damage (Robbins et al., 2010; Strachan & 
Read, 2011; Weinberg, 2007). Tumour suppressor genes rarely contribute directly to 
cancer formation; instead it is primarily their inactivation or destruction, through 
mutation or suppression of gene expression that allows the further progression of 
early dysplasias and adenomas into malignancy. 
 
Apoptosis is the process of programmed cell death. It is achieved through 
highly regulated and controlled biochemical and molecular events that lead to 
cellular changes and eventually death. Genes regulating apoptosis include those 
involved in TNF, FAS and Caspase pathways. Changes in apoptosis-regulating genes 
result in increased cell survival and this is generally achieved through mutations 
leading to enhanced activity of genes suppressing apoptosis or reduced expression of 
cell-death promoting genes (Robbins et al., 2010; Strachan & Read, 2011; Weinberg, 
2007). 
 
Finally, genes involved in various DNA repair mechanisms are also implicated 
in carcinogenesis. Loss-of-function mutations in genes involved in DNA repair 
impairs the cellular ability to identify and repair genetic damage, which leads to the 
high rates of acquired mutations commonly seen in carcinogenesis. ATM, CHEK1, 
CHEK2, BRCA1 and BRCA2 are examples of genes associated with inherited 
disorders and familial cancer syndromes, which are usually the result of 
chromosomal abnormalities like breaks, abnormal chromosome numbers and 
widespread mutations. These genes have also been studied and associated with some 
cases of sporadic cancer (Robbins et al., 2010; Strachan & Read, 2011; Weinberg, 
2007). 
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 Due to the complexity of the cellular networks and the large number of genes 
involved with potential roles in the development and progression of breast cancer, we 
will focus on some of the most important genes identified to date in subsection 2.5.1. 
We will also discuss microRNAs (miRNAs) and their role as epigenetic modifiers of 
gene expression in relation to breast cancer as part section 2.6.3 of this review to give 
a more comprehensive overview due to their importance for the topic of this study. 
 
2.5.1 Genes and breast cancer 
 
As mentioned before, approximately 5-10% of breast cancers are caused by the 
inheritance of a susceptibility gene or a set of genes. These genes can be divided into 
three different groups: High risk, high penetrance, breast cancer susceptibility genes, 
moderate risk breast cancer susceptibility genes with moderate penetrance and low-
penetrance variants for some other identified genes (Oldenburg, Meijers-Heijboer, 
Cornelisse, & Devilee, 2007; Ben Zhang et al., 2011). Families with multiple 
affected first-degree relatives, especially with subjects affected before menopause 
and/or medical history of other types of cancer increase the possibility of breast 
cancer development within their members. Most common single gene mutations are 
associated with increased susceptibility to breast cancer, autosomal dominant 
syndromes and familial forms and they include BRCA1, BRCA2, p53, PTEN, ATM 
and CHEK2 briefly outlined in Table 2-5 and Table 2-6 (Robbins et al., 2010; 
Strachan & Read, 2011; Weinberg, 2007).  Due to their apparent role in the 
development of sporadic forms of breast cancer, the main features and current 
findings in relation to these genes will be discussed in further detail.  
 
BRCA1: BRCA1 is a tumour suppressor gene of about 100 kilobases (kb) 
localised in chromosome 17q21, it contains 24 exons, 22 of which are protein 
coding. (Martin & Weber, 2000). It was initially identified by linkage analysis in 
1994 (Hall et al., 1990; Miki et al., 1994) and it is one of four high penetrance genes 
described so far in relation with breast cancer. Prevalence of heterozygous carriers of 
the high-risk mutation in the general Caucasian population is one in 1000 (0.10%) 
and it has been shown to confer female carriers a cumulative lifetime risk of about 50 
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to 85% for developing breast cancer. The BRCA1 protein, containing about 1863 
amino acids, interacts with transcripts of some of the other genes described in this 
section, including TP53, RB, ATM and BRCA2. It is involved in DNA-damage repair, 
cell-cycle regulation, transcriptional regulation and chromatin remodelling (Carter, 
2001; Martin & Weber, 2000; Oldenburg et al., 2007; Welcsh & King, 2001; Ben 
Zhang et al., 2011). More than 500 sequence variations, mainly deletions or 
insertions of nucleotides, have been described and associated with breast cancer, 
including the founder mutations identified in the Ashkenazi Jewish population 
(185delAG and 5382insC) (Carter, 2001; Martin & Weber, 2000). BRCA1 
expressing tumours are commonly of the basal type, which will be discussed ahead 
in more detail in the molecular classification of breast cancer (Ben Zhang et al., 
2011).   
 
BRCA2: BRCA2 is a tumour suppressor gene, spanning about 70kb of genomic 
DNA, localised in chromosome 13 (13q12.3) and it contains 27 exons, one of which 
is not translated. Initially identified by linkage analysis in 1995, it is a high 
penetrance gene involved in inherited forms of breast cancer. At least 250 mutations 
in the gene have been identified and they include a founder mutation in the 
Ashkenazi Jewish population (6174delT).  Prevalence of heterozygous carriers of the 
high risk BRCA2 mutations in the general Caucasian population is about 1 in 750 
(0.13%) and mutation carriers have a lifetime breast cancer risk estimated in the 
range of 60 to 85% (Martin & Weber, 2000; Oldenburg et al., 2007; Wooster et al., 
1995). BRCA2 encodes a protein of about 3418 amino acids, which has a role in 
DNA recombination and repair pathways, interacting with other genes described in 
this section, such as  including CHEK2 and ATM, and it may possibly be involved in 
cytokinesis (Martin & Weber, 2000; Ben Zhang et al., 2011).  
 
p53: TP53 or p53, also known as “the guardian of the genome” is a commonly 
altered gene in most human cancers. It is localised on chromosome 17p13.1 and it is 
involved in inducing apoptosis or cell-cycle arrest in response to cellular stress, 
through modulation of transcription of about a dozen genes. It is one of the high 
penetrance risk genes identified in relation to breast cancer since inheritance of a p53 
mutant allele causes Li-Fraumeni syndrome, which involves multiple early-onset 
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 cancers, including breast cancer in adulthood. 90% of all mutations for p53, which 
account for over 2,000 in total, are located in exons 5 to 8 of the gene and more than 
90% of mutation carriers are expected to develop cancer by age 70. Patients with 
ductal and medullary tumours below 60 years of age typically carry mutations 
located in these genomic regions of the p53 gene and they are about 30 to 50% of 
sporadic breast cancer cases. It has also been studied as a marker for breast cancer- 
specific mortality, showing an increase of 2.27-fold in overall relative risk. Germline 
mutations of ATM and CHEK2 required for p53 activation also appear to increase 
susceptibility to breast cancer (Martin & Weber, 2000; Oldenburg et al., 2007; Ben 
Zhang et al., 2011). 
 
ERBB2 (HER2): ERBB2, also known as HER2/neu, is a proto-oncogene 
localised on chromosome 17q21.1. It encodes the human epidermal growth factor 
receptor 2, which is a transmembrane tyrosine kinase receptor, a member of a family 
of growth factor receptors that also includes EGFR (ERBB1), ERBB3 (HER3) and 
ERBB4. HER2 is part of the RAS-MEK and AKT cellular pathway, it does not bind to 
any particular ligand and therefore it requires interaction with other members of the 
family, mainly HER3, to perform its cellular activity (See Figure 2-3). 20% of breast 
cancers have HER2/neu amplification and/or overexpression of HER2 protein, which 
correlates with these tumours being more aggressive and resulting in a reduced 
patient’s survival time. It is well known and studied because it is the target of 
specific therapy. Trastuzumab (Herceptin®) is a humanised monoclonal antibody 
that binds to ERBB2 and it is used as an adjuvant therapeutic agent. It reduces 
recurrence of tumours and prolongs survival when combined with chemotherapy in 
patients who are HER2/neu positive (Abeloff et al., 2008). 
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 Figure 2-3 ERBB2 Receptor and intracellular signalling pathways. Reproduced from 
Johnston & Dowsett, 2003. Copyright © 2003, with permission from Nature 
Publishing Group. 
 
PTEN: PTEN, phosphatase and tensin homolog, is a tumour suppressor gene 
localised on 10q23.3, which inactivates the signal of phosphatidylinositol 3-kinase 
(PI3K). PI3K produces phosphatidylinositol-3,4,5-triphosphate, a second messenger 
responsible of the activation of AKT and other pathways involved in cellular 
proliferation and apoptosis inhibition. High penetrance germline mutations of PTEN 
produce inherited cancer predisposition through Cowden syndrome (CS). CS is a 
clinical syndrome featuring a high incidence of neoplasms which include breast 
carcinoma. Female patients carrying a PTEN mutation have a 25 to 50% lifetime 
breast cancer risk. This gene usually becomes inactive through point mutations and 
methylation, which causes genetic instability. Although 11 to 41% of sporadic breast 
cancers cases show loss of heterozygosity for PTEN, to date no somatic mutations in 
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 the PTEN gene have been identified in the remaining allele or in this gene in breast 
cancer families without features of Cowden syndrome (Martin & Weber, 2000; 
Oldenburg et al., 2007; Ben Zhang et al., 2011). 
 
ATM: The ATM gene is located on chromosome 11q22-23. It produces a 
protein that plays an important role in sensing and signalling DNA double-strand 
breaks and genome instability. It becomes very active when cells are irradiated and it 
autophosphorylates, regulating other tumour suppressor proteins, including tumour 
suppressor proteins p53, BRCA1 and checkpoint kinase CHEK2. Homozygous or 
heterozygous mutations in the ATM gene are associated with ataxia telangiectasia 
(AT), an autosomal recessive disorder presenting with movement disorder (ataxia) 
secondary to cerebellar degeneration, telangiectasia, immunodeficiency, 
chromosomal instability and increased susceptibility to cancer. AT female patients 
have an estimated relative risk for breast cancer of about 2.3. No germline mutations 
in the ATM gene have been identified in studies of sporadic breast cancer cases; 
haplotype analysis of common variants for the ATM gene suggested a slight 
association with breast cancer risk but large population studies are required for 
further validation of these results (Einarsdottir et al., 2006; Oldenburg et al., 2007; 
Szabo et al., 2004). 
 
CHEK2: The tumour suppressor gene CHEK2 is located on chromosome 
22q12.1. It has been found to confer low to moderate risk for breast cancer, due to 
moderate penetrance and it is involved in DNA repair of double strand-breaks. The 
CHEK2 protein is a G2 check point kinase that requires phosphorylation by ATM, 
usually after exposure to ionising radiation, and it also phosphorylates other cell 
cycle proteins such as BRCA1 and p53. A 1100delC mutation of CHEK2 was found 
in a patient with Li-Fraumeni syndrome with no mutation in TP53 (Li-Fraumeni 
variant syndrome) and this variant was detected in about 1% of the healthy control 
population and about 1.5 to 3 times more commonly in patients with breast cancer. 
Furthermore, a two-fold increase in risk of breast cancer was found in 
CHEK2*1100delC mutation carrier patients with no mutation in BRCA1/2 using 
segregation analysis (Einarsdottir et al., 2006; Oldenburg et al., 2007; Ben Zhang et 
al., 2011).  
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Table 2-5 Autosomal dominant inherited breast cancer syndromes. 
CATEGORY CLINICAL SYNDROME - GENE (Location) 
% OF 
BREAST 
CANCERS 
FUNCTION 
BREAST 
CANCER 
RISK BY 
AGE 70 
MECHANISM 
IN SPORADIC 
BREAST 
CANCER 
Autosomal Dominant 
Inherited Cancer 
Syndromes.  
 
Individuals have an increased 
risk of developing breast 
cancer after inheritance of a 
single autosomal dominant 
mutant gene. It involves 
usually a single point 
mutation in a single allele for 
a tumour suppressor gene. 
Li-Fraumeni Syndrome - p53 (17p13.1) < 1% Tumour suppressor 
gene involved in cell 
cycle control, DNA 
replication, DNA 
repair and apoptosis. 
> 90% Mutations in 
20%. 
LOH in 30% to 
42%.  
Most frequent in 
triple negative 
cancers. 
Li-Fraumeni Variant Syndrome - CHEK2 (22q12.1) ~ 1% Cell cycle checkpoint 
kinase.  
Involved in 
recognition and repair 
of DNA damage. 
Activates BRCA1 and 
p53 by 
phosphorylation 
10 - 20% Mutations are 
rare (< 5%).  
Loss of protein 
expression in 1/3 
of cases. 
Rare Syndromes:                                                                          < 1%       
Cowden Syndrome – PTEN 
 Peutz-Jeghers Syndrome - LKBI/STK11  
Ataxia telangiectasia – ATM 
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 Table 2-6 Familial forms of breast cancer. 
CATEGORY CLINICAL SYNDROME - GENE (Location) 
% OF 
BREAST 
CANCERS 
FUNCTION 
BREAST 
CANCER 
RISK BY 
AGE 70 
MECHANISM 
IN SPORADIC 
BREAST 
CANCER 
Familial Breast Cancer.     
                                                         
They occur at higher 
frequency within a family 
without a defined pattern of 
transmission. Usually early 
age at onset, tumours in two 
or more relatives and multiple 
or bilateral tumours. It is 
likely that familial 
susceptibility depends on 
multiple penetrating alleles. 
BRCA1 (17q21) < 2% Tumour suppressor 
gene.  
Involved in 
transcriptional 
regulation and repair of 
double stranded DNA 
breaks. 
40 - 90% Mutations are 
rare. 
Inactivated in 
50% of some 
subtypes by 
methylation. 
BRCA2 (13q12-13) < 1% Tumour suppressor. 
Involved in 
transcriptional 
regulation and repair of 
double stranded DNA 
breaks. 
30 - 90% Mutations and 
loss of expression 
are rare. 
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As previously stated, breast cancer is a complex disease. It originates from an 
interaction between genetic and environmental factors and it involves different types 
of tumours derived from tissues in the mammary glands. This might explain why all 
of the single genes previously discussed have not shown strong association with the 
sporadic forms of the disease. They have different cellular roles as tumour suppressor 
genes or proto-oncogenes; hence they could be involved in the development and 
progression of sporadic cases of breast cancer. However, in spite of the evidence 
about their association to the inherited forms of breast cancer, they do not 
sufficiently explain breast cancer aetiology and natural history of breast carcinoma 
for all forms of the disease. 
 
Genetic studies on breast cancer have been conducted in different ways to 
address a diverse range of research questions. Some of these approaches include 
studies on common genetic variants, like single nucleotide polymorphisms (SNPs), 
to determine if they play a role in the biogenesis of breast cancer. Additional avenues 
of research include gene expression studies aimed to develop molecular profiles that 
could be used in the diagnosis or treatment of breast cancer. We will briefly discuss 
these two approaches as part of this section of the literature review to present key 
findings in the field of genetics in relation to breast cancer. Research focused on 
miRNA genes and their role in breast cancer will be covered in section 2.6.3 of this 
review to provide a more in-depth view of the subject due to its importance for the 
general and specific aims of this study. 
  
2.5.1.1 Single nucleotide polymorphisms and breast cancer 
 
A single base mutation can be classified as a single nucleotide polymorphism 
(SNP) when the frequency of the minor allele exceeds 1% in at least one population. 
There are around 10 million SNPs in the human genome; about one SNP every 100 
to 400 base pairs and about 56% of SNPs have been successfully typed. They form 
haplotypes, which comprise genetic variants on the same chromosome that are 
inherited together having little chance of recombination. They tend to be transmitted 
as blocks within small chromosomal regions, that is, they tend to be in linkage with 
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 one another. Linkage disequilibrium is a term used to define the correlation between 
SNPs at nearby sites descended from single, ancestral chromosomes. This allows the 
prediction of the genotypes at a large number of SNP loci from identification of 
representative SNPs called “tag SNPs” or “haplotype tag SNPs”  (Brown, 2007; Dutt 
& Beroukhim, 2007; LaFramboise, 2009; Reich et al., 2001). 
 
It is very likely that more than a single gene variant is required to address 
tumour heterogeneity in breast cancer. Therefore, genome-wide association studies 
(GWAS) have been conducted to try to identify genes and genetic variants associated 
with this particular disease. Results from 14 GWAS conducted between 2007 and 
2010 show association between breast cancer incidence in different cohorts and 49 
low penetrance genetic variants of different genes or loci. Seven single nucleotide 
polymorphisms (SNPs) are the most common variants found from these GWAS and 
they include: Two single nucleotide polymorphisms in intronic regions of fibroblast 
growth factor receptor 2 (FGFR2) gene: rs1219648 and rs2981579 (Fletcher et al., 
2011; Hunter et al., 2007; Li et al., 2011; G. Thomas et al., 2009; Turnbull et al., 
2010) and; 5 SNPs located in intergenic regions. The five intergenic SNPs are one 
SNP on chromosome 2q35 between TNP1 and DIRC3 (rs13387042), one SNP on 
chromosome 3p24.1 near to the SLC4A7 gene (rs4973768), one SNP on chromosome 
5q11.2 between the RPL26P19 and MAP3K1 genes (rs889312), one SNP located on 
chromosome 8q24.21 between the SRRM1P1 and POU5F1B genes (rs1562430) and 
one SNP located on chromosome 16q12.1-2 between the TOX3 and CHD9 genes 
(rs3803662) (Easton et al., 2007; Fletcher et al., 2011; Li et al., 2011; Stacey et al., 
2007; G. Thomas et al., 2009; Turnbull et al., 2010). These variants are located in 
relation to genes that are involved in molecular functions or cellular processes linked 
to cancer development and their roles remain unclear because they are part of 
complicated gene regulatory networks which are still under investigation.  
 
In addition, due to the limitations of the platforms used to undertake GWAS 
research, primarily microarray, the full array of human polymorphisms have not been 
assessed for association with breast cancer. Many of the intergenic SNPs may have 
been associated with breast cancer through linkage to functional SNPs in gene 
sequences, while other areas of the genome may have had very little assessment due 
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to the lack of a known common SNP in the region to be included on GWAS 
microarrays. Regions previously thought to be intergenic and thus of less interest 
during the development of GWAS microarrays may contain microRNA genes and 
similar non-protein coding sequences nonetheless important for control of cellular 
growth.  Lack of assessment of previously unknown SNPs and microRNA containing 
regions means that research examining the role of SNPs in breast cancer aetiology 
should take these into consideration to improve our understanding of the disease. 
Indeed, this is one of the main rationales for the development of this research. 
 
2.5.1.2 Molecular classification of breast cancer 
 
Molecular classification of breast carcinoma was developed to try to determine 
suitable therapy and predict prognosis and response to therapy. As a result, 5 
different patterns of gene expression have been identified using microarray 
technologies (Blenkiron et al., 2007; Perou et al., 2000; Robbins et al., 2010; Schnitt, 
2010; Sørlie et al., 2003): 
 
a. Luminal A: They account for 40 to 55% of no special type (NST) cancers. 
The category consists of breast cancers that are ER-positive and 
HER2/neu-negative. They express genes under the control of ER and also 
genes characteristic of luminal cells. Usually well differentiated, they 
occur mainly in postmenopausal women. They are slow growing and 
respond well to hormonal treatment. 
 
b. Luminal B: They correspond to about 15 to 20% of NST cancers and they 
are also known as triple-positive cancers. They are ER-positive, usually 
highly proliferative and poorly differentiated (having high grading) and 
overexpress HER2/neu.  Luminal B tumours are likely to respond well to 
chemotherapy and are often lymph node positive. 
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 c. Normal breast-like: They are about 6 to 10% of NST breast cancers. They 
are well differentiated, ER-positive, HER2/neu-negative and they are very 
similar in gene expression to normal breast tissue. 
 
d. Basal-like: 13 to 25% of no special type breast cancer tumours fall within 
this group. They are ER-negative, progesterone receptor (PR)-negative and 
HER2/neu-negative and they have a similar gene expression pattern to 
myoepithelial and putative stem cells. They can be grouped with other 
types of breast carcinomas that are “triple-negative” carcinomas such as 
medullary carcinomas and metaplastic carcinomas. Basal-like carcinomas 
are poorly differentiated and have a high proliferation rate. They usually 
metastasise to brain and viscera. Although they are associated with poor 
prognosis, about 15 to 20% of cancers in this subgroup are sensitive to 
chemotherapy and likely to be cured. They are frequently associated with 
BRCA1 dysfunction, which occurs in about 80% of basal like tumours. 
 
e. HER2 Positive: This subgroup comprises about 7 to 12% of ER- negative 
no special type carcinomas, which also over express HER2/neu protein. 
They are poorly differentiated, have a high proliferation rate and they 
usually are associated with a high frequency of brain metastasis (Blenkiron 
et al., 2007; Perou et al., 2000; Robbins et al., 2010; Schnitt, 2010; Sørlie 
et al., 2003). 
 
As a result of this molecular profiling classification, two main multigene 
prediction score sets were designed and validated and they are pending approval 
from the U.S. Food and Drug Administration (FDA). Both methods, the 21-gene 
predictor set, commercially available under the name of Oncotype Dx® (Genomic 
Health, Inc., Redwood City, CA), and the technology 70-gene predictor set, 
commercially available as MammaPrint® (Agendia, Inc., Amsterdam, The 
Netherlands) (Paik et al., 2004; Schnitt, 2010; van de Vijver et al., 2002) are based 
on quantitative real time polymerase chain reaction (qPCR) and microarray 
technologies, respectively. Oncotype Dx® produces a score for recurrence of breast 
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carcinoma and it classifies patients as low, moderate or high risk based on testing for 
16 target transcripts, including ER, PR and HER2. The TAILORx (Trial Assigning 
Individualized Options for Treatment (Rx)) trial is currently in progress and it aims 
to validate the “recurrence score”, which also appears to correspond to likelihood of 
response to chemotherapy and endocrine therapy. On the other hand, the 
MammaPrint® predictor set, currently under validation in the ongoing MINDACT 
(Microarray In Node Negative Disease may Avoid Chemotherapy) trial, aims to 
identify patients with good and poor prognostic signatures, likely to benefit from the 
use of adjuvant therapy. Thus, molecular classification and profiling of patients using 
the multigene predictor sets is currently being used to try to individualise therapy for 
breast cancer patients to improve outcomes (Abeloff et al., 2008; Galanina, Bossuyt, 
& Harris, 2011; Paik et al., 2004; Schnitt, 2010; van de Vijver et al., 2002). 
 
2.6 MICRORNAS AND BREAST CANCER 
 
2.6.1 MicroRNA biogenesis and functions. 
 
MicroRNAs (miRNAs) are small non-coding single stranded RNA molecules 
of about 21 to 25 nucleotides in length, involved in gene regulation at the 
translational level. They are part of a family of small RNAs that also include small 
nucleolar RNA (snoRNA), short interfering RNA (siRNA) and piwi-interacting RNA 
(piRNA). miRNAs are estimated to account for about 1% of the human genome and 
they were initially identified in Caenorhabditis elegans (R. C. Lee, Feinbaum, & 
Ambros, 1993; Reinhart et al., 2000). They regulate important cellular processes like 
cell growth, differentiation and cell survival and therefore they have been linked to 
cancer and tumour development (Thalia A. Farazi et al., 2011; Robbins et al., 2010; 
Westholm & Lai, 2011; Zuoren Yu et al., 2010).  
 
52% of miRNA genes are located in different non-random positions within the 
genome in regions of chromosomal instability or cancer-associated regions. The 
majority of miRNA genes are found in intergenic regions, 1 kb away from known 
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 genes, and about one third of miRNA genes are found in the introns of protein-
coding genes. Many of these genes are transcribed independently and they have 
promoter regions that allow gene expression in a cell-type specific manner. Many 
others form genomic clusters, about 113 in total which can be up to 51 kb in length, 
and they are probably transcribed as a single polycistronic transcript (Thalia A. 
Farazi et al., 2011; Lynam-Lennon, Maher, & Reynolds, 2009). 1881 micro RNA 
precursors and 2588 mature sequences have been identified for the human genome 
according to miRBase (www.mirbase.org), a miRNA database, in their latest release: 
miRBase release 21 (June 2014) (Kozomara & Griffiths-Jones, 2011, 2014). 
 
miRNAs are transcribed from long microRNA primary transcripts (pri-
miRNAs) about 1kb in size that contain up to six miRNA precursors (pre-miRNA). 
Pre-miRNAs are stem-loop molecules of about 55 to 70 nucleotides in length and 
they are produced by canonical and non-canonical pathways. Non-canonical 
pathways are also called “mirtron” pathways, which are well described in 
invertebrates but they have not been experimentally demonstrated in mammalians or 
humans (Ha & Kim, 2014; Westholm & Lai, 2011). In the canonical pathway, pre-
miRNAs are produced when pri-miRNA are cleaved by the complex Drosha – 
DCGR8 (DiGeorge syndrome critical region gene 8, also known as pasha) within the 
cellular nucleus (Yoontae Lee et al., 2003). Pre-miRNA are then transported to the 
cytoplasm by XPO5 (exportin5) and the nuclear protein ran-GTP. In the cytoplasm 
pre-miRNAs are processed by DICER1, a ribonuclease type III enzyme, and double-
stranded RNA binding domain (dsRBD) proteins TARBP2 and/or PKRA producing 
a duplex molecule that contains both single-stranded mature miRNA strand and a 
complementary strand (miRNA*) (Chendrimada et al., 2005; Yi, Qin, Macara, & 
Cullen, 2003). The miRNA:miRNA* molecule is loaded into the RNA-induced 
silencing complex (RISC), where the mature miRNA sequence is merged into the 
Argonaute/EIFC2C (Ago) proteins and the miRNA* is released and degraded (Thalia 
A. Farazi et al., 2011; Lynam-Lennon et al., 2009; Westholm & Lai, 2011).  
 
Ago proteins bound to mature miRNA mediate target messenger RNA 
(mRNA) recognition and interaction between these three components resulting in 
gene regulation. The mRNA target is recognised by pairing of the miRNA seed 
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region (nucleotides 2 to 8) located in the 5’-end of the miRNA and the 
complementary sequence mainly located in the 3’ untranslated region (3’-UTR) 
region of target mRNA but binding sites can also found in the coding region 
(Khvorova, Reynolds, & Jayasena, 2003; Lai, 2002; Y. Lee, Jeon, Lee, Kim, & Kim, 
2002). This process is mediated and regulated by Ago proteins and the mRNA 
processing bodies (P-bodies), which are cytoplasmic structures that contain 
regulatory proteins from the GW182/TNRC6 family of proteins. If the seed region of 
the miRNA and the target region of mRNA are highly complementary, the RISC 
complex will cleave the target mRNA, a process known as RNA interference. If there 
is not enough complementarity between miRNA seed region and target mRNA 
regulation occurs by repression of translation, a process that has not yet been fully 
elucidated but that may occur before or after mRNA translation (see Figure 2-4) 
(Thalia A. Farazi et al., 2011; Lynam-Lennon et al., 2009; Westholm & Lai, 2011). 
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Figure 2-4 Copyright © 2006. Canonical pathway of miRNA genesis and mRNA 
regulation. Reprinted by permission of Nature Publishing Group (Esquela-Kerscher 
& Slack, 2006). 
 
Each miRNA may bind to up to 200 gene targets and each gene could have 
multiple binding sites for different miRNAs. Therefore they have been reported to 
regulate up to 60% of the genes within the human genome and targets for miRNAs 
are still under current investigation and validation (Bartel, 2009; Rajewsky, 2006).  
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2.6.2 MicroRNAs in cancer 
 
It is very likely that miRNAs play an important role in cancer biology because 
of the complexity of the molecular processes and mediators involved in miRNA 
genesis and miRNA-mRNA regulation and because they are involved in cell 
development, proliferation and death. Oncogenic miRNAs, or oncomirs, are known 
to regulate cancer pathways and they can control neoplastic development by reducing 
the expression of tumour suppressor genes or enhancing expression of certain 
oncogenes (Baohong Zhang, Pan, Cobb, & Anderson, 2007). 
 
Research studies have been conducted since microRNAs were initially 
described and they have linked miRNAs to different types of cancer. Because of the 
large number of miRNA genes currently identified and the large number of different 
approaches used to study them, we will focus on some of the most important studies 
published to date in relation to different types of cancers; those addressing breast 
cancers will be further covered in subsection 2.6.3 of this review.  
 
Initially, research studies focused on the expression patterns of different 
microRNAs in relation to cancer. The first reports of miRNA involvement in cancer 
date back about 12 years when Calin et al found MIR15 and MIR16 to be deleted or 
downregulated in patients with chronic lymphocytic leukaemia (CLL), the most 
common form of leukaemia in adults, as well as in prostate cancer cell lines in a 
study published in 2002 (Calin et al., 2002). A t(8, 17) translocation in an aggressive 
type of B cell leukaemia was also found to produce loss of expression of MIR142 
resulting in overexpression of MYC (Gauwerky, Huebner, Isobe, Nowell, & Croce, 
1989; Lagos-Quintana et al., 2002). In a review published in 2003, McManus et al 
postulated that microRNAs could play a role in cancer as either tumour suppressor 
(TS) genes or oncogenes (McManus, 2003). Following this, a study in colorectal 
carcinoma identified reduced expression of MIR143 and MIR145 (Michael, O' 
Connor, van Holst Pellekaan, Young, & James, 2003) and a different study showed 
that reduced expression of MIRLET7A1 was associated with a poor prognosis in lung 
cancer (Takamizawa et al., 2004).  Downregulation of MIR145 is also a common 
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 finding previously reported in colorectal (Arndt et al., 2009; Michael et al., 2003), 
bladder (Chiyomaru et al., 2010), lung (Cho, Chow, & Au, 2009, 2011) and 
oesophageal (Kano et al., 2010) cancers and it has been associated with poor 
prognosis for cancer patients. 
 
On the other hand, two separate studies identified expression of MIR155 to be 
increased in paediatric Burkitt lymphoma (Metzler, Wilda, Busch, Viehmann, & 
Borkhardt, 2004) Hodgkin´s lymphoma (HL), primary mediastinal B cell lymphoma 
(PMBL), diffuse large B cell lymphoma (DLBCL) and CLL (Eis et al., 2005; Kluiver 
et al., 2005).Similarly, Chen et al found markedly elevated levels of MIR21 in 
glioblastoma tumour tissue and glioblastoma cell lines (Chan, Krichevsky, & Kosik, 
2005). Calin et al determined that microRNAs were frequently located in cancer 
associated genomic regions as well as fragile chromosomal sites and they proposed 
that microRNAs can act both as tumour suppressor or oncogenes due to the variety 
of genes they regulate and the complexity of their networks (Calin, Sevignani, et al., 
2004).  
 
The microRNA 17-92 cluster host gene (MIR17HG) located on chromosome 
13q31.3 was the first miRNA cluster to be associated with cancer. The miRNA 17-92 
cluster host gene transcript is about 800bp in length and contains six miRNAs: 
MIR17, MIR18A, MIR19A, MIR20A, MIR19B1 and MIR92A1, which belong to 4 
seed families (miRNA 17, miRNA 18, miRNA 19 and miRNA 92). Based on their 
seed sequences, two related paralogues of this cluster have also been identified in the 
human genome: miRNA 106b-25 cluster located on chromosome 7 (7q22.1) in the 
13th intron of gene MCM7 and miRNA 106a-363 cluster located on chromosome X 
(Xq26.2) (Ventura et al., 2008). In 2004 Ota et al observed amplification of 
MIR17HG in DLBCL and lymphoma cell lines which was corroborated by another 
study in 2005 (L. He et al., 2005; Ota et al., 2004). He et al demonstrated increased 
expression of MIR17HG in B cell lymphomas in cell lines and tumour samples and 
they also found this cluster gene promoted accelerated tumour development in a 
murine model. Therefore they named MIR7HG as oncomir-1 (L. He et al., 2005).  It 
has also been implicated to play a role in different types of cancer including lung 
Chapter 2: Literature Review 61 
cancer, breast cancer, colon cancer gastric cancer and pancreatic cancer (Hayashita et 
al., 2005; Mendell, 2008; Mogilyansky & Rigoutsos, 2013; Volinia et al., 2006). 
 
Research studies have been conducted to identify specific miRNA expression 
profiles for different types of cancer. For example, Lu et al analysed the expression 
of 217 microRNAs using bead-based flow cytometry in 334 samples of leukaemia 
and solid cancers and they were able to correlate miRNA expression with 
developmental lineage and differentiation state (J. Lu et al., 2005). Using a 
microarray platform, Volinia et al investigated the miRNA profile of 363 cancer 
samples, including B-cell chronic lymphocytic leukaemia (BCLL), breast, colon, 
lung, pancreas, prostate and stomach cancer to compare them to 177 normal tissue 
samples. 228 miRNA genes were evaluated and they identified 36 microRNA genes 
to be over expressed and 21 to be downregulated in cancer cells versus normal 
tissues (Volinia et al., 2006). Many other profiling studies have been conducted in 
different types of cancer including chronic lymphocytic leukaemia (CLL) (Calin, 
Liu, et al., 2004), papillary thyroid carcinoma (H. He et al., 2005), breast cancer 
(Iorio et al., 2005), colon cancer (Cummins et al., 2006), glioblastoma (Ciafre et al., 
2005), lung cancer (Yanaihara et al., 2006), hepatocellular carcinoma (Murakami et 
al., 2006) and pancreatic tumours (Roldo et al., 2006). All these studies consistently 
show that expression patterns for cancer tissues involve both overexpressed and 
downregulated miRNA genes which may corroborate what was previously proposed 
by McManus in 2003 (McManus, 2003).  Some of the miRNAs that were most 
commonly identified in these studies are shown in Table 2-7.
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Table 2-7 Some of the miRNAs and their target genes most commonly found in relation to cancer.  
miRNA Upregulated Downregulated Predicted target genes References 
MIR17HG Lymphomas, lung cancer, breast 
cancer, colon cancer, gastric 
cancer, pancreatic cancer 
 E2F1, BCL2L11, 
PTEN 
He et al., 2005; Iorio et al., 2005; 
Mendell , 2008; Ota et al., 2004; 
Volinia et al., 2006 
MIR21 Brain cancer, breast cancer, 
glioblastomas, acute myeloid 
leukaemia, colon cancer, 
pancreatic cancer, prostate cancer, 
liver cancer 
 BCL2, PTEN, PDCD4, 
TPM1, TIMP3 
Ciafre et al., 2005; Chan et al., 
2005; Iorio et al., 2005; 
Murakami et al., 2006; Volinia et 
al., 2006 
MIR221 Brain Cancer, colon Cancer, 
pancreatic cancer, prostate cancer, 
papillary thyroid carcinoma 
 CDKN1B, CDK1C, 
PTEN, TIMP3 
Ciafre et al., 2005; Chan et al., 
2005; Cummins et al., 2006; He et 
al., 2005; Roldo et al., 2006; 
Volinia et al., 2006 
MIR155 Lymphomas Breast Cancer MAF, AGTR1 Eis et al., 2005, Kluiver et al., 
2005; Iorio et al., 2005 
MIR15A  Chronic lymphocytic leukaemia, 
prostate cancer, multiple myeloma 
BCL2, WT1, RAB9B Calin et al., 2002; Calin et al., 
2004 
MIR16-1  Chronic lymphocytic leukaemia, 
prostate cancer, multiple myeloma 
BCL2, WT1, RAB9B Calin et al., 2002; Calin et al., 
2004 
MIR34A  Pancreatic cancer, colon cancer, 
breast cancer, liver cancer 
CDK4, CDK6, CCNE2, 
E2F3, MET 
Blenkiron et al, 2007; Cummins et 
al., 2006; Iorio et al., 2005; 
Farazi et al., 2011; Murakami et 
al., 2006; Roldo et al., 2006 
MIR145  Breast Cancer, colorectal cancer ERG Cummins et al., 2006; Iorio et al., 
2005; Michael et al., 2003 
miRNA Let-7 family  Lung cancer, breast cancer, 
haematopoietic malignancies 
RAS family, MYC, 
HMGA2 
Blenkiron et al., 2007; Yanaihara 
et al., 2006; 
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MicroRNAs have been used in cancer diagnosis through the following 
approaches: Profiling of tumours based on differential expression of miRNAs can be 
used to identify tissue of origin in cancers of unknown primary site, to identify 
tumour subtype and/or predict prognosis (Calin & Croce, 2006; J. Lu et al., 2005; 
Paranjape, Slack, & Weidhaas, 2009; Baohong Zhang, Pan, et al., 2007). Profiling of 
circulating blood or tumour derived exosomal miRNAs has also been studied for 
their potential use as a non-invasive method for early detection of cancer (X. Chen et 
al., 2008; Heneghan et al., 2010; Kosaka, Iguchi, & Ochiya, 2010; Mitchell et al., 
2008; Roth et al., 2010; W. Zhu, Qin, Atasoy, & Sauter, 2009).  
 
It has been recognised that changes in miRNA synthesis and expression in 
relation to cancer could occur through many different mechanisms and some of these 
include: point mutations in miRNA and mRNA sequences, epigenetic changes like 
mRNA gene methylation, loss or mutation in the promoter regions for specific 
miRNA clusters and alterations in pathway related RNA binding protein (RBP) 
(Thalia A. Farazi et al., 2011; H.-C. Lee et al., 2011; Lynam-Lennon et al., 2009; 
Ryan, Robles, & Harris, 2010; G. Sun et al., 2009; Westholm & Lai, 2011). 
Therefore, the study of single nucleotide polymorphisms (SNPs) in miRNA 
sequences has emerged as an approach to investigate cancer predisposition, as well 
as explain changes in miRNA biogenesis and function (Paranjape et al., 2009; G. Sun 
et al., 2009). 
 
1899 SNPs in 961 pre-miRNAs, 601 miR-SNPs in 470 miRNA mature 
sequences and 203 miR-SNPs located in the seed region of 170 mature miRNAs 
were identified in 2013 by Han et al (M. Han & Zheng, 2013)  in  a genome-wide 
scan analysis of the SNPs contained in the NCBI dbSNP database (build 137 for 
humans) (Smigielski, Sirotkin, Ward, & Sherry, 2000) and the genomic locations and 
sequences of pre-miRNAs and mature miRNAs from the miRBase (release 18.0, 
November 2011) (Kozomara & Griffiths-Jones, 2011). This highlights miRNA SNPs 
(miR-SNPs) as the most common type of genetic variation in miRNA sequences and 
neighbouring regions and they have been determined to alter miRNA biogenesis and 
processing (R. Duan, Pak, & Jin, 2007; Gottwein, Cai, & Cullen, 2006; Ryan et al., 
2010; G. Sun et al., 2009), which could have an effect on numerous targets and 
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 diverse functional consequences. Therefore miR-SNPs may be ideal candidate 
biomarkers to use in early diagnosis of cancer, to determine prognosis and to predict 
outcome in cancer patients, and this hypothesis has obtained significant support from 
a number of studies in different types of cancer. Some of the most relevant miR-SNP 
studies in various types of cancer will be the focus of subsection 2.6.2 since similar 
studies in relation to breast cancer will be discussed further in subsection 2.6.3 of this 
review.  
 
In 2008, a miR-SNP in MIR196A2 (rs11614913) which is present in the mature 
sequence was found to increase processing of the mature miRNA and be associated 
with significantly decreased survival in patients with non-small cell lung cancer (Z. 
Hu et al., 2008). rs2910164 present in the precursor sequence of MIR146A was found 
to reduce the amount of both pre- and mature MIR146A and it was also shown to 
affect the Drosha/DGCR8 processing step (Z. Hu et al., 2009; Jazdzewski et al., 
2008; Shen et al., 2008). Hu et al also showed that rs11614913 (MIR196A2), 
rs2910164 (MIR146A), rs2292832 (MIR149) and rs3746444 (MIR499A) were 
associated with increased breast cancer risk in Chinese women (Z. Hu et al., 2009). 
Similarly, two separate studies showed rs2910164 to be associated with papillary 
thyroid carcinoma (Jazdzewski et al., 2008) and hepatocellular carcinoma (T. Xu et 
al., 2008). Ye et al showed that rs6505162 located in the precursor of MIR423 to be 
significantly associated with oesophageal cancer risk (Ye et al., 2008). All of the 
previously mentioned studies show that the effects of miR-SNPs can be modulated in 
a cell type-specific manner, implying that not all functional miR-SNPs affect cancer 
risk globally. However, there are still a few issues to overcome in regards to miR-
SNP studies in relation to cancer and they include the following: Minor allele 
frequencies of many identified miR-SNPs are still unknown, pointing to the need to 
conduct population studies to determine whether these are polymorphic in specific 
populations; most studies focus on the analysis of pre and mature regions of miRNAs 
because further clarification of the extent of the pri region is still required for many 
miRNAs to determine the true extent of miRNA-related genetic variation; 
identification of tag SNPs for miRNA-related SNPs will be useful to identify miR-
SNPs which are in linkage disequilibrium and therefore inherited together; and 
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finally the inclusion of more miR-SNPs in genome wide association studies (GWAS) 
to identify low penetrance susceptibility mutations. 
 
2.6.3 MicroRNAs and breast cancer 
 
In an effort to understand the role of miRNAs in breast cancer, they have been 
studied using microRNA expression evaluation in different breast cancer cell lines 
and normal and breast cancer tissue samples. This approach is potentially valuable as 
miRNAs could be used as a diagnostic tool for prediction of breast cancer 
development and tumour profiling, as therapeutic targets for cancer treatment and as 
prognostic markers to predict metastasis and to evaluate treatment response and 
patient survival (Paranjape et al., 2009). 
 
In 2005, Iorio et al examined expression of 246 miRNA using 76 breast tumour 
samples and they identified 29 miRNAs that showed significantly different levels of 
expression in cancer samples versus normal breast tissue (Iorio et al., 2005). They 
identified 5 miRNAs to be the most consistently deregulated across all tumour 
samples: MIR10B, MIR125B1 and MIR145 were significantly down-regulated and 
MIR21 and MIR155 were significantly up-regulated, suggesting their role as tumour 
suppressor genes or oncogenes, respectively. However they failed to identify 
miRNAs that were differentially expressed between tumour subtypes. A following 
study conducted by Mattie et al in 2006 was able to distinguish HER2+/ER- and 
HER-/ER+ breast cancer using profiling of 204 miRNAs in 20 tumour samples. This 
study also identified a subset of miRNAs specific to HER2+ tumours (MIRLET7F1, 
MIRLET7G, MIR107, MIR10B, MIR126, MIR154 and MIR195) and to ER+/PR+ 
tumours (MIR142 5p, MIR200A, MIR205 and MIR25) (Mattie et al., 2006).  
 
A further study conducted by Blenkiron et al using a bead-based flow 
cytometric platform showed that miRNAs are differentially expressed between 
molecular subtypes of breast cancer (Luminal A, Luminal B, Basal-like and HER2 
positive), previously described in section 2.5.1.2 on molecular classification of breast 
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 cancer (Blenkiron et al., 2007). Blenkiron et al also evidenced changes in miRNA 
biosynthesis in 93 frozen breast cancer tumour samples due to changes in gene 
expression of post-transcriptional mediators. Basal-like, HER2 positive and luminal 
B type tumours showed down regulation of DICER1 expression and a higher 
expression of AGO2. Oestrogen receptor (ER) status was also found to be associated 
with gene expression changes and ER negative tumours showed AGO2 and DROSHA 
to be up regulated and DICER1 to have lower levels of gene expression (Blenkiron et 
al., 2007).  
 
Sempere et al found that altered microRNA expression corresponded to 
particular epithelial cell subpopulation using microarray analysis, northern blot and 
in-situ hybridization (ISH) with archived formalin-fixed paraffin-embedded breast 
cancer tissue samples breast cancer. They found MIR145 and MIR205 to be restricted 
to the myoepithelial/basal cell compartment of normal ducts and lobules and their 
expression was significantly down-regulated in tumour breast samples. On the other 
hand MIR21 was found to be present in luminal epithelial cells in normal breast 
tissue and its expression significantly increased in breast cancer samples compared to 
normal tissue (Sempere et al., 2007). 
 
Lowery et al validated three different miRNA cluster signatures to be 
predictive of oestrogen receptor (ER) (MIR342, MIR299, MIR217, MIR190, 
MIR135B and MIR218), progesterone receptor (PR) (MIR520G, MIR377, 
MIR518A1, MIR520F and MIR520C) and HER2/neu receptor (MIR520D, MIR181C, 
MIR302C, MIR376B and MIR30E) status in breast cancer using artificial neural 
network algorithms, miRNA microarray and quantitative PCR (qPCR) (Lowery et 
al., 2009).  There is room for debate in regards to some of the findings for some of 
the miRNA signatures previously mentioned. For instance, Blenkiron et al showed 
MIR342 to be downregulated in Basal-like and HER2 positive type tumours 
(Blenkiron et al., 2007). There is also some contradicting evidence in relation to 
HER2 positive tumours; since the cluster microRNA signature developed and 
validated by Lowery et al found MIR342 expression to be higher in ER positive, 
HER2/neu positive and luminal B type tumours and lowest in Basal-like tumours 
(Lowery et al., 2009). Finally, Buffa et al (Buffa et al., 2011) found that high levels 
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of expression of MIR342 were associated with good prognosis in ER negative 
tumours. Target genes for MIR342 include RRM2, PGM2L1 and TLE1, which could 
be potential therapeutic targets for breast cancer. Some of the differences in the 
results of these studies could be the result of differences in methods of collection, 
preservation and storage of primary tumours used, resulting in RNA degradation and 
distortion of qPCR results. There are also differences in the experimental methods 
used and statistical analysis of results which could lead to the inconsistencies in 
findings. 
 
We will discuss some of the miRNAs most commonly identified to have a role 
in breast cancer development before we move on to discuss findings in relation to 
miR-SNPs and breast cancer. These miRNAs are summarised in Table 2-8 along 
with some of their gene targets. 
 
As mentioned before, MicroRNA-10b (MIR10B) has been described as an 
oncogene and it was initially identified in the work conducted by Iorio et al (Iorio et 
al., 2005). They found MIR10B to be down-regulated across tumour samples but 
further studies showed different findings. Studies by Mattie et al (Mattie et al., 2006) 
and Liu et al (Y. Liu et al., 2012) showed MIR10B to be significantly up-regulated 
particularly in metastatic breast cancer. Differences in the results found could be the 
result of the primary sample used and methodological approach. Studies conducted 
by Iorio et al and Mattie et al both used cryopreserved tumour samples, while Liu et 
al used freshly isolated tumour tissue. Moreover, there were significant differences in 
their methods because not every study considered important features such as tumour 
size, ERBB2 status, ER/PR positivity, tumour staging and grading and lymph node 
metastasis in their analysis. Target genes for MIR10B include FLT1, BDNF, 
HOXD10, CDH1 and TGFB1 (X. Han et al., 2014; Y. Liu et al., 2012; Mattie et al., 
2006). 
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Table 2-8 Summary of the most significantly associated microRNAs in breast cancer and their target 
genes 
MiRNA PREDICTED TARGET GENES AUTHOR 
MIR10B FLT1 
BDNF 
HOXD10 
CDH1 
TGFB1 
Iorio et al., 2005  
Volinia et al., 2006  
Blenkiron et al., 2007 
Ma et al.,  2007 
Liu et al., 2012 
MIR17HG NCOA3 
E2F1 
MYC 
RB1 
CCND1 
O’Donnell et al., 2005 
Hossain et al., 2006 
Yu et al., 2008 
Leivonen et al., 2009 
Mogilyansky et al., 2013 
MIR125A - MIR125B ERBB2 
ERBB3 
YES1 
Iorio et al., 2005) 
Volinia et al., 2006 
ETS1 
AKT3 
FGFR2 
MAP3K10 
MAP3K11 
MAPK14 
MIR145 MYCN Iorio et al., 2005 
Volinia et al., 2006 
Blenkiron et al., 2007 
Sempere et al., 2007 
FOS 
CCND2 
MAP3K3 
MAP4K4 
MIR155 SOCS1 
TP53INP1 
VHL 
APC 
WEE1 
RAB6A 
RAB6C 
Iorio et al., 2005  
Volinia et al., 2006  
Blenkiron et al., 2007 
Jiang et al., 2010 
Zhang et al., 2013 
Kong et al., 2014 
MIR21 Caspase protease family Iorio et al., 2005  
Volinia et al., 2006 
Si et al., 2007 
Zhu et al., 2007 
 
TPM1 
PDCD4 
PTEN 
BCL2 
TGFB1 
RAB6A 
RAB6C 
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As was mentioned in subsection 2.6.2 of this review the microRNA 17-92 
cluster host gene (MIR17HG) has been associated with different types of cancer 
including lymphomas, lung cancer, colon cancer, gastric cancer and pancreatic 
cancer. MIR17HG was the first miRNA cluster to be identified in relation to cancer 
and subsequently named oncomir-1 (L. He et al., 2005; Ota et al., 2004). It has been 
found to inhibit tumour growth in breast cancer cell lines and it targets cell cycle 
regulators including NCOA3, E2F1, MYC, RB1 and CCND1(Hossain, Kuo, & 
Saunders, 2006; Leivonen et al., 2009; Z. Yu et al., 2008) .  
 
He et al demonstrated increased expression of MIR17HG in B cell lymphomas 
in cell lines and tumour samples they also found this cluster gene to promote 
accelerated tumour development in a murine model. (L. He et al., 2005) and it has 
also been implicated to play a role in different types of cancer including lung cancer, 
breast cancer, colon cancer gastric cancer and pancreatic cancer (Hayashita et al., 
2005; Mendell, 2008; Mogilyansky & Rigoutsos, 2013; Volinia et al., 2006) 
 
Mattie et al found microRNA-125a (MIR125A) and miRNA-125b (MIR125B) 
to be downregulated in in HER2+ breast cancer. Both miRNAs are considered to be 
tumour suppressor genes and they target important genes including ERBB2 (HER2), 
ERBB3 (HER3) and FGFR2 (Scott et al., 2007).Overexpression of ERBB2 is also 
associated with poor prognosis for breast cancer patients (Ross & Fletcher, 1998). 
 
MIR145 has been previously reported to play a role in cancer biogenesis and 
progression for other types of cancer (Arndt et al., 2009; Chiyomaru et al., 2010; Cho 
et al., 2009, 2011; Kano et al., 2010; Michael et al., 2003). As previously mentioned, 
it has also been found to have a tumour suppressor role in breast tissue particularly in 
the myoepithelial/basal cell compartment and it is found to be downregulated in 
breast cancer tissue samples (Iorio et al., 2005; Sempere et al., 2007; Volinia et al., 
2006). Research using breast cancer cell lines showed it regulates some important 
genes involved in modulation of apoptosis, shown in Table 2-8 (Spizzo et al., 2010; 
S. Wang et al., 2009). In vitro studies by Michael et al using MCF-7 and T47-D cell 
lines showed down regulation of MIR145 (Michael et al., 2003).  Finally studies 
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 conducted by Goette et al (Goette et al., 2010) and Radojicic et al (Radojicic et al., 
2011) showed down-regulation of MIR145 to be associated with a more aggressive 
behaviour of breast cancer based on results performed in both breast cancer cell line 
and tissue samples. 
 
miRNA-155 (MIR155) has been determined to be upregulated in breast cancer 
according to studies previously mentioned (Iorio et al., 2005; Volinia et al., 2006). It 
is considered to be an oncogene because it has been shown to target tumour 
suppressor genes including SOCS1, TP53INP1 and VHL according to studies 
performed both in breast cancer cell lines and tumour tissue samples. It has also been 
associated with poor prognosis in patients with triple negative breast cancer (Czyzyk-
Krzeska & Zhang, 2014; Jiang et al., 2010; Kong et al., 2014; C.-M. Zhang, Zhao, & 
Deng, 2013) 
 
miRNA-21 (MIR21) has been found to be consistently up-regulated in different 
types of cancer (Chan et al., 2005; Y. Hu et al., 2011; Tetzlaff et al., 2007; Volinia et 
al., 2006). In 2005 Iorio et al identified MIR21 to be up-regulated in breast cancer 
tumour samples as well (Iorio et al., 2005). As previously mentioned, Sempere et al 
found it to be expressed in luminal epithelial cells and to be further increased in 
malignant tissue when compared to normal samples (Sempere et al., 2007) and 
Radojicic et al found it to be overexpressed in triple negative tumours (Radojicic et 
al., 2011). Moreover, overexpression of MIR21 has been associated with metastasis 
and poor prognosis for breast cancer sufferers (Yan et al., 2008). Using cell culture 
and a xenograft carcinoma mouse model, Si et al identified that knock-down of 
MIR21 resulted in increased apoptosis and reduced tumour proliferation (Si et al., 
2007). This group established that the oncogenic role of MIR21 was the result of the 
inhibition of a tumour suppressor gene (TPM1) (S. Zhu, Si, Wu, & Mo, 2007). Other 
studies have identified additional targets of MIR21 in breast cancer including 
PDCD4, Caspase protease family, BCL2 and PTEN amongst others (Thalia A. Farazi 
et al., 2011; Frankel et al., 2008; Robbins et al., 2010; Z. X. Wang, Lu, Wang, 
Cheng, & Yin, 2011; Wen et al., 2007).  
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Other miRNA findings in relation to breast cancer include the following: 
MIR222 host gene (MIR222HG) targets CDK inhibitor to regulate cell cycle both in 
breast cancer MCF-7 cell line and HER2/neu positive breast tumours and it is also 
associated with Tamoxifen resistance (Thalia A. Farazi et al., 2011; Negrini & Calin, 
2008; Robbins et al., 2010; Zuoren Yu et al., 2010); epigenetic modification such as 
inactivation of expression by methylation of MIR9-1, MIR124-2HG, MIR148, 
MIR152 and MIR663 has been described in breast cancer (Lehmann et al., 2008) and 
copy number alteration of miRNA genes has also been evidenced in breast cancer 
using array-based comparative genomic hybridization (L. Zhang et al., 2006). Other 
miRNAs have been associated with metastasis including the microRNA let-7 family, 
MIR10B, MIR9-1 and MIR31. On the other hand MIR335, MIR206 and MIR126 have 
been implicated to have a role as breast cancer metastasis suppressor miRNAs 
(Thalia A. Farazi et al., 2011; Negrini & Calin, 2008; Robbins et al., 2010; Zuoren 
Yu et al., 2010). 
 
MicroRNAs mentioned in this literature review have been evaluated in 
different studies using breast cancer cell lines and breast cancer tissue samples, 
however recent studies have been conducted to try to measure microRNA expression 
in blood products. Evaluation of circulating microRNAs in breast cancer patients 
could be used for early diagnosis, follow up and to characterise novel miRNAs. 
MicroRNAs are remarkably stable molecules and therefore it was hypothesised that 
they should be present in the circulation of cancer patients. Heneghan et al 
investigated whether cancer specific miRNAs (MIR10B, MIR16, MIR21, MIR145, 
MIR155, MIR195 and MIRLET7A1) were detectable and expression was altered in 
serum, plasma or whole blood obtained from cancer patients in comparison to age-
matched controls. They identified whole blood as the best source of circulating 
miRNAs and using quantitative PCR (qPCR) they also showed changes in miRNA 
expression for MIR195 and MIRLET7A1 when comparing cancer patients to controls 
and also when miRNA expression was measured before and after surgical treatment 
(Heneghan et al., 2010). However, Roth et al (Roth et al., 2010) showed contrasting 
results when they evaluated levels of MIR10B, miR34A, MIR141 and MIR155 in 
blood serum of post-operative breast cancer patients and in breast cancer cell lines. 
Using blood serum, they found MIR155 in breast cancer patients with no metastasis 
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 and MIR-10B, MIR34A and MIR155 in patients with metastatic breast cancer were 
significantly higher than healthy controls. Therefore differences in results obtained 
for both studies using similar miRNA panels, need to be addressed, primarily by 
evaluating these circulating microRNAs using bigger and more thoroughly 
characterised cohorts.  
 
Using a different approach, Wu et al (Q. Wu et al., 2011) performed next-
generation sequencing of microRNAs, comparing breast tissue samples and normal 
breast tissue and validated the top five miRNAs found to be altered more than 
fivefold using RT- PCR in serum samples from breast cancer patients and controls. 
This study found significantly elevated levels of MIR21 and MIR29A in breast cancer 
patients compared to controls, which could be used as early non-invasive markers for 
the detection of breast cancer, a finding that requires further validation in a bigger 
sample population and correlation with clinical features if it is to translate to clinical 
practice (Budhu, Ji, & Wang, 2010; Heneghan et al., 2010; Roth et al., 2010; Q. Wu 
et al., 2011). 
 
2.6.4 MicroRNA SNPs (miR-SNPs) and breast cancer 
 
Scientific literature addressing SNPs in microRNA genes in relation to breast 
cancer is scarce but it seems to be increasing as it has been recognised that point 
mutations in miRNA sequences can affect their synthesis and expression (Gong et 
al., 2012; H.-C. Lee et al., 2011; Mishra et al., 2008). 
 
A SNP located in the terminal loop of the precursor of MIR27A, rs895819, has 
been associated with gastric cancer and colorectal cancer. However findings for this 
polymorphism in relation to breast cancer remain controversial. Initially, rs895819 
was found to reduce risk of developing breast cancer in German families with a 
history of non-BRCA related breast cancer (1217 patients versus 1422 controls) 
(Rongxi Yang et al., 2010), as well as in individuals from Jewish families with 
mutant BRCA2 (58 patients vs 48 control) (Kontorovich, Levy, Korostishevsky, Nir, 
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& Friedman, 2010). However two studies by Zhang et al, conducted on Chinese 
women (252 patients versus 248 controls) (M. Zhang et al., 2012); and Catucci et al, 
conducted on Italian women with non-BRCA related familial breast cancer (1205 
cases versus 1593 controls)  (Catucci et al., 2012), failed to replicate these findings. 
It was argued that the genotyping results using the TaqMan Assay obtained by 
Catucci et al (Catucci et al., 2012) were affected and biased by a nearby SNP 
(rs11671784) (R. Yang & Burwinkel, 2012). To make matters worse, a recent study 
by Zhang et al conducted in Chinese women (264 patients versus 255 controls) 
identified an association between rs895819 and reduced sporadic breast cancer risk 
(N. Zhang et al., 2013) contradicting the result previously found in a similar 
population (M. Zhang et al., 2012). Most recently, Zhong et al conducted a meta-
analysis of the published studies for rs895819 in an effort to clarify the conflicting 
results in relation to cancer risk. As a result, they were able to identify the G allele in 
rs895819 to be associated with decreased risk in breast cancer cases and in the 
Caucasian population (Zhong, Chen, Xu, Li, & Zhao, 2013). 
 
In 2009 Kontorovich et al identified the AA genotype of rs560516, present in 
MIR423 to reduce the risk of developing both ovarian and breast cancer in 
individuals from Jewish families with mutant BRCA2 (Kontorovich et al., 2010). On 
the other hand, a study conducted by Smith et al in 2012 showed that the presence of 
the CC genotype for the same miR-SNP was significantly associated with reduced 
risk of sporadic breast cancer development in Australian Caucasian individuals (R. 
A. Smith et al., 2012).  It is argued that this contrasting result may be due to the 
difference in ethnicities for the population examined as well as the type of cancer 
(familial versus sporadic). It may also be due to the effect this miR-SNP has on 
expression or processing of the mature sequence of the microRNA or how it interacts 
with BRCA2 mutations.   
 
The microRNA SNP rs2910164 present in MIR146A constitutes another 
example of conflicting results in breast cancer susceptibility studies for miR-SNPs. 
Shen et al initially reported that the presence of this polymorphism was associated 
with a younger age of diagnosis in 2008. This study, conducted in the United States, 
included patients with familial breast cancer with different ethnic backgrounds (35 
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 Caucasian, 4 African American and 3 unknown) and they determined the C allele to 
significantly lower the age of diagnosis in breast cancer patients, as well as increase 
the levels of expression for the mature MIR146A (Shen et al., 2008). However a 
similar study that year conducted on Chinese individuals (1009 cases versus 1093 
controls) failed to find association with age of diagnosis or risk of breast cancer 
development (Z. Hu et al., 2009). In 2010 Pastrello et al conducted a similar study in 
Italian patients diagnosed with non-BRCA related familial breast cancer  (348 cases 
versus 148 controls) and they found the presence of the C allele to be associated with 
a younger age of diagnosis (Pastrello, Polesel, Della Puppa, Viel, & Maestro, 2010). 
These results confirmed those found by Shen et al (Shen et al., 2008) and 
contradicted the results of Hu et al (Z. Hu et al., 2009) and this may be explained by 
the difference in the ethnicity of the populations examined, attributable to genetic or 
environmental factors differing between them. On the other hand, Catucci et al 
conducted a similar study for rs2910164 in German and Italian individuals with non-
BRCA related familial breast cancer (1894 versus 2760) and they found no 
association to breast cancer risk or age of onset (Catucci et al., 2010). Also on the 
previous year, a study by Hoffman et al conducted in the United States failed to 
identify association between rs2910164 and sporadic breast cancer. It is worth noting 
that this study included patients with different ethnic backgrounds (about 9% of 
patients were African American or other mixed ethnicities) and also about 20% of 
individuals in both cases and controls had familial history of breast cancer (1st degree 
relative), which may have introduced bias to the study results (Hoffman et al., 2009).  
Garcia et al conducted a genotyping study on French individuals with familial 
history of breast cancer and either BRCA1 or BRCA2 mutations both in cases and 
controls (1130 individuals and 596 individuals respectively). Results from this study 
did not show an association between breast cancer risk and rs2910164 (Amandine I. 
Garcia et al., 2011). A meta-analysis was conducted in 2011 by Gao et al to try to 
clarify the conflicting results obtained for rs2910164 to date in relation to breast 
cancer. Results of this meta-analysis showed no association between this miR-SNP 
and breast cancer risk, however it is to be noted that the studies included in the 
analysis contained a mixture of different ethnic backgrounds (Caucasians, African 
Americans, unknown ethnicities and Chinese) and this was not considered as part of 
the analysis, raising potential questions about its utility (Gao et al., 2011). Three 
studies were conducted in 2012 in relation to rs2910164 and breast cancer and they 
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included two case control genotype association analyses and one meta-analysis. 
Alshatwi et al performed a genotyping analysis in Saudi-Arabian patients with 
sporadic breast cancer (100 cases vs 100 controls) and they showed no association 
between the presence of mutation to breast cancer risk (Alshatwi et al., 2012).  
Similarly, Esteban Cardeñosa et al showed no association between rs2910164 and 
breast cancer risk, for both sporadic and familial types, or any association with age of 
onset in their study conducted on a Spanish Caucasian population (538 cases versus 
189 controls) (Esteban Cardenosa et al., 2012). However, a meta-analysis by Lian et 
al published that year showed significant association between the CC genotype of 
rs2910164 and breast cancer risk only in European Caucasians (Lian, Wang, & 
Zhang, 2012). Interestingly, a very similar meta-analysis by Wang et al, which 
included most of the studies analysed by Lian et al (Lian et al., 2012), reported no 
association between rs2910164 and breast cancer risk (P. Y. Wang et al., 2013). 
Finally, a recent study by Bansai et al conducted in 121 patients with sporadic breast 
cancer and 164 controls from a North-Indian population identified that the presence 
of the C allele significantly decreased the risk of developing breast cancer (Bansal et 
al., 2014).  
 
Conflicting results obtained for rs2910164 may be due to the variations in the 
studies in terms of ethnicity of participants and type of cancer that were evaluated, as 
well as the statistical approach to analyse the results. It is also worth noting that only 
one study evaluated risk of familial breast cancer in a Caucasian population (Catucci 
et al., 2010) and there is no replication of these results, since the following studies 
for sporadic breast cancer were not performed in a purely Caucasian populations. To 
the best of our knowledge there is no evidence in the literature about the association 
of this miR-SNP with risk of sporadic breast cancer in a purely Caucasian 
population. Therefore, more research for this miR-SNP is required using well-
characterised cohorts to determine whether there is an association with risk of 
developing breast cancer.   
  
Another example of conflicting evidence in terms of association analysis with 
breast cancer risk is seen in the results of the studies conducted for rs11614913 
present in MIR196A2. A study previously mentioned, conducted by Hu et al on 
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 Chinese women identified significant association between presence of mutation in 
rs11614913 and a higher risk of developing breast cancer (Z. Hu et al., 2009). On the 
other hand, Hoffman et al showed that the presence of mutation in rs11614913 
significantly decreased risk of breast cancer, a fact that was corroborated by both 
their methylation assay of a CpG island upstream from the precursor of MIR196A2 
and their functional validation in vitro using the MCF-7 breast cancer cell line 
(Hoffman et al., 2009).  However in 2010, Catucci et al failed to identify an 
association between rs11614913 and breast cancer risk or age of onset (Catucci et al., 
2010). A meta-analysis conducted by Gao et al showed the CC genotype of 
rs11614913 to be associated with an increased breast cancer risk (Gao et al., 2011), 
which contradicted the results obtained by Hoffman et al (Hoffman et al., 2009). In 
211, a study performed by Jedlinski et al in an Australian Caucasian sporadic breast 
cancer cohort (193 cases versus 190 controls) showed no association to breast cancer 
risk (Jedlinski, Gabrovska, Weinstein, Smith, & Griffiths, 2011). Linhares et al 
showed that the presence of the CC allele significantly decreased the risk of breast 
cancer in their study conducted in Brazilian women (388 cases and 388 controls) 
(Linhares et al., 2012). Zhang et al found a marginally significant association 
between the presence of mutation in rs11614913 and decreased risk of breast cancer 
in their study in a Chinese cohort (252 cases versus 248 controls) (M. Zhang et al., 
2012). A previously mentioned meta-analysis conducted by Wang et al showed 
significant association between CC genotype of rs11614913 and increased breast 
cancer risk (P. Y. Wang et al., 2013). A study by Bansal et al, previously mentioned, 
conducted in a North Indian population showed no association between mutation at 
this loci and breast cancer risk (Bansal et al., 2014). Looking at patient outcomes 
instead of risk, a recent study conducted in a Korean population by Lee et al 
identified the presence of mutation in rs11614913 to be significantly associated with 
poor prognosis for patients with sporadic breast cancer, which implicates some role 
for the polymorphism in breast cancer aetiology (S. J. Lee et al., 2014). Despite the 
conflicting evidence presented in here, it is more likely that rs11619913 is not 
associated with sporadic breast cancer risk in Caucasian individuals, since it is a 
common finding for the only two studies that evaluated this miR-SNP in purely 
Caucasian breast cancer cohorts (Catucci et al., 2010; Jedlinski et al., 2011). 
However further studies in larger cohorts may be required to ascertain this finding 
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and determine whether the role in patient outcome identified by Lee et al can be 
replicated.  
 
Finally rs3746444 present in MIR499 has been associated with increased breast 
cancer risk in Asian populations according to the results obtained in the studies 
conducted by Hu et al (Z. Hu et al., 2009) and Chen et al (P. Chen, Zhang, & Zhou, 
2012). However studies performed in populations of other ethnicities have failed to 
replicate this finding (Bansal et al., 2014; Catucci et al., 2010; P. Y. Wang et al., 
2013), which may suggest that the effects of this miR-SNP are specific to certain 
ethnicities or affected by environmental factors. 
 
2.7 SUMMARY AND IMPLICATIONS 
 
Breast cancer represents a significant burden of disease, in particular to the 
Australian population. Both incidence and mortality rates are increasing despite our 
current knowledge on the disease (AIHW, 2009, 2012).  
 
It is a complex disease caused by the interplay between our genetic 
susceptibility and a number other risk factors (Martin & Weber, 2000; Robbins et al., 
2010). Single gene mutations associated with the most commonly found types of 
familial breast cancer have already been identified, but they only account to about 
10% of all cases and even in familial cancer, not all mutations have been identified 
(Robbins et al., 2010; Strachan & Read, 2011; Weinberg, 2007). We still lack 
knowledge about the genetics mechanisms involved in development of the sporadic 
forms of the disease. Complicated gene networks interacting with the environment 
may be at play in the aetiology of the disease and we need to identify mediators with 
an important role in the pathophysiology of breast cancer. MicroRNA genes have 
been identified to regulate a large number of genes involved in molecular pathways 
important for cancer development. Therefore, a deeper understanding of these genes 
is required to develop diagnostic or therapeutic strategies that will allow earlier 
detection or will have a big impact for breast cancer sufferers in their prognosis. 
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Deregulation of microRNA genes has been identified as a feature present in 
most types of cancer, in particular breast cancer. However, we still lack detailed 
knowledge of the mechanisms that result in the miRNA expression patterns seen in 
relation to breast cancer. It has been proposed that changes in the sequence of 
miRNA genes might have an impact on their biogenesis and function in relation to 
cancer and functional sequence variants have been identified. Single nucleotide 
polymorphisms (SNPs) are the most common type of variation identified in miRNA 
sequences and they are very likely to be key players in the development of cancer. A 
large number of miR-SNPs have been identified to date and only a few have been 
associated with breast cancer. Moreover, there is conflicting evidence for some of the 
miR-SNPs that have been previously studied in relation to breast cancer.  Further 
studies to validate those in larger cohorts are needed, as well as studies to address a 
large number of miR-SNPs not previously analysed, in order to successfully identify 
those variants significantly associated with breast cancer.  
 
One of the many problems that research studies face today in relation to 
validating polymorphisms in miRNA genes; is the availability of large and well 
characterized cohorts and the resources to recruit them. Additionally, genomic DNA 
of good quality is essential to perform genotyping association studies that will 
successfully identify miRNA variants. Therefore, it is important to use a DNA 
extraction method that is cost-effective and time efficient and that will result in 
optimal DNA yield. It is even more important when we have to deal with a large 
number of samples in order to be quick and effective in the establishment of the 
study population. 
 
 Careful selection of the miRNA variants to investigate in relation to breast 
cancer is another key step. It requires careful assessment of the validity of previous 
reports for miRNA genes and their selected variants. It is also important to consider 
their prevalence and the potential impact they may have in the target study 
population. Selection of an efficient and reliable genotyping technique is also 
fundamental to obtain valid results. 
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 Therefore our study aimed to establish a new prospective large cohort of DNA 
samples obtained from Cancer patients recruited in Queensland in collaboration with 
the Queensland Cancer Council that would serve as a replication population to our 
previously established case control population. To validate any positive association 
result it is important to test for association in a second independent case-control 
population. Hence the establishment of a large second independent cohort was a 
primary aim of this research. We also developed a selection process for miR-SNPs to 
validate in both our Australian Caucasian case control cohorts to identify variants 
that could be further analysed in order to determine their role in breast cancer 
development.
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3.1 STUDY POPULATIONS 
 
3.1.1 Genomics Research Centre Breast Cancer Population (GRC-BC 
population) 
 
The Genomics Research Centre Breast Cancer (GRC-BC) population was 
obtained from two facilities: 244 Caucasian Australian breast cancer patients residing 
in the South East Queensland Region recruited from the Gold Coast Hospital, 
Southport and 187 female individuals matched for age (± 5 years) and ethnicity with 
no history of personal or familial breast cancer collected at the Genomics Research 
Centre Clinic, Southport. All participants supplied informed written consent and 
research was approved by Griffith University’s Human Ethics Committee (Approval: 
MSC/07/08/HREC and PSY/01/11/HREC) and the Queensland University of 
Technology Human Research Ethics Committee (Approval: 1400000104). The mean 
age for cases and controls in the GRC-BC population was 57.52 years and 57 years, 
respectively.  
 
3.1.2 The Griffith University – Cancer Council Queensland Breast Cancer 
Biobank (GU-CCQ BB) 
 
The Griffith University – Cancer Council Queensland Breast Cancer Biobank 
(GU-CCQ BB) was established as a collaboration between the Genomics Research 
Centre and the Cancer Council of Queensland. All women aged 20 to 79 years 
resident in Queensland with a histologically confirmed diagnosis of invasive breast 
cancer between have been notified to the Queensland Cancer Registry since January 
2010 and recruitment will extend throughout the following 5 years. 929 Patients were 
recruited at the Cancer Council Queensland as part of this 5-year population-based 
longitudinal study of women newly diagnosed with breast cancer. Exclusion criteria 
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for this study include women unable to speak or understand English and women with 
cognitive impairment.  
 
All patients provided informed written consent to participate and clinical and 
demographic information was obtained from through the database at the Queensland 
Cancer Registry, computer assisted telephone interview (CATI), self-administered 
questionnaires (SAQ) and the Genomics Research Centre General Questionnaire. 
Data was collected over two main time points: 4 to 6 months post diagnosis (Time 1) 
and 18 months post diagnosis [approximately 12 months after initial interview] 
(Time 2). Patients were also requested to provide a blood sample for molecular and 
genetic marker analysis at Time 1 (4 to 6 months post diagnosis).  
 
Control population comprised 102 healthy female volunteers with no personal 
or familial history of breast cancer matched by age (± 5 years) and ethnicity and it 
was recruited at the Genomics Research Centre Clinic, Southport. Individuals from 
the control population provided written consent to participate and research was 
approved by Griffith University’s Human Ethics Committee (Approval: 
MSC/07/08/HREC and PSY/01/11/HREC) and the Queensland University of 
Technology Human Research Ethics Committee (Approval: 1400000104). Mean 
ages for cases and controls was 60.17 years and 60.20 years respectively. 
 
3.2 CASE - CONTROL ASSOCIATION STUDIES 
 
3.2.1 Genomic DNA Extraction 
 
There are a number of DNA extraction techniques available to perform nucleic 
acid extraction from the blood samples obtained for our case and control population. 
DNA extraction can be performed using laboratory protocols that involve organic 
and non-organic reagents, centrifugation methods and there is also a wide range of 
commercially available kits (J. J. Greene & Rao, 1998; Grimberg et al., 1989; Miller, 
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 Dykes, & Polesky, 1988). We conducted a review of the evidence supporting DNA 
extraction techniques most commonly used at research facilities to determine the 
most suitable protocol for the establishment of the GU-CCQ BB population. Results 
from our literature review are shown in Chapter Five.  As it is further described in 
detail in Chapter Four, we tested 3 different protocols including a commercially 
available kit to determine the most suitable one in terms of cost-effectiveness to use 
for DNA extraction of the samples obtained for the DNA biobank (Chacon-Cortes, 
Haupt, Lea, & Griffiths, 2012). Our study showed the modified salting-out DNA 
extraction method, developed by Nasiri et al (Nasiri, Forouzandeh, Rasaee, & 
Rahbarizadeh, 2005), to have the best performance in terms of cost-effectiveness and 
time-efficiency. This method is very similar to traditional salting out extraction 
protocols, but it replaces proteinase K with laundry detergent instead, as a reagent for 
the lysis and removal of contaminants in DNA isolation, reducing time (no overnight 
incubation) and general costs overall. However, it maintains similar results, in terms 
of quality and quantity of final DNA yield obtained, as the ones observed with 
traditional salting out method and commercially available DNA extraction kit 
(Chacon-Cortes et al., 2012). Therefore, DNA isolation from blood samples from the 
GU-CCQ BB population were performed using the modified salting-out protocol 
initially developed by Nasiri et al (Nasiri et al., 2005), which is further described in 
detail in Appendix A.  
 
Following DNA extraction from blood,  samples were assessed for integrity 
(260/280 nm ratio and absorbance spectrum) and concentration (obtained in ng/µl) 
using the Thermo Scientific NanoDropTM 8000 UV-Vis Spectrophotometer 
(Thermo Fisher Scientific Inc., Wilmington, DE. USA). To ensure consistency of 
DNA sample evaluation, samples were measured in duplicate to check for 
consistency and the average result was kept on record for our sample population 
database.  
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3.2.2  Genotyping Techniques 
 
As previously mentioned, this project aimed to investigate genetic variants 
(miR-SNPs) in microRNA genes identified to play a role in breast cancer biology. 
Therefore, we chose the following genotyping techniques to conduct the case-control 
association studies presented in Chapters Six to Eight: Genotyping using High-
Resolution Melting (HRM) analysis and Multiplex PCR and matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) analysis 
 
3.2.2.1 Genotyping by High Resolution Melting Analysis (HRM) 
 
High resolution melting (HRM) is a genotyping method that involves melting 
curve analysis of real- time PCR by continuously monitoring each cycle. It relies on 
the same principle of real-time PCR where a fluorescent dye, which produces a 
signal only when it is attached to double stranded DNA (dsDNA), is monitored to 
produce a graph that will be specific for homozygotes and heterozygotes from a 
chosen SNP. High level of fluorescence is observed at low temperatures when the 
DNA is still in double stranded form and fluorescence decreases when the 
temperature rises denaturing DNA into single strands.  
 
The highest rate of fluorescence decrease is generally at the melting 
temperature of the DNA sample (Tm). The Tm is defined as the temperature at which 
50% of the DNA sample is double-stranded and 50% is single-stranded. The Tm is 
typically higher for DNA fragments that are longer and/or have a high GC content. 
SNPs or sequence variations are classified into four different classes (I to IV) 
according to the expected shift in Tm. SNPs in class I correspond to base changes C/T 
and G/A, which occur in approximately 64% of the human genome. Class II includes 
C/A and G/T base changes and they occur in about 20% of the human genome. SNPs 
in class I and II generally produce large changes in Tm (> 0.5°C). Class III includes 
SNPs with C/G base changes, which usually produce a small change in Tm (0.2 to 
0.5°C) and they are found in approximately 9% of the human genome. Finally, SNPs 
in class IV are found in 7% of the human genome and they correspond to A/T base 
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 changes producing a very small change in Tm (< 0.2°C). Changes in the binding 
strength of the fluorescent dye to the amplicon are plotted showing the level of 
fluorescence vs. the temperature, generating a melting curve. Melt curves generated 
after High Resolution Melting analysis are normally plotted with fluorescence on the 
Y axis and temperature on the X axis. These are similar to real-time PCR 
amplification plots but with the substitution of temperature for cycle number (Liew 
et al., 2004; Liew, Wittwer, & Voelkerding, 2010; Reed, Kent, & Wittwer, 2007; 
Wittwer, Reed, Gundry, Vandersteen, & Pryor, 2003). 
 
 
Figure 3-1  Example of High Resolution Melt (HRM) curves showing three different 
miR-SNP genotypes. 
HRM curve seen from genotyping experiments for miR-SNP rs2910164 showing 
similar shape for both homozygous genotypes and a distinct curve for heterozygous 
genotype. 
 
A temperature shift along the x-axis in a HRM melt curve is characteristic of 
homozygous allelic variants. In contrast, a change in the shape is indicative of 
heterozygotes and these changes provide clear distinctions between all three potential 
genotypes allowing both automatic and visual calling of genotypes (See Figure 3-1). 
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It is a reliable and fast technique, but it requires careful optimization to be able to 
produce distinctive melting curves shapes for proper identification of the different 
genotypes from the chosen amplicon (Liew et al., 2004; Liew et al., 2010; Reed et 
al., 2007; Wittwer et al., 2003). Specific details of the protocol used for HRM 
genotyping are detailed in the methods section of Chapter 6. 
 
3.2.2.2 Multiplex PCR and matrix-assisted laser desorption/ionisation time-of-
flight mass spectrometry (MALDI-TOF MS) analysis. 
 
Matrix-assisted laser desorption ionisation time-of flight (MALDI-TOF) was 
developed both by Tanaka et al and Karas and Hillenkamp in 1988 and it was 
initially used to study proteins and peptides (Karas & Hillenkamp, 1988; Tanaka et 
al., 1988). MALDI-TOF has also been developed since then to be used in other 
applications including DNA methylation analysis, expression profiling, mutation 
detection and SNP analysis (Buetow et al., 2001; Griffin & Smith, 2000; Gut, 2004; 
Werner et al., 2002). To date MALDI-TOF mass spectrometry (MS) analysis has 
been used successfully in different SNP genotyping studies (Adkins, Strom, 
Jacobson, Seemann, & et al., 2002; Falzoi, Mossa, Congeddu, Saba, & Pani, 2010; 
Hung et al., 2005; Little, Braun, Darnhofer-Demar, & Koster, 1997; Little, Braun, 
O'Donnell, & Koster, 1997; Nakai et al., 2002; Shi, Xiang, Li, & Shen, 2011; 
Stepanov & Trifonova, 2013; Syrmis et al., 2013).  
 
Multiplex PCR and Chip-based SNP genotyping using MALDI-TOF MS 
analysis allows high-throughput genotyping in single tube reactions based on primer 
extension. This technique consists of an initial locus-specific PCR to amplify the 
target region where the SNP is located, followed by an extension reaction where an 
extension primers anneals immediately upstream to the target site. This extension 
reaction contains mass modified dideoxynucleotide terminators with differences 
large enough to be detected by the mass spectrometry detection system. Products are 
then loaded onto a chip coated with a matrix that allows crystallization of the PCR 
product. A laser is fired at the crystals to ionise the molecules and they travel through 
a vacuum tube with an ion detector located at the end.  The software in the detection 
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 system calculates the mass of the fragments based on the time it takes fragments to 
reach the detector and the mass determines the specific genotype of the fragments 
present in each reaction (Gabriel, Ziaugra, & Tabbaa, 2001).  
 
Details of the protocol used for genotyping by multiplex PCR and MALDI-
TOF MS analysis used in our miR-SNP association studies are presented in 
Appendix C. 
 
3.2.2.3 Sanger Sequencing 
 
Sanger sequencing has been widely used since it was initially developed by 
Frederick Sanger and colleagues in 1974 (Sanger, Nicklen, & Coulson, 1977). It was 
used in the human genome project (Lander et al., 2001) and it has been highly 
developed over the past decades. The principle behind it is to generate all possible 
single stranded DNA molecules differing in one nucleotide in length that are 
complementary to a template. It basically starts by annealing an oligonucleotide of 
about 20 bases specific to a sequence of a target gene in the 5’ end of a denatured 
template. Complementary strand is catalysed by DNA polymerase in presence of 
four deoxynucleotide triphosphates (dNTPs), creating molecules that differ in length 
by one nucleotide randomly terminated by the incorporation of a random 
dideoxynucleotide triphosphate (ddNTP). DNA is denatured again and fragments are 
separated, a process that was initially done manually on polyacrylamide gel 
electrophoresis and which is nowadays performed automatically using different 
techniques and equipment including fluorescently tagged chain-terminators, scanning 
of laser induced fluorescence, reading using thermostable polymerases or capillary 
electrophoresis (Gibson & Muse, 2009; Pettersson, Lundeberg, & Ahmadian, 2009; 
L. M. Smith et al., 1986).  
 
Disadvantages of this technique include high costs and limitations to detect 
rare mutations due to analogue nature of the sequence output. New sequencing 
technologies are being developed to address these issues, which involve sequencing-
by-synthesis principle in a parallel format, making them able to detect rare mutations 
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in a more affordable manner, including pyrosequencing (Gibson & Muse, 2009; 
Morozova & Marra, 2008; Pettersson et al., 2009; Strausberg, Levy, & Rogers, 
2008). 
 
Automated DNA Sanger sequencing was used to validate results from 
genotyping techniques or on samples that were not adequately genotyped by any 
other technique. Details of the Sanger sequencing protocol used in our genotyping 
studies are described in Appendix C. 
 
3.2.3 Statistical Analysis 
 
We examined the power of our available 2 populations (GRC-BC and CCQ-
GU BB) for breast cancer association analysis. Power analysis indicated that even if 
any of the analysed polymorphism had a relatively small effect size (w ≥ 0.2) in the 
risk of developing breast cancer, both our populations (GRC-BC and CCQ-GU BB) 
are of sufficient size to have ~80% or greater power to detect an allelic association at 
the 0.05 level. 
 
We determined genotype and allele frequencies for each miRNA SNP in our 
case and control populations. Hardy-Weinberg equilibrium (HWE) was used to 
evaluate deviation between observed and ideal Hardy-Weinberg frequencies.  (Guo 
& Thompson, 1992; Hardy, 1908). HWE states that the frequencies of alleles and 
genotypes in a population always remain constant due to the presence of random 
mating in absence of evolutionary influences. It is represented by the following 
equation: p2 + 2pq + q2 = 1, where p represents proportion of individuals carrying the 
dominant allele (homozygous) and q represents the proportion of individuals 
carrying the recessive allele. We compared our genotyping results to an ideal Hardy-
Weinberg population to identify significant deviation which indicates selection bias, 
population stratification, inbreeding or genotyping error (Guo & Thompson, 1992; 
Hardy, 1908; Wigginton, Cutler, & Abecasis, 2005).   
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 Following this, we evaluated differences in genotype and allele frequencies 
between cases and controls using Chi-square analysis for each independent 
population to determine association with breast cancer. Chi-square analysis (χ
2
) is a 
non-parametric test used to examine the association between two variables at the 
categorical level. It compares observed population values against values for an 
expected population, using the differences between them to determine a p-value. The 
equation of the chi-squared is χ2 = Σ [(O-E)2 / E] where the observed frequency in 
this study was the cancer affected population while the expected frequency was the 
control population (Fisher & Yates, 1963). The α for p-values was set at 0.05 to 
determine statistical significance indicating that the differences observed would not 
happen by chance 95% of the time. Some limitations for Chi-square analysis include 
a large enough sample size so that the minimum expected frequency is five in each 
category and normal distribution of the data. We also calculated odds ratio (OR) and 
a confidence interval (CI) of 95% to assess disease risk (Fisher & Yates, 1963; 
Rosner, 2006).  
 
We used the G*Power statistical package version 3.1.9.2 (Heinrich-Heine-
Universitat Dusseldorf) to determine the power of our study (Faul, Erdfelder, 
Buchner, & Lang, 2009; Faul, Erdfelder, Lang, & Buchner, 2007). All other 
statistical analyses for genotypes and alleles were performed using Plink software 
version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007). 
 
Genetic linkage is an association between genetic polymorphisms which occurs 
when there is non-random association of their alleles as a result of their proximity on 
the same chromosome. Haplotypes comprise of SNPs or genetic variants on the same 
chromosome that are inherited together which have little chance of recombination 
and Linkage disequilibrium (LD) refers to the correlation between neighbouring 
haplotypes descended from single, ancestral chromosomes (Hong & Park, 2012; 
NAP, 2012; Reich et al., 2001). Therefore, where appropriate, we performed linkage 
disequilibrium (LD) and haplotype block association analysis on the combined 
genotyping data using Haploview software version 4.2 (Daly Lab, Broad Institute, 
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Cambridge, MA, USA) (Barrett, Fry, Maller, & Daly, 2005) to determine association 
between haplotypes and disease risk.   
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 ABSTRACT 
 
Genomic DNA obtained from patient whole blood samples is a key element for 
genomic research. Advantages and disadvantages, in terms of time-efficiency, cost-
effectiveness and laboratory requirements, of procedures available to isolate nucleic 
acids need to be considered before choosing any particular method. These 
characteristics have not been fully evaluated for some laboratory techniques, such as 
the salting out method for DNA extraction, which has been excluded from 
comparison in different studies published to date. We compared three different 
protocols (a traditional salting out method, a modified salting out method and a 
commercially available kit method) to determine the most cost-effective and time-
efficient method to extract DNA. We extracted genomic DNA from whole blood 
samples obtained from breast cancer patient volunteers and compared the results of 
the product obtained in terms of quantity (concentration of DNA extracted and DNA 
obtained per ml of blood used) and quality (260/280 ratio and Polymerase Chain 
Reaction product amplification) of the obtained yield. On average, all three methods 
showed no statistically significant differences between the final result, but when we 
accounted for time and cost derived for each method, they showed very significant 
differences. The modified salting out method resulted in a 7 and 2 fold reduction in 
cost compared to the commercial kit and traditional salting out method, respectively 
and reduced time from 3 days to one hour compared to the traditional salting out 
method. This highlights a modified salting out method as a suitable choice to be used 
in laboratories and research centres, particularly when dealing with a large number of 
samples. 
 
4.2 INTRODUCTION 
 
Genomic research studies benefit from the use of large populations. Biobanks 
are becoming more popular and they are being recognized as a useful tool for 
research in the field (Cambon-Thomsen, 2003; Cambon-Thomsen, Ducournau, 
Gourraud, & Pontille, 2003). Whole blood is one of the available sources to obtain 
genomic DNA (gDNA) required for experimental purposes in human science 
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research. After blood samples are collected, DNA extraction is the initial step of 
laboratory procedures required to perform any chosen molecular application. 
Therefore, it is essential to choose the appropriate DNA extraction method to obtain 
high-yield and high-quality genomic DNA from any selected population of samples. 
Technical requirements, time-efficiency and cost-effectiveness of the chosen method 
are among the issues to consider when choosing a particular technique, especially if 
you are dealing with a large number of samples. 
 
DNA extraction techniques have come a long way since they were initially 
described and most of them follow the same basic steps. They include the use of 
organic and non-organic reagents, centrifugation methods (J. J. Greene & Rao, 1998) 
and a variety of commercially available kits. One of these methods is DNA 
extraction by salting out. It was initially described by Miller et al in 1988 (Miller et 
al., 1988) and it is one of the techniques used for DNA isolation in many science 
research facilities. In order to purify genomic DNA, laboratory protocols may require 
the use of organic solvents such as phenol, chloroform and isoamyl alcohol or 
enzymes such as proteinase K (Grimberg et al., 1989).  As a result such protocols can 
be expensive and time-consuming and they require the use of toxic materials. In an 
effort to modify the methods used to isolate DNA, variations to the initially describe 
techniques have been tested. In 2005, Nasiri et al described a different approach to 
the traditional salting-out method, in which they did not require the use of toxic 
reagents or long digestions with proteinase K to purify DNA. Instead of those, they 
used a common, easily available laundry detergent in the process and the protocol 
was optimized to obtain high-quality and high-yield genomic DNA (Nasiri et al., 
2005). Their research study showed the modified protocol to be a fast, safe and 
efficient technique. It has been used as a protocol for DNA extraction in different 
research facilities around the world (Garcia-Sepulveda, Carrillo-Acuña, Guerra-
Palomares, & Barriga-Moreno, 2010; Iri-Sofla, Rahbarizadeh, Ahmadvand, & 
Rasaee, 2011; B. Liu et al., 2010; Trejo-de la O et al., 2008; Y. Wu et al., 2011; Y. 
Zhang et al., 2009) and it has shown to be a suitable method. However, there is 
limited evidence attesting to its advantages in important characteristics like cost-
effectiveness, time efficiency and technical requirements when compared to other 
available methods. There are a number of studies which have evaluated different 
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 DNA extraction techniques using whole blood samples (Abd El-Aal, Abd Elghany, 
Mohamadin, & El- Badry, 2010; Di Pietro, Ortenzi, Tilio, Concetti, & Napolioni, 
2011), but they excluded the salting out method and modified salting out from their 
comparisons. In order to assess the modified salting-out protocol described by Nasiri 
et al (Nasiri et al., 2005), we compared it against a traditional salting out method and 
against an established kit method to determine which of these available procedures 
was the best choice to obtain high-quality and high-quantity DNA. 
 
4.3 MATERIALS AND METHODS 
 
4.3.1 Samples 
 
Eleven whole blood samples obtained from breast cancer patients residing in 
the South East Queensland Region, recruited from the Gold Coast Hospital, 
Southport were randomly selected for this study. Collection of samples was approved 
by Griffith University’s Ethics Committee and it was performed in 2003-2004. 
Samples were collected in EDTA tubes and stored at - 80oC prior to DNA extraction 
about 8 years before gDNA extraction. It was noted that a number of the blood 
samples showed some marked clotting, which may have been the result of incorrect 
mixing prior to freezing and long term storage prior to their use. 
 
4.3.2 Genomic DNA extraction methods 
 
Three genomic DNA extraction methods were evaluated on the previously 
selected samples, as follows: 
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5.4.2.1 Traditional salting out method 
 
5 ml of whole blood were thawed and poured into a 50 ml falcon tube. 10 ml of 
NKM buffer (3 mM MgCl2, 140 mM NaCl, 30 mM KCl) was added to the samples 
and tubes were shaken vigorously. After centrifugation at 4600 rcf for 25 minutes at 
4ºC, supernatant was discarded and 5 ml of RSB buffer (40mM Tris-HCl pH 7.5, 3 
mM MgCl2, 40mM NaCl) was added to the falcon tube to break up the pellet. Tubes 
were shaken vigorously again and RSB buffer was added to bring the volume up to 
15 ml in total. Mixture was centrifuged at 3800 rcf for 15 minutes at 4°C, supernatant 
was discarded and pellets were resuspended by adding 0.5 ml of RSB buffer. 2 ml of 
lympholysis buffer (50 mM EDTA pH 8.0, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
10% SDS) and 125 µl of proteinase K solution (2 mg/ml proteinase K, 1 mM CaCl2 
– 1 mM Tris pH 7.5) were added to the samples and falcon tubes were placed 
overnight in a 37°C shaking water bath. On the following day 2ml of sterile saturated 
NaCl (6M) solution was added and samples were mixed by inversion. Tubes were 
centrifuged at 2400 rcf for 15 minutes at 4°C. Supernatant was carefully transferred 
to a 10ml tube and they were centrifuged again at 2400 rcf for 15 minutes at 4°C.  
Supernatant was transferred into a new 50ml falcon tube and two volumes of -20°C 
chilled absolute (100%) ethanol were added. DNA strand precipitate was transferred 
using an inoculating loop into a labelled 2ml tube containing 1ml of 1X TE buffer 
(10mM Tris pH 8.0, 1mM EDTA). Extracted DNA was allowed to dissolve by 
incubating at 37°C overnight and samples were stored at 4°C after quantification and 
testing. 
 
5.4.2.2 Modified salting out method 
 
5 ml of whole blood were thawed and transferred into a 15 ml falcon tube. 8 ml 
of lysis buffer (0.3 M sucrose, 0.01 M TrisHCl, pH 7.5, 5 mM MgCl2, 1% Triton 
X100) were added to each sample and they were mixed by inversion. Tubes were 
centrifuged at 2500 rcf for 30 minutes at 4°C. Supernatant was discarded without 
disturbing pellet on the bottom. 300 µl of 10 mM TrisHCl, pH 8.0 were added to the 
falcon tube and the pellet was broken by pipetting. Samples were transferred to fresh 
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 microfuge tubes and they were resuspended by vortexing. After centrifugation at 
2500 rcf for 20 minutes at 4oC, supernatant was discarded. 330 µl of 10 mM 
TrisHCl, pH 8.0; 330 µl of commercial laundry powder (Biozett Attack© Front 
Loader, Kao Marketing Pty. Ltd., Australia) solution (30 mg/ml) and a glass bead 
were added to the pellet. Samples were vortexed for 1 minute and 250 µl of 6M NaCl 
were added and samples were vortexed again for 20 seconds. Mixture was 
transferred to fresh 2 ml microfuge tubes and they were centrifuged at 15000 rcf for 
10 minutes. Supernatant was transferred to fresh microfuge tubes and DNA was 
precipitated by addition of 1 to 2 volumes of -20°C chilled absolute (100%) ethanol. 
Using an inoculating loop, washed twice in 70% ethanol, DNA strands were placed 
into one labelled 2 ml tube containing 1 ml of 1X TE buffer (10 mM Tris pH 8.0, 1 
mM EDTA). DNA was allowed to dissolve by incubating at 70°C for 5 minutes.  
Samples were finally stored at 4°C after quantification and testing. 
 
5.4.2.3 QIAGEN© QIAamp® DNA Blood Maxi Kits (QIAGEN Pty Ltd, PO 
Box 25, Clifton Hill, Victoria 3068, Australia) 
 
5ml of whole blood were thawed and the protocol was carried out according to 
manufacturer’s instructions in their handbook. Obtained gDNA samples were stored 
at 4°C after quantification and testing. 
 
4.3.3 Evaluation of extracted DNA 
 
Genomic DNA extracted from blood samples was evaluated using the 
following procedures: 
  
5.4.3.1 gDNA yield concentration and quality evaluation by 
spectrophotometry 
 
To assess integrity and quantity of genomic DNA extracted from blood 
samples using each method, we performed spectrophotometry measurements using 
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The Thermo Scientific NanoDrop™ 1000 Spectrophotometer (Thermo Fisher 
Scientific Inc, Wilmington, DE. USA.). Samples were measured in duplicate and the 
average result was used for comparisons. Results for DNA quality (260/280 nm ratio 
and absorbance spectrum) and concentration (measured in ng/µl) were compared for 
each individual sample and using the average of all samples from each method. 
Statistical analysis of the results was performed using Office Excel Spreadsheet 2007 
(Microsoft®) and IBM® SPSS® software version 19 (IBM Company ©). 
 
5.4.3.2 Polymerase Chain Reaction 
 
Extracted samples were also tested using standard polymerase chain reaction 
(PCR) to amplify the methylenetetrahydrofolate reductase (MTHFR) gene producing 
a fragment of about 190 base pairs using the following primer sequence:  5’- 
TGAAGGAGAAGGTGTCTGCGTTA.  Reaction mixture contained 0.2 µl of 
GoTaq® Flexi DNA polymerase (Promega, Madison, WI, USA) 100 nM of each 
primer, 1X PCR Buffer, 1.75 nM MgCl2, 200 nM of deoxynucleotides (dNTPs) and 
40 ng of gDNA in a final reaction volume of 20µl. Reactions were performed using 
Applied Biosystems Veriti™ Thermal Cycler (Applied Biosystems, Foster City, 
California, USA) with cycling conditions as follows: Initial cycle of denaturation at 
94oC for 10 minutes, followed by 30 cycles of denaturation at 94oC for 10 seconds, 
and annealing at 58oC for 45 seconds and extension at 72oC for 45 seconds followed 
by additional 7 minutes at 72oC and a final hold at 4oC for 5 minutes. Each DNA 
sample was run in duplicate and against a negative control. Product amplification 
was determined by electrophoresis on 2% agarose gel stained with ethidium bromide, 
visualized under U.V. light using Gel Doc XR System (Bio-Rad) and Quantity One® 
software. 
 
4.4 RESULTS 
 
In an initial experiment, 10 ml of whole blood from 5 different patient samples 
were split to be extracted using both the traditional salting out and the modified 
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 salting out method according to the protocols outlined above. The average values of 
measures obtained by spectrophotometry from initially extracted gDNA samples are 
shown in Table 4-1. 
 
Table 4-1 Spectrophotometry measures from whole blood samples (BC319-BC323) 
 
TRADITIONAL SALTING OUT 
METHOD 
MODIFIED SALTING OUT 
METHOD 
Sample ID Final 
gDNA 
Yield 
(µg) 
Obtained 
gDNA Yield 
(µg) per ml 
of blood 
260/280 
nm 
Ratio 
Final 
gDNA 
Yield 
(µg) 
Obtained 
gDNA Yield 
(µg) per ml 
of blood 
260/280 
nm 
Ratio 
BC319 6.54 1.30 1.63 250.99 50.20 1.73 
BC320 17.34 3.47 1.99 168.55 33.71 1.68 
BC321 13.07 2.61 1.80 33.72 6.74 1.82 
BC322 43.27 8.65 1.90 19.68 3.94 1.72 
BC323 13.99 2.80 1.84 14.16 2.83 1.44 
Average 18.84 3.77 1.83 97.42 19.48 1.68 
 
On average final gDNA yield and obtained gDNA yield per ml of blood was 
significantly higher when using the modified salting out method but 260/280 nm 
ratio was slightly lower to the results obtained using the traditional salting out 
method. However, when performing statistical analyses (independent t-test and 
ANOVA) on the results obtained, there were no statistically significant differences 
for final gDNA yield and obtained gDNA yield per ml of blood (P = 0.176 for both 
measures) and for 260/280 nm ratio (P = 0.116). Because both methods proved to be 
comparable in terms of effectiveness, we decided to compare them against a 
commercially available DNA extraction kit, believed to be more effective and 
efficient than the ones previously mentioned.   
 
Six different new 15 ml whole blood patient samples were split to extract 
gDNA, using all previously selected methods: traditional salting out, modified 
salting out and QIAGEN© QIAamp® DNA Blood Maxi Kit. gDNA extracted from 
each sample using each method was evaluated by spectrophotometry and the results 
obtained are presented in Table 4-2.  
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Table 4-2 Spectrophotometry measures from gDNA extracted from whole blood samples using 3 different extraction methods 
 
TRADITIONAL SALTING OUT 
METHOD MODIFIED SALTING OUT METHOD QIAGEN
© QIAamp® DNA Blood Maxi Kit 
Sample ID Final gDNA 
Yield (µg) 
Obtained     
gDNA Yield 
(µg) per ml 
of blood 
260/280 nm 
Ratio 
Final gDNA 
Yield (µg) 
Obtained     
gDNA Yield 
(µg) per ml 
of blood 
260/280 nm 
Ratio 
Final gDNA 
Yield (µg) 
Obtained 
gDNA Yield 
(µg) per ml 
of blood 
260/280 nm 
Ratio 
BC316 50.55 10.11 1.86 67.48 13.50 1.65 112.00 22.40 2.12 
BC317 26.22 5.24 1.59 30.55 6.11 1.76 84.55 16.91 1.78 
BC324 10.46 2.09 1.66 27.21 5.44 1.82 47.26 9.45 2.59 
BC325 31.00 6.20 1.77 44.68 8.94 1.71 60.98 12.20 1.67 
BC326 50.01 10.00 1.83 38.46 7.69 1.76 11.99 2.40 2.06 
BC327 27.64 5.53 1.80 34.46 6.89 1.82 54.41 10.88 1.91 
Average 32.65 6.53 1.75 40.47 8.09 1.75 61.86 12.37 2.02 
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As shown in Table 4-2, on average, QIAGEN© QIAamp® DNA Blood Maxi 
Kit provided higher final gDNA yield, obtained higher gDNA yield per ml of blood 
and a better 260/280 nm ratio than traditional and modified salting out methods. On 
the other hand, the modified salting out method resulted, on average, in higher final 
gDNA yield and obtained higher gDNA yield per ml of blood than traditional salting 
out method. However, they both had the same average result for 260/280 nm ratio 
measure. It appeared as if QIAGEN © QIAamp® DNA Blood Maxi Kit provided a 
more highly concentrated and better quality gDNA than the other two methods. 
Although, statistical analysis using ANOVA showed that the results from all 3 
methods were not significantly different (p value= 0.110 for gDNA yield) and a 
marginally significant difference (p value = 0.05) was obtained for the 260/280 nm 
ratio. Furthermore, using an independent t-test to compare modified salting out 
method and QIAGEN © QIAamp® DNA Blood Maxi Kit, there were no statistically 
significant differences between these results (P value = 0.187 for gDNA yield and P 
value= 0.076 for 260/280 nm ratio). 
 
Once quality and quantity of gDNA obtained was evaluated, a polymerase 
chain reaction (PCR) to investigate amplification of the methylenetetrahydrofolate 
reductase (MTHFR) gene was performed on all samples obtained from traditional 
and modified salting out method. PCR was run using the experimental conditions 
previously exposed in our methods section and the results from this experiment are 
shown in Figure 4-1.  
 
PCR product amplification for the MTHFR gene was equally achieved using 
gDNA samples extracted from both traditional and modified salting out. gDNA 
quality was shown to be similar and both techniques were able to result in suitable 
products for future use in molecular applications (Figure 4-1). 
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 Figure 4-1 Agarose gel showing PCR product amplification on DNA extracted by 
traditional salting out method(lanes 1-6) and modified salting out method(lanes 7-12) 
 
When analysing the costs derived from the use of either one of the previously 
exposed methods, based on prices from our local providers, we were able to define 
the information summarized in the following table (Table 4-3). 
 
Table 4-3 Time and Cost summary for different gDNA extraction methods 
gDNA Extraction Method 
Cost per gDNA 
extraction from 
5ml of whole 
blood sample 
Cost of gDNA 
extraction from 
100 Samples 
Overnight steps 
Traditional salting out 
method 
AUD 3.65 AUD 365.00 Incubation 37oC 
Modified salting out 
method 
AUD 1.90 AUD 190.00 None 
QIAGEN© QIAamp® 
DNA Blood Maxi Kit 
AUD 12.3 AUD 1,230.00 None 
 
As shown in Table 4-3, QIAGEN © QIAamp® DNA Blood Maxi Kit is the 
most expensive out of all the techniques chosen for extraction comparison. It is 
almost seven times more expensive than the modified salting out method. The 
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modified salting out method and QIAGEN © QIAamp® DNA Blood Maxi Kit both 
require about the same time to be performed, taking on average about 1 hour per 
sample extracted. On the other hand, the traditional salting out method requires the 
most time to be performed because it involves an overnight incubation at 37°C to 
allow proteinase K digestion and it almost doubles the cost of the modified salting 
out protocol. As a result the modified salting out method proved to be the most cost-
effective technique, reducing expenses about seven times less per sample than the 
commercial kit and approximately half the costs of traditional salting out method. 
 
4.5 DISCUSSION 
 
Genomic DNA (gDNA) is a key component in order to perform molecular 
applications involving genomic studies. Whole blood is the primary source for DNA 
isolation and there are a number of different methods to choose to prepare this 
material. They go all the way from old-school basic laboratory protocols to 
commercially available tested kits and they have been tested and improved over the 
years. Nonetheless, there are a number of advantages and disadvantages to each one 
of the available choices and they must be considered before choosing a particular 
technique. Issues like the time, direct costs and indirectly generated costs and 
efficiency from each method should be carefully evaluated, especially when dealing 
with large populations and particular baseline conditions of the samples to extract.  
 
Because of technological advances, some protocols have been disregarded 
despite their potential advantages, particularly in terms of costs. Although it is being 
widely used nowadays, the salting out method has been excluded from studies where 
comparisons have been made between available techniques for DNA isolation.  
Therefore, we decided to compare a modified version of the salting out method to the 
traditional protocol and also to one of the commercially available choices to 
determine their advantages. Our results show that despite some differences in total 
gDNA obtained from one individual to the next, all of these techniques do not differ 
significantly in the quality and quantity of DNA yield obtained from whole blood 
samples, previously frozen. They all result in gDNA that can be used safely for 
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molecular genomic studies. However, when you take time and money into 
consideration some important differences were observed. The modified salting out 
and QIAGEN © QIAamp® DNA Blood Maxi Kit method significantly reduce the 
amount of time required for DNA extraction, from up to 3 days to about 1 hour. 
When compared to the traditional salting out method, the modified salting out 
method provides an additional advantage, in spite of their similarities in time 
performance to QIAGEN © QIAamp® DNA Blood Maxi Kit. With our findings 
showing almost a 7-fold cost reduction when using modified salting out method 
instead of the commercially available kit and almost half a reduction in costs to the 
traditional salting out technique.  
 
In conclusion, any of these three techniques perform similarly in terms of 
quantity and quality of final product, but our results showed the modified salting out 
method to be the most cost-effective and time-efficient technique to isolate gDNA 
from whole blood samples.  
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5.2 ABSTRACT 
 
DNA extraction has considerably evolved since it was initially performed back 
in 1869. It is the first step required for many of the available downstream 
applications used in the field of molecular biology. Whole blood samples are one of 
the main sources used to obtain DNA and there are many different protocols 
available to perform nucleic acid extraction on such samples. These methods vary 
from very basic manual protocols to more sophisticated methods included in 
automated DNA extraction protocols. Based on the wide range of available options, 
it would be ideal to determine the ones that perform best in terms of cost-
effectiveness and time-efficiency. 
 
We have reviewed DNA extraction history and the most commonly used 
methods for DNA extraction from whole blood samples, highlighting their individual 
advantages and disadvantages. We also searched current scientific literature to find 
studies comparing different nucleic acid extractions methods to determine the best 
available choice. Based on our research we have determined that there is not enough 
scientific evidence to support one particular DNA extraction method from whole 
blood samples. Choosing a suitable method is still a process that requires 
consideration of many different factors and more research is needed to validate 
choices made at facilities around the world. 
 
5.3 INTRODUCTION 
 
Human health studies in the field of molecular biology require the use of 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and protein samples. 
Successful use of available downstream applications will benefit from the use of high 
quality and high quantity DNA. Therefore, nucleic acid extraction is a key step in 
laboratory procedures required to perform further molecular research applications. It 
is essential to choose a suitable extraction method and there are a few considerations 
to be made when evaluating the available options. These may include technical 
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requirements, time-efficiency, cost-effectiveness, as well as biological specimens to 
be used and their collection and storage requirements (Carpi, Di Pietro, Vincenzetti, 
Mignini, & Napolioni, 2011).  
 
Whole blood is one of many different available sources to obtain genomic 
DNA (gDNA) and it has been widely used in facilities around the world. Therefore, 
we will focus on DNA extraction protocols using whole blood samples. Issues 
regarding collection, storage and manual handling of human whole blood specimens 
escape the scope of this publication and will not be covered. However, they are 
important and they should be considered as they could potentially impact on the 
performance and success of any DNA extraction technique chosen. 
 
5.4 INITIAL DEVELOPMENT OF DNA EXTRACTION TECHNIQUES 
 
Friedrich Miescher was the first scientist to isolate DNA, while studying the 
chemical composition of cells. In 1869, he used leucocytes that he collected from the 
samples on fresh surgical bandages and he conducted experiments to purify and 
classify proteins contained in these cells. During his experiments, he identified a 
novel substance in the nuclei, which he called “nuclein” (Dahm, 2005). He then 
developed two protocols to separate cells’ nuclei from cytoplasm and to isolate this 
novel compound, nowadays known as DNA, which differed from proteins and other 
cellular substances. This scientific finding, along with the isolation protocols used, 
was published in 1871 in collaboration with his mentor Felix Hoppe-Seyler (Dahm, 
2005; Holmes, 2001). However, it was only in 1958, that Meselson and Stahl 
developed a routine laboratory procedure for DNA extraction. They performed DNA 
extraction from bacterial samples of E.Coli using a salt density gradient 
centrifugation protocol (Holmes, 2001; Meselson & Stahl, 1958). Since then, DNA 
extraction techniques have been adapted to perform extractions on many different 
types of biological sources.  
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DNA extraction methods follow some common procedures aimed to achieve 
effective disruption of cells, denaturation of nucleoprotein complexes, inactivation of 
nucleases and other enzymes and removal of biological and chemical contaminants 
and finally DNA precipitation (Tan & Yiap, 2009). Most of them follow similar 
basic steps and they include the use of organic and non-organic reagents and 
centrifugation methods. Finally they have developed into a variety of automated 
procedures and commercially available kits (Carpi et al., 2011; J. J. Greene & Rao, 
1998; Price, Leslie, & Landers, 2009; Tan & Yiap, 2009).  
 
Initially we will discuss protocols and steps aimed to achieve cell lysis, 
inactivation of cellular enzymes and denaturation of cellular complexes and DNA 
precipitation, which require similar procedures and/or reagents during DNA 
extraction from whole blood samples. Key differences in steps aiming to remove 
biological and chemical contaminants will be highlighted further ahead when we 
discuss each protocol in detail.   
 
As previously mentioned, lysis of cells is a common step to most DNA 
extraction protocols and it is commonly achieved through the use of detergents and 
enzymes. SDS and Triton X-100 are examples of popular detergents used to 
solubilize cell membranes. Enzymes are also combined with detergents to target cell 
surface or cytosolic components. Proteinase K is a commonly used enzyme used in 
various protocols in order to cleave glycoproteins and inactivate RNases and 
DNases. Other denaturants such as urea, guanidium salts and chemical chaotropes 
have also been used to disrupt cells and inactivate cellular enzymes, but these can 
impact on quality and nucleic acid yield (Boom et al., 1990; Carpi et al., 2011; 
Herzer, 2001; Price et al., 2009). 
 
 DNA precipitation is achieved by adding high concentrations of salt to DNA-
containing solutions, since cations from salts such as ammonium acetate counteract 
repulsion caused by negative charge of phosphate backbone. A mixture of DNA and 
salts in the presence of solvents like ethanol, used in final concentrations from 70% 
to 80%, or isopropanol (final concentrations of 40-50%) causes nucleic acids to 
Chapter 5: Methods for extracting genomic DNA from whole blood samples: current perspectives. 109 
precipitate. Some protocols include washing steps with 70% ethanol to remove 
excess salt from DNA. Finally nucleic acids are resuspended in water or TE buffer 
(10mM Tris, 1mM ethilenediaminetetraacetic acid (EDTA)) (Boom et al., 1990; 
Herzer, 2001; Price et al., 2009). TE buffer is commonly used for long term DNA 
storage because it prevents it from being damaged by nucleases, inadequate pH, 
heavy metals and oxidation by free radicals. Tris provides safe a safe pH of 7 to 8 
and EDTA chelates divalent ions used in nuclease activity and counteracts oxidative 
damage from heavy metals (Herzer, 2001). 
 
5.5 MAIN TYPES OF DNA EXTRACTION METHODS FROM HUMAN WHOLE 
BLOOD SAMPLES 
 
Table 5-1 shows the main categories and sub-categories of DNA extraction 
methods from whole blood samples that are generally used in research facilities 
worldwide. Laboratory reagents commonly used for each stage of the nucleic acid 
extraction protocol are included in this table in order to highlight similarities and 
differences between them. 
 
DNA extraction techniques included in Table 5-1 will be discussed in more 
detail in the following sections, along with a brief summary of the technique history 
and background. In recent years, some of these protocols have been adapted to 
microdevices that would develop miniaturized total chemical analysis system 
(μTAS) or microfluidic genetic analysis (MGA) microchips (Duarte et al., 2010; 
Price et al., 2009). However, we will limit the scope of our review to those 
techniques that are available for macroscale nucleic acid extraction.
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Table 5-1 DNA extraction methods commonly used for extraction from whole blood samples 
DNA 
Extraction 
Method  
(Main 
category) 
DNA Extraction 
 Method  
(Sub-category) 
DNA Extraction Protocol Stage 
Cell Lysis Denaturation of 
Nucleoproteins/ 
Inactivation of 
cellular enzymes 
Removal of Contaminants DNA precipitation 
Solution 
Based DNA 
Extraction 
Methods 
Salting Out Methods • SDS 
• SDS/ 
Proteinase k 
• Triton X-100 
• Proteinase K 
• Laundry 
powder 
• Potassium acetate 
• Sodium acetate 
• Sodium chloride 
• Ethanol 
• Isopropanol 
Organic 
Solvent/Chaotropes 
Methods 
• SDS 
• SDS/ 
Proteinase k 
• Guanidine 
thiocyanate 
(GTC) 
• Phenol 
• Phenol 
• Phenol: chloroform 
• Phenol: chloroform 
isoamyl alcohol  
• Sodium acetate/ethanol 
• Sodium 
acetate/isopropanol 
Solid Phase 
DNA 
Extraction 
Methods 
Glass Milk/ Silica 
Resin Methods 
• SDS 
• Triton X-100 
• Guanidine 
thiocyanate 
• Glass Milk (Silica in 
chaotropic buffer) 
• Silica matrix 
• Diatomaceous earth  
• Ethanol 
• Isopropanol 
Anion Exchange 
Methods 
• Heat • Chelex 
• Chelex/Prote
inase K 
• Chelex • N/A 
Magnetic Beads 
Methods 
• SDS • N/A • Sodium Chloride/ 
Polyethylene glycol  
• Magnetic beads 
Abbreviations: DNA, deoxyribonucleic acid; N/A, not applicable; SDS, sodium dodecyl sulfate 
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5.5.1 Solution based DNA extraction methods 
 
As previously mentioned, solution based protocols have two main approaches: 
I) Solutions based methods using organic solvents and II) those based on a salting 
out technique. Further description of both methods follows. 
 
Solution based DNA extraction methods using organic solvents 
 
DNA extraction protocols using organic solvents derived originally from a 
series of related RNA extraction methods. Some of the main steps used in these 
methods are:  I) Cell lysis undertaken by adding a detergent/chaotropic-containing 
solution, including sodium dodecyl sulfate (SDS) or N-Lauroyl sarcosine. II) 
Inactivation of DNases and RNases usually through the use of organic solvents, III) 
purification of DNA and removal of RNA, lipids and proteins and finally IV) 
resuspension of extracted nucleic acids (Carpi et al., 2011; Sambrook & Russell, 
2001; Tan & Yiap, 2009).  
 
This method was initially developed in 1977 when an RNA extraction 
technique using guanidium isothyocyanate was used by Ulrich et al to isolate 
plasmid DNA (Ullrich et al., 1977). This technique was later modified by Chirgwin 
et al in 1979 and it required the use of guanidium thyocyanate and long hours of 
ultracentrifugation through a cesium chloride (CsCl) cushion (Chirgwin, Przybyla, 
MacDonald, & Rutter, 1979). In an effort to improve this method, Chomczynski et al 
in 1987 developed a protocol for RNA extraction using guanidium thiocyanate-
phenol-chloroform and much shorter centrifugation (Chomczynski & Sacchi, 1987, 
2006). This last RNA extraction protocol was able to isolate RNA, DNA and 
proteins, but in order to be used as a DNA extraction technique, guanidium 
thiocyanate-phenol-chloroform was later replaced by a mixture of phenol: 
chloroform: isoamyl alcohol since the former solvent did not completely inhibit 
RNase activity (Sambrook & Russell, 2001). Phenol is a carbolic acid that denatures 
proteins quickly, but it is highly corrosive, toxic and flammable. This organic solvent 
is usually added to the sample and then using centrifugal force a biphasic emulsion is 
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obtained. The top hydrophilic layer contains diluted DNA and the bottom 
hydrophobic layer is composed of organic solvents, cellular debris, proteins and 
other hydrophobic compounds. DNA is then precipitated after centrifugation by 
adding high concentrations of salt, such as sodium acetate and ethanol or isopropanol 
in 2:1 or 1:1 ratios. Excess salt can be removed by adding 70% ethanol and the 
sample is then centrifuged to collect the DNA pellet which can be resuspended in 
sterile distilled water or TE buffer (10mM Tris; 1mM EDTA pH 8.0) (Carpi et al., 
2011; Tan & Yiap, 2009).  
 
Because these techniques involve the use of toxic and corrosive organic 
solvents, safety is a main concern. Personal protective equipment, safety measures 
involving the use of a biohazard hood and training are required. Phenol/chloroform 
needs to be equilibrated to an adequate pH and protocol conditions should be 
optimized (Price et al., 2009).  In an effort to improve safety and ease of use of these 
protocols, certain modifications have been introduced to avoid physical contact with 
solvents. These include incorporating a silica gel polymer (S. Thomas, Tilzer, & 
Moreno) or replacing solvents with other substances like benzyl alcohol (Ness., 
Cimler., Rich B. Meyer, & Vermeulen.). 
 
Solution based DNA extraction methods using salting out 
 
Some nucleic acid extraction techniques that avoid the use of organic solvents 
have also been developed over the years (Carpi et al., 2011; J. J. Greene & Rao, 
1998; Sambrook & Russell, 2001). In 1988, Miller et al published a protocol that 
achieved DNA purification through protein precipitation at high salt concentration 
(Miller et al., 1988). The traditional protocol involves initial cell disruption and 
digestion with SDS-Proteinase K, followed by addition of high concentrations of 
salts, usually 6M NaCl. The mixture is then centrifuged to allow proteins to 
precipitate to the bottom, with the supernatant containing DNA then transferred to a 
new vial. DNA is then precipitated using ethanol or isopropanol in the same manner 
as described for organic solvent methods (Carpi et al., 2011; F. Greene et al., 2002; 
Grimberg et al., 1989; Miller et al., 1988).  
Chapter 5: Methods for extracting genomic DNA from whole blood samples: current perspectives. 113 
 However, the use of proteinase K can be time consuming and expensive when 
compared to other reagents used in different solution-based approaches, so there 
have been a few attempts to find alternative reagents for deproteinisation of DNA 
(Bahl & Pfenninger, 1996; Drabek & Petrek, 2002; Gaaib, Nassief, & Al-Assi, 2011; 
Debomoy K Lahiri & Nurnberger Jr, 1991). In 1991, Lahiri et al developed a DNA 
extraction protocol from blood samples that eliminated the use of organic solvents 
and prolonged incubation with Proteinase K. Their protocol used Nonidet P-40 (NP-
40, Sigma) to lyse blood cells and high salt buffers and 10% SDS to inactivate and 
remove contaminants. Another protocol is the modified salting out method published 
in 2005 by Nasiri et al in 2005 (Nasiri et al., 2005), which replaced Proteinase K 
digestion with the use of  laundry powder. This modified technique has been 
successfully used as a DNA extraction protocol in many facilities around the world 
(Arévalo-Herrera et al., 2011; Garcia-Sepulveda et al., 2010; Iri-Sofla et al., 2011; B. 
Liu et al., 2010; H. Liu et al., 2013; Trejo-de la O et al., 2008; Y. Wu et al., 2011; Y. 
Zhang et al., 2008; Y. Zhang et al., 2009). 
 
5.5.2 Solid phase DNA extraction methods 
 
Purification of DNA using the liquid/solid phase approach can be traced back 
to 1979 when Vogelstein et al used silica in a glass powder form in their protocol to 
purify DNA fragments previously separated by agarose gel electrophoresis 
(Vogelstein & Gillespie, 1979).  Solid phase extraction methods for DNA extraction 
from blood samples were initially described in 1989 by McCormick et al. They 
published a technique using siliceous-based insoluble particles,  chemically similar to 
phenol, that interact with proteins to allow DNA purification (McCormick, 1989). A 
number of different procedures using the liquid/solid DNA extraction approach have 
been developed since then and they are used in the majority of commercially 
available extraction kits.  
 
These techniques will absorb DNA under particular pH and salt content 
conditions through any of the following principles: I) hydrogen-binding in the 
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presence of a chaotropic agent to a hydrophilic matrix, II) ionic exchange using an 
anion exchanger under aqueous conditions and III) affinity and size exclusion 
mechanisms (Price et al., 2009; Tan & Yiap, 2009). Most of these methods follow a 
series of similar steps to achieve cell disruption, DNA adsorption, nucleic acid 
washing and final elution. Most solid phase techniques use a spin column to bind 
nucleic acid under centrifugal force. Spin columns are made of silica matrices, glass 
particles or powder, diatomaceous earth or anion exchange carriers and these 
compounds generally need to be conditioned using buffer solutions at specific pH to 
turn them into the required chemical form. Blood cells previously degraded using 
particular lysis buffers are applied to the columns and centrifuged and the DNA 
binds to column aided by pH and salt concentration conditions provided by binding 
solutions. Some proteins and other biochemical compounds may also bind to the 
column and they are later removed using washing buffers containing competitive 
agents during a series of washing steps. DNA is finally eluted in sterile distilled 
water or TE buffer (Carpi et al., 2011; Price et al., 2009; Tan & Yiap, 2009). 
 
4.5.2.1 DNA extraction methods using silica and silica matrices 
 
Silica matrices have unique properties for DNA binding. They are positively 
charged and have high affinity towards the negative charge of the DNA backbone. 
High salt conditions and pH are achieved using sodium cations, which bind tightly to 
the negatively charged oxygen in the phosphate backbone of DNA. Contaminants are 
removed with a series of washing steps, followed by DNA elution under low ionic 
strength (pH ≥ 7) using TE buffer or sterile distilled water. Commercially available 
kits using silica based approach are manufactured by Clontech (NucleoSpin™), Mo 
Bio Laboratories (Ultraclean™ BloodSpin™), QIAGEN (QiaAmp®), Promega 
(Wizard™), Epoch Biolabs (EconoSpin™), Sigma Aldrich (GenElute™) amongst 
others.  In these protocols blood samples are incubated for a few minutes with a lysis 
buffer and most protocols take about 40 minutes to one hour to complete producing 
high yields of DNA with minimum contamination (Carpi et al., 2011; Price et al., 
2009; Tan & Yiap, 2009).  
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A substance that contains high amounts of silica (up to 94%), known as 
kieselguhr, diatomite or diatomaceous earth has also been used for DNA purification. 
It was initially described by Boom et al in 1990 (Boom et al., 1990).  It binds DNA 
in the presence of chaotropic agents, followed by washing with a buffer containing 
alcohol and finally DNA is eluted in a low salt buffer or sterile distilled water. 
BioRad (Quantum Prep®) is an example of a DNA extraction product developed 
using diatomaceous earth (Price et al., 2009).  
 
DNA extraction kits have also evolved and they are incorporated into semi- 
and fully automated equipment able to perform protocols from sample lysis to some 
downstream applications like polymerase chain reaction (PCR), such as BioRobot 
EZ1® Advanced (QIAGEN), Biomek® 4000 Laboratory Automation Workstation 
(Beckman Coulter, Inc., Brea, CA, USA), amongst others.  Pipetting error, reduced 
number of sample transfer and less protocol time are among the advantages of these 
devices, however they should be carefully considered given the high cost of some of 
the available choices of equipment. They have also been incorporated into 
miniaturized total chemical analysis systems, which are silicon microchips where 
DNA purification separation and detection is achieved (Price et al., 2009). 
 
4.5.2.2 DNA extraction using anion exchange resins 
 
Positively charged chemical substances able to bind to negatively charged 
nucleic acids or contaminants or enzymes, such as nucleases, are called anion 
exchange resins and they have also been used as part of DNA extraction protocols 
from blood samples (Herzer, 2001). 
 
Chelex® 100 resin is made of styrene divinylbenzene copolymers that contain 
paired imminodiacetate ions. It is used in DNA extraction protocols as a chelating 
ion exchange resin that binds polyvalent metal ions, such as nucleases, commonly 
used in DNA extraction from forensic samples. The initial laboratory protocol, using 
blood as a biological source, was described by Wash et al in 1991 (Walsh, Metzger, 
& Higushi, 2013). Based on this initial approach, other protocols have been 
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developed to perform nucleic acid extraction from whole blood samples. They 
require small sample volumes (under 1 ml of blood) and are usually performed in a 
single tube reaction with different steps and reagents involved. Blood samples could 
be lysed using proteinase K and/or incubation at high temperature, and removal of 
contaminants is achieved by adding Chelex® 100 resin which precipitates them. 
Single stranded DNA is obtained and it remains suspended in the supernatant, which 
can be immediately used in downstream application or can be transferred to a new 
vial for long-term storage (Butler, 2009; NFSTC, 2006; Walsh et al., 2013).   
 
Selingson et al (Seligson & Shrawder) used anion exchange materials as part of 
their invention to isolate nucleic acid samples from a variety of sources, including 
whole blood samples. Selingson’s protocol uses a column containing a resin with 
positively charged diethylaminoethyl cellulose (DEAE) groups on its surface to bind 
negatively charged phosphates of the backbone of DNA. The strength of DNA 
binding to column, as well as RNA and other impurities, can be altered through salt 
concentrations and pH conditions of buffers used in this nucleic acid isolation 
protocol. Contaminants such as protein and RNA can be washed from the DNA-
containing column using medium salt buffers (Seligson & Shrawder; Tan & Yiap, 
2009). 
 
4.5.2.3 DNA extraction methods using magnetic beads 
 
Nucleic acid extraction techniques using magnetic separation have been 
emerging since the early 90’s. They were originally used to extract plasmid DNA 
from bacterial cell lysates by Hawkins et al in 1994 (Hawkins, O'Connor-Morin, 
Roy, & Santillan, 1994) and by 2006 Saiyed et al (Saiyed, Bochiwal, Gorasia, 
Telang, & Ramchand, 2006; Saiyed, Ramchand, & Telang, 2008) developed and 
validated a protocol using naked magnetic nanoparticles for genomic DNA 
extraction from whole blood samples.   
 
Magnetic particles are made of one or several magnetic cores, such as 
magnetite (Fe3O4) or maghemite (gamma Fe2O3), coated with a matrix of polymers, 
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silica or hydroylapatite with terminal functionalized groups. In the protocol 
developed by Saiyed et al, 30 µl of whole blood are mixed with an equal volume of 
1% (w/v) SDS solution. The tube is mixed by inversion two or three times and 
incubated at room temperature one minute. 10 µl of magnetic nanoparticles are 
added to this mixture, followed by addition of 75µl of binding buffer (1.25 M sodium 
chloride and 10% polyethylene glycol 6000). The solution is mixed by inversion and 
allowed to rest for 3 minutes at room temperature and the magnetic pellet is 
immobilized using an external magnet to discard the supernatant. The magnetic 
pellet is washed with 70% ethanol and dried. The magnetic pellet is resuspended in 
50 µl of TE buffer and magnetic particles bound to DNA are eluted by incubation at 
65ºC in continuous agitation (Saiyed et al., 2006; Saiyed et al., 2008). 
 
5.6 CHOOSING THE APPROPRIATE PROTOCOL 
 
The ideal extraction method should fit the following criteria: It should be 
sensitive, consistent, quick and easy to use and depending on the country in which it 
is used it may be important to minimize specialized equipment or biochemical 
knowledge. It should also pose minimum risk to users, as well as avoid possible 
cross-contamination of samples. Finally and most importantly, the DNA extraction 
technique chosen should be able to deliver pure DNA samples ready to be used in 
downstream molecular applications (Boom et al., 1990; Debomoy K. Lahiri, Bye, 
Nurnberger Jr, Hodes, & Crisp, 1992; Price et al., 2009). 
 
The quality and quantity of genomic DNA extracted from blood samples is a 
key feature most facilities consider when choosing a protocol. Measuring UV light 
absorbance using spectrophotometry at different wavelengths (230, 240, 260 and 
280nm) is an initial quick and efficient way of determining purity and concentration 
of nucleic acid samples. Concentration is usually calculated from DNA absorbance 
reading at 260 nm using Beer-Lambert Law. Purity of nucleic acid samples is 
assessed on 260/280 absorbance ratio and values in the range of 1.8 to 2.0 are 
generally considered acceptable. 260/230 absorbance ratios between 2.0 and 2.2 are 
also considered to be adequate as a secondary measure of purity for DNA 
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(Huberman, 1995; Sahota, Brooks, & Tischfield, 2007; Sambrook & Russell, 2001; 
Troutman et al., 2002). 
 
Lahiri et al (Debomoy K. Lahiri et al., 1992) published a study in 1992 where 
they compared ten solution-based extraction methods for DNA extraction using 
whole blood as source. They compared a protocol previously developed by their 
group (method 10a and 10b) (Debomoy K Lahiri & Nurnberger Jr, 1991), which 
required no use of organic solvents or enzyme digestion against nine other methods 
previously published and used for DNA extraction from blood. On their study, Lahiri 
et al (Debomoy K. Lahiri et al., 1992) extracted whole blood samples from 5 
individuals in triplicate using the aforementioned methods. They determined DNA 
concentration from samples using spectrophotometry absorbance reading at 260nm 
and assessed quality through 260/280 absorbance ratio and electrophoresis on 
agarose gel, as well as restriction enzyme digestion and southern blot. A summary of 
some of the protocol features, as well as findings, is presented in Table 5-2.  
 
Table 5-2 Summary of comparative study of DNA extraction methods by Lahiri et al 
Method Enzyme Digestion 
Hazardous 
Reagents 
RNase 
Treatment 
Time 
(Hours) 
260/280 
Ratio 
DNA Yield 
(μg) 
10a No No No 1 1.81 210 
10b No No No 1 1.8 175 
6 Yes Yes No 6 1.94 174 
9 No Yes No 3 1.7 170 
7 Yes Yes No 6 1.81 147 
3 Yes Yes Yes 3 1.81 135 
2 Yes No Yes 5 1.7 95 
8 Yes Yes No Overnight 1.74 130 
1 Yes No No Overnight 1.75 116 
5 Yes Yes No Overnight 1.72 75 
4 Yes Yes No Overnight 1.72 55 
Note: Reprinted from J Biochem Biophys Methods 1992;25(4). Lahiri DK, Bye S, Nurnberger Ji Jr, 
Hodes Me, Crisp M. A non-organic and non-enzymatic extraction method gives higher yields of 
genomic DNA from whole-blood samples than do nine other methods tested. 193–205. Copyright © 
1992, with permission from elsevier. Abbreviations: DNA, deoxyribonucleic acid; RNase, ribonucleic 
acid. 
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All protocols tested were able to isolate DNA with relatively good purity 
(260/280 ratios from 1.7 to 1.94), but DNA obtained with methods 2, 5 and 6 showed 
different amounts of degradation evidenced in gel electrophoresis. Seven of the 
protocols tested, methods 3 to 9, required use of organic solvents and/or hazardous 
substances such as phenol: chloroform or chloroform. Methods 1 and 2 did not use 
organic compounds, but method 1 was the most time consuming. It required 
overnight incubation with proteinase K, a problem solved in protocol 2 by incubating 
samples for 30 minutes with both proteinase K and RNase A reducing DNA 
extraction time to 5 hours. Method 10 (version a and b) was the quickest of all DNA 
isolation methods (1 hour) and it removed enzyme digestion and the use of organic 
solvents/hazardous substances. Both versions of this protocol were able to recover 
similar or higher DNA yields than the other tested protocols, with about comparable 
260/280 ratios. Based on their study findings, Lahiri et al were able to conclude that 
the DNA extraction method they developed was the quickest and safest of the 
solution-based method tested, recovering DNA of comparable quality and quantity 
(Debomoy K. Lahiri et al., 1992). 
 
Abd El-Aal et al compared a combination of manual and automated extraction 
methods for DNA extraction from whole blood samples. Their study included six 
techniques:  phenol-chloroform purification, DNA extraction using microwave 
thermal shock, DNA extraction with Wizard Genomic DNA Purification Kit 
(Promega Corporation, Madison, WI, USA), magnetic separation (LC MagNA Pure 
Compact Instrument – Roche Diagnostics) both manually and partially automated 
using the Precision™ XS Microplate Sample processor from Biotek Instruments 
(Vermont, USA) and finally they modified the Wizard SV 96 Genomic DNA 
Purification Kit (Promega) combining it with magnetic  separation using the MagNA 
Pure purification method. They extracted 96 blood samples and used 100 μl as the 
initial volume. However, they failed to mention how many samples were extracted 
using each method and the number of experimental replicates performed. Their 
results showed DNA extracted for each protocol with final concentrations ranging 
from 0.50 to 0.98 μg/μl. While phenol-chloroform, manual magnetic separation and 
the combined Promega-MagNA pure method isolated DNA showed relatively similar 
DNA concentrations (0.72 to 0.79 μg/μl); magnetic separation and microwaving 
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technique achieved the highest and lowest DNA concentrations, 0.98 μg/μl and 0.50 
μg/μl respectively. In their comparisons, they established five categories for 
simplicity of extraction: extremely simple; simple; less simple; more simple and 
difficult; but their system can be confusing since they failed to present criteria used 
for each category. However, they categorized phenol/chloroform as difficult and 
automated MagNA Pure as extremely simple using their previously mentioned 
category system. They also have five categories for cost of each protocol, with 
automated MagNA Pure technique as the most expensive and microwaving as the 
cheapest method. Their costing categories were also not defined and there is no 
actual mention of specific costs for each method in their study. Based on previously 
mentioned findings, they concluded that magnetic separation using an automated 
protocol performed best in terms of simplicity of extraction, purity of extracted DNA 
and speed, even though it is the one with the highest cost. They also concluded that it 
was essential to optimize any method chosen and they recommended the use of 
magnetic separation, because it required minimal starting material and it was both 
cost-effective and user-friendly. However, as previously stated there is no mention of 
how cost-effectiveness was determined (Abd El-Aal et al., 2010). 
 
Lee et al (J.-H. Lee, Park, Choi, Lee, & Kim, 2010) extracted DNA from 22 
whole blood samples using three automated extraction systems. All three protocols 
compared were based on solid phase extraction techniques: QIAamp® Blood Mini 
Kit (Qiagen, Hilden, Germany) with QIAcube, which uses a silica membranes and 
resins within a spin column to bind DNA and two other protocols that are based on 
magnetic based DNA isolation techniques MagNA Pure LC Nucleic Acid Isolation 
Kit I with MagNA Pure LC (Roche Diagnostics, GmbH, Manheim, Germany) and 
Magtration-Magnazorb DNA common kit-200N with Magtration System 12GC 
(Precision System Science (PSS) Co. Ltd., China, Japan)). DNA concentration was 
measured by spectrophotometry and purity was assessed by 260/280 ratio, DNA 
electrophoresis on agarose gel and PCR. Statistical analysis was performed to 
validate study results and they are summarized in Table 5-3.  
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Table 5-3 Summary of results from comparative study on DNA extraction techniques by Lee et al 
DNA Extraction Method 
Mean 
Corrected 
DNA 
Concentration 
(ng/µl) ± SD 
DNA 
Concentration 
range (min-
max) 
Mean 
260/280 
Ratio ± SD 
260/280 
Range 
(min-
max) 
QIAamp® Blood Mini Kit 
(Qiagen, Hilden, Germany) 
with QIAcube 
25.42  ± 8.82 
 
13.49 - 52.85 
 
1.84  ± 0.09 
 
1.59 - 2.04 
 
MagNA Pure LC Nucleic 
Acid Isolation Kit I with 
MagNA Pure LC 
22.66  ± 7.24 
 
9.59 - 46.70 
 
1.88  ± 0.08 
 
1.6 - 1.97 
 
Magtration-Magnazorb 
DNA common kit-200N 
with Magtration System 
12GC 
22.35  ± 6.47 
 
12.57 - 35.08 
 
1.70  ± 0.08 
 
1.56 -1.90 
 
Note: Reproduced from Lee J-H, Park Y, Choi JR, Lee eK, Kim H-S. Comparisons of three automated 
systems for genomic DNA extraction in a clinical diagnostic laboratory. Yonsei Med J. 
2010;51(1):104–110.49 
Abbreviations: DNA, deoxyribonucleic acid; min, minimum; max, maximum; SD, standard deviation. 
 
Results showed no statistical difference between DNA concentrations obtained 
among the three commercial methods, but DNA purity was slightly lower for 
Magtration-Magnazorb DNA common kit-200N when compared to the other two 
methods. DNA extracted was of similar quality based on results from PCR and 
electrophoresis on agarose gel. Therefore, they concluded that effectiveness for all 
systems was equivalent and they all produced acceptable nucleic acid isolation (J.-H. 
Lee et al., 2010). 
 
Table 5-4  was adapted from a review published by Carpi et al in 2011 (Carpi 
et al., 2011), where they reviewed DNA extraction methods used in a wide range of 
biological sources, including 6 methods used on whole blood samples. Summary of 
the three evaluated features for nucleic acid isolation methods, such as use of toxic 
compounds, cost per sample and time required.  
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Table 5-4 Summary of features evaluated for deoxyribonucleic acid (DNA) extraction methods 
reviewed by Carpi et al.1 
DNA Extraction 
Method 
Toxic 
Compounds 
Cost estimate per 
sample ($) 
Time Required 
(hours) 
Phenol-Chloroform 
method 
Phenol, 
Chloroform 
<5 
 
>3 
 
Silica gel method Phenol, 
Chloroform 
<5 
 
>3 
 
Benzyl alcohol 
method 
Benzyl alcohol <5 >3 
Salting out method None <5 >3 
Magnetic bead-based 
method 
None >5 
 
>0.5 
 
Note: Copyright © 2011. Bentham Science Publishers. Carpi FM, Di Pietro F, vincenzetti S, 
Mignini F, Napolioni v. Human DNA extraction methods: patents and applications. Recent Pat DNA 
Gene Seq. 2011;5(1):1–7. Reprinted by permission of eureka Science Ltd.1 
 
Based on the methods included in Table 5-4, it can be noted that magnetic 
bead-based method is the quickest DNA extraction protocol requiring over 30 
minutes to be performed, whereas all the other protocols require more than 3 hours. 
Also, the magnetic bead-based method is the most expensive one costing more than 
$5 per sample extracted. However, there is no mention in this review of the 
differences when comparing quality and quantity of nucleic acid isolated for each 
method (Carpi et al., 2011). 
 
Chacon-Cortes et al evaluated cost effectiveness and time efficiency of three 
available DNA extraction techniques from whole blood samples: a traditional salting 
out method, a modified salting out method and a commercially available kit based on 
solid-phase DNA extraction method (QIAGEN© QIAamp® DNA Blood Maxi Kits 
(QIAGEN Pty Ltd, Victoria, Australia) (Chacon-Cortes et al., 2012). Modified 
salting out protocol (Nasiri et al., 2005) replaced the sample overnight incubation 
step from the traditional salting out method (Miller et al., 1988), required for 
contaminant removal using proteinase K, with the use of laundry detergent to reduce 
time of extraction to about one hour. 5 ml of whole blood from 6 breast cancer 
patients were manually extracted using each protocol and techniques were compared 
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in terms of quality and quantity of DNA extracted, as well as required cost and time. 
DNA quantity was measured using spectrophotometry and DNA quality was 
assessed by both 260/280 ratio and agarose gel electrophoresis of PCR product. A 
summary of findings is presented in Table 5-5 (Chacon-Cortes et al., 2012). 
 
Table 5-5 Summary of results from comparative study of DNA extraction methods by Chacon-Cortes 
et al 
DNA Extraction 
Method 
Average Final 
gDNA Yield 
(μg) 
Average 
260/280 
Ratio 
Cost estimate 
per sample 
(AUD) 
Time 
Required 
(hours) 
Traditional Salting 
Out Method 
32.65 1.75 3.65 Overnight 
Modified Salting 
Out Method 
40.47 1.75 1.9 1 
QIAGEN© 
QIAamp® DNA 
Blood Maxi Kit 
61.86 2.02 12.3 1  
Note: Copyright © 2012. Springer. Mol Biol Rep. 2012;39:5961–5966. Comparison of genomic DNA 
extraction techniques from whole blood samples: a time, cost and quality evaluation study. Chacon-
Cortes D, Haupt L, Lea R, Griffiths L. Reproduced with kind permission from Springer Science and 
Business Media.50 
Abbreviations: AUD, Australian dollars; gDNA, genomic deoxyribonucleic acid. 
 
As shown in Table 5-5 QIAGEN© QIAamp® DNA Blood Maxi Kits produced 
the highest yield and 260/280 ratio from all methods evaluated with average measure 
of 61.86 µg and 2.02 respectively, but traditional and modified salting out protocols 
both produced similar results in terms of DNA yield and 260/280 ratios.  However, 
statistical analysis using ANOVA showed that DNA yield and 260/280 ratio results 
were not significantly different for all 3 methods (P-value of 0.110 and 0.05 
respectively).  On the other hand, the traditional salting out method required an 
overnight incubation step and the QIAGEN© QIAamp® DNA Blood Maxi Kit was 
the most expensive of all the methods included costing about 12.30 Australian 
dollars, almost 7 times than the modified salting out protocol. Therefore, based on 
these findings the modified salting out protocol developed by Nasiri et al (Nasiri et 
al., 2005) proved to be to be the most cost-effective and time-efficient technique to 
isolate gDNA from whole blood samples (Chacon-Cortes et al., 2012). 
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Unfortunately, no other solid phase extraction methods for DNA extraction were 
included in this study. 
 
5.7 CONCLUSIONS 
 
DNA extraction has evolved for the past 145 years and it has developed into a 
diversity of laboratory techniques. This review highlights currently available 
methods for DNA extraction from whole blood samples and it summarizes 
comparison studies using different nucleic acid extraction approaches published to 
date. DNA extraction has evolved from solution and solid-phase manual techniques 
initially performed manually into incorporating these into automated methods. There 
is no consensus on a gold standard method for DNA extraction from whole blood 
samples and they all differ in many different aspects. Studies comparing extraction 
techniques and highlighting their strengths and weaknesses are limited and to our 
knowledge there is no publication that evaluates all approaches in terms of all 
possible features. Therefore, it is very difficult to determine the best choice available. 
Facilities around the world usually choose a method based on the availability of 
equipment, sample and reagents, as well as considering speed, extraction efficiency 
and quality, technical requirements and cost, but based on our review findings there 
is not enough scientific evidence to support these choices  
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6.2 ABSTRACT 
 
Background: Breast Cancer (BC) is primarily considered a genetic disorder 
with a complex interplay of factors including age, gender, ethnicity, family history, 
personal history and lifestyle with associated hormonal and non-hormonal risk 
factors. The SNP rs2910164 in MIR146A (a G to C polymorphism) was previously 
associated with increased risk of BC in cases with at least a single copy of the C 
allele in breast cancer, though results in other cancers and populations have shown 
significant variation. Methods:  In this study, we examined this SNP in an Australian 
sporadic breast cancer population of 160 cases and matched controls, with a replicate 
population of 403 breast cancer cases using High Resolution Melting. Results: Our 
analysis indicated that the rs2910164 polymorphism is associated with breast cancer 
risk in both a primary and replicate population (p= 0.03 and 0.0013, respectively). In 
contrast to the results of familial breast cancer studies, however, we found that the 
presence of the G allele of rs2910164 is associated with increased cancer risk, with 
an OR of 1.774 (95% CI 1.402-2.237). Conclusions: The microRNA MIR146A has a 
potential role in the development of breast cancer and the effects of its SNPs require 
further inquiry to determine the nature of their influence on breast tissue and cancer. 
 
6.3 BACKGROUND 
 
Breast cancer (BC) is the leading cause of death amongst Australian women 
with risk increasing with age and with an average age of diagnosis of 60 years 
(Australia, 2011). BRCA1 and BRCA2 are the two most commonly associated genes 
in familial BC. With familial BC cases comprising only 5-10% of all BC cases, 
sporadic BC cases have a much higher incidence rate (Anderson, 1991). Causes of 
sporadic BC are not yet clearly understood and it is regarded as the more complex 
form of the disease. miRNAs are a highly conserved class of small (~22 nucleotides), 
endogenous, non-protein coding RNAs recently found to play a role not only in BC 
but also in various other cancers. These miRNAs bind to target mRNA regions where 
they can both inhibit transcription or initiate mRNA cleavage (Bartel, 2004; Lynam-
Lennon et al., 2009). Depending on target interaction, miRNAs can be classified as 
128Chapter 6: Association of the microRNA-SNP rs2910164 in MIR146A with sporadic breast cancer susceptibility: a case control study. 
  
either cancer causing (oncogenic) or tumour-suppressing (non-oncogenic). 
Polymorphisms in miRNAs potentially alter these interactions by interfering, 
generating or removing miRNA-binding sites as well as affecting expression of 
miRNAs. Thus, these polymorphisms have the potential to significantly alter how the 
miRNA interacts with its target/s and its effect on cellular biology. Consequently, the 
identification of these SNPs and their association with disease susceptibility could be 
used for improved diagnostic and therapeutic strategies.  
 
MIR146A is a miRNA located on human chromosome 5 at locus 5q34 and has 
been linked with BRCA1/BRCA2 activity, as these are among its potential targets. 
The SNP rs2910164 is located in the middle of the stem hairpin in the miRNA and 
leads to a G:U pair mismatch (instead of C:U) in the structure of MIR146A. In a 
study by Shen et al (Shen et al., 2008), this polymorphism was linked with age of 
diagnosis in breast and ovarian cancer patients and was the first research to show 
association of MIR146A with breast cancer. The study reported that the presence of 
at least one C allele lowered the age of diagnosis in BC patients with the level of 
expression of mature MIR146A 60% higher in C allele carriers (n= 124 white 
Caucasian women, 42 diagnosed with familial BC, 82 diagnosed with ovarian 
cancer). In addition the authors identified an association of MIR146A with 
BRCA1/BRCA2 by confirming that MIR146A could directly bind to the 3’UTR of 
both genes and therefore play a role in regulating their expression. Interestingly, a 
similar study conducted by Hu et al in 2009 on Han Chinese familial BC cases 
(n=1009), produced contradictory results. In their study, although a much larger 
cohort was examined, no association of the MIR146A SNP with age of BC diagnosis 
was demonstrated; suggesting the effect of genotype or alleles for the SNP 
rs2910164 may be population specific or modulated by environmental factors (Z. Hu 
et al., 2009). In 2010, Pastrello et al conducted a similar study on Italian patients 
diagnosed with familial BC and negative for BRCA1/BRCA2 mutations (n=101) to 
ascertain if rs2910164 had any association with age of diagnosis (Pastrello et al., 
2010). Their results confirmed those by Shen et al and contradict those found by Hu 
et al (Z. Hu et al., 2009; Shen et al., 2008). In addition, a study by Alshatwi et al in 
Saudi-Arabian breast cancer patients indicated that while miR146a expression was 
significantly altered in breast cancer patients compared to controls, rs2910164 did 
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not appear to be associated with breast cancer risk, though their population was only 
100 individuals and the ages of some of their patients indicated a potential familial 
aspect in these cases (Alshatwi et al., 2012). Due to the variations in these studies 
and the lack of research in a purely sporadic population of breast cancer patients in 
Caucasians, we examined this SNP in a case-control Australian Caucasian sporadic 
breast cancer population. 
 
6.4 MATERIALS AND METHODS 
 
6.4.1 Study Cohort 
 
The study population (GRC-BC population) consisted of 160 Caucasian 
Australian females, who were recruited on a voluntary basis with the criteria of being 
diagnosed with sporadic breast cancer, showing no family history of the disease. 
These women were matched for age (±5 years), Caucasian ethnicity and sex to a 
control cohort of healthy individuals likewise showing no family history of breast or 
related cancers. The case and control populations had average ages of 58±12 and 
57.5±11.6 years, respectively. Case samples were recruited from the Gold Coast 
Hospital, Southport, Australia, inviting all women with breast cancer attending to 
participate. Control samples were recruited by the Genomics Research Centre Clinic, 
Southport, Australia by invitation for healthy women from the community to 
volunteer for the research.  
 
The secondary replication population consisted of 403 sporadic breast cancer 
patient samples obtained from the Griffith University-Cancer Council Queensland 
Breast Cancer Biobank (GU-CCQ BB). These individuals were all those currently 
available, recruited on a prevalence basis, but with confirmed diagnosis on the 
Queensland Cancer Registry. The secondary population consisted of an additional 89 
healthy controls, representing the currently available healthy women volunteers, 
recruited and matched on a first-available-match basis to one of the cases as for the 
130Chapter 6: Association of the microRNA-SNP rs2910164 in MIR146A with sporadic breast cancer susceptibility: a case control study. 
  
primary population (age (±5 years), ethnicity and sex). Biobank samples and controls 
had average ages of 61.09±25.09 and 60.2±28.2 years, respectively.  
 
The project was carried out with the approval of the Griffith University Human 
Research Ethics Committee, approval numbers: MSC/07/08/HREC and 
PSY/01/11/HREC. All participants supplied informed written consent. 
 
6.4.2 Genotyping 
 
The candidate SNP in this study was identified using dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP). Primers were designed using Primer3 
(http://frodo.wi.mit.edu/) and checked for specificity through BLAST 
(http://blast.ncbi.nlm.nih.gov). The SNPs were genotyped using high resolution melt 
(HRM) analysis on a RotorGene-Q (Qiagen, Australia). The primer sequences used 
were: forward 5’-TTACAGGGCTGGGACAG-3', reverse-5' -
CCTCAAGCCCACGATGA-3'. PCR amplification and HRM analyses were carried 
out in a 12µL reaction containing: 2µL of 20ng/µL genomic DNA, 1µL of 10µM 
each forward and reverse primers, 2.3µL of 25mM MgCl2, 0.8µL of 5µM dNTPs, 
2.4µL of 5X GoTaq Buffer, 0.1µL of 5Units/µL GoTaq and 1.75µL dH2O. PCR 
conditions were: 95oC for 1 minute, followed by 40 cycles of 95oC for 15 seconds, 
62oC for 15 seconds and 75oC for 30 seconds, followed by 7 minutes at 72oC. 
Melting analysis was carried out between 78oC and 86oC with data collected every 
0.1oC. Two negative controls and two positive controls (Homozygous G and 
Heterozygous CG) were included in each run to ensure a maintained high quality of 
genotyping. Each sample was performed in duplicate. Sanger Sequencing (DNS) was 
used on a random selection of four of each genotype in each population for 
validation of genotypes identified by HRM.  
 
Following HRM, the number of samples that were able to be accurately 
genotyped was 143 cases and 157 controls for the GRC-BC population and the full 
403 cases and 89 controls for the GU-CCQ BB population. Samples which were 
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unable to provide an unambiguous genotype result or would not amplify in PCR for 
direct sequencing were discarded. 
 
6.4.3 Statistical Analysis 
 
Analysis was undertaken using chi-square analysis in the SPSS statistics 
package. Analysis was undertaken using the Chi-square test of independence and 
Odds Ratios and 95% confidence intervals were calculated from the combined results 
of both populations. All populations also underwent testing for Hardy Weinberg 
equilibrium. The α was set at 0.05. 
 
6.5 RESULTS 
 
Following detection by HRM and sequencing validation, we obtained and 
compared the observed genotypic and allelic frequencies for rs2910164 between the 
case and control populations. There were some shifts in genotype frequencies 
between the case and control populations, with the C allele approximately 10% rarer 
in the case population, reflected in decreases in the CC and GC genotypes in cases 
compared to controls, as seen in Table 6-1. Hardy-Weinberg analysis indicated that 
both populations were in Hardy-Weinberg equilibrium. Chi square analysis indicated 
that the genotype differences were not significant, but that allelic frequencies 
between the populations were significantly altered (p= 0.11 and 0.03 respectively).  
 
Table 6-1  Genotype and allele frequencies for GRC-BC population 
 Genotypes Alleles 
 GG GC CC G C 
Cases 80 49 14 209 77 
(n=143) (55.9%) (34.3%) (9.8%) (73.1%) (26.9%) 
Controls 70 63 24 203 111 
(n=157) (44.6%) (40.1%) (15.3%) (64.6%) (35.4%) 
Allele Analysis x2 = 4.95 P = 0.03 
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Because the primary breast cancer population (GRC-BC) showed a significant 
allelic association between rs2910164 alleles and breast cancer susceptibility, we 
undertook genotyping in our secondary population (GU-CCQ BB). The results of 
this genotyping showed a similar trend, with the C allele being approximately 10% 
rarer in the case population compared to the controls, with both CC and GC 
genotypes rarer in the case population compared to controls (Table 6-2). As for the 
initial population, both case and control populations for the secondary analysis were 
in Hardy-Weinberg equilibrium. Chi square analysis on the secondary association 
population indicated that the differences between cases and controls were significant 
for both genotype and allelic frequencies, at p= 0.00088 and 0.0013, respectively.  
 
Table 6-2 Genotype and allele frequencies for GU-CCQ BB population 
 Genotypes Alleles 
 GG GC CC G C 
Cases 245 144 14 634 172 
(n=403) (60.8%) (35.7%) (3.5%) (78.6%) (21.4%) 
Controls 42 36 11 120 58 
(n=89) (47.2%) (40.4%) (12.4%) (67.4%) (32.6%) 
Allele Analysis x2 = 10.29 P = 0.00134 
 
 
Since both populations showed significant association with breast cancer 
susceptibility, we undertook odds ratio calculations to determine the magnitude of 
the effect. All three models tested (G vs. C for additive, GG vs. GC+CC for recessive 
and GG+GC vs. CC for dominant inheritance models) showed increases in breast 
cancer risk associated with a higher dose of the G allele, with the G vs. C model 
showing the most precise odds estimate, with an OR of 1.774 (95% CI 1.402 - 
2.237). A summary of combined statistical analysis for both populations can be 
found in Table 6-3 and the complete Odds Ratios can be found in Table 6-4. 
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Table 6-3 Combined primary and secondary population genotype and allele frequencies and analysis 
results. 
 Genotypes Alleles 
 GG GC CC G C 
Cases 325 193 28 843 249 
(n=546) (59.5%) (35.3%) (5.2%) (77.2%) (22.8%) 
Controls 112 99 35 323 169 
(n=246) (45%) (40.2%) (14.2%) (65.7%) (34.3%) 
Genotype 
Analysis x
2 = 24.78 P = 0.000004 Allele Analysis x
2 = 23.28 P = 0.000001 
 
 
Table 6-4 Odds Ratios for combined population analysis results. 
Odds Ratios OR 95% CI 
G vs. C model 1.774 1.402 - 2.237 
GG vs. GC and CC model 1.8428 1.3584 – 2.4999 
GG and GC vs. CC model 3.0687 1.8206 - 5.1725 
 
6.6 DISCUSSION 
 
Our results indicate that the presence of the G allele for rs2910164 increases 
the risk for sporadic breast cancer in a Caucasian population, confirmed through 
analysis in two independently collected populations. These results show some 
deviation from the expected frequency of the C allele in the general population 
compared to reported frequencies for the rs2910164 SNP in Caucasian populations. 
The reported allelic frequency as per the 1000 Genomes Project in Europeans is G-
78.2% and C-21.8%, while HapMap gives frequencies of G-76.5% and C-23.5%. 
Data from other populations in both the 1000 Genomes Project and HapMap, 
however, show that rs2910164 varies significantly in different ethnic groups, and in 
Asians, the most common allele is C, with frequencies of C-60% and G-40%. More 
importantly for this research, a subset breakdown within the European population 
shows that Italians have an increased frequency of the C allele compared to other 
European groups, at C-27% and G-73%. It thus seems possible that our elevated C 
allele count is the result of a contribution from Italian and related Caucasian 
subgroups, especially given that sequencing of HRM analysed samples showed 
confirmation of the genotype calls in both cancer and control populations.  
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The results also show some variation form the implications of previous 
research on rs2910164 in breast cancer, though those studies have also shown 
conflicting results. In 2008, Shen et al identified an increased risk of breast cancer 
amongst patients who had a single copy of the C allele and that the binding capacity 
of MIR146A to BRCA1 was significantly higher in vitro when cells were transfected 
with C allele mimics as compared to the G allele (Shen et al., 2008). These results 
led them to draw the conclusion that the CC or CG variant of the rs291016 
polymorphism increases susceptibility to familial BC. A similar study conducted by 
Hu et al in 2009 found contrasting results (Z. Hu et al., 2009). The Hu et al study 
involved 1009 familial breast cancer patients and 1093 healthy controls from a Han 
Chinese population. In this study, no association of miR146a with increased risk of 
familial breast cancer was observed. More recently, a study conducted by Catucci et 
al in 2010 on 1894 familial breast cancer patients and 2760 healthy controls from 
German and Italian populations also demonstrated no association with increased risk 
of familial breast cancer and miR146a (Catucci et al., 2010). The discrepancy 
between the results obtained from previous studies, including the current study may 
be due to the varied ethnic backgrounds investigated, however, the observed 
differences are more likely a result of fundamental differences in the type of breast 
cancer addressed in the population cohorts examined.  
 
This difference is that each of the previous breast cancer association studies 
have been carried out in populations of individuals with familial cancer, most of 
whom show symptoms of BRCA pathway malfunction, but lack BRCA1 or BRCA2 
mutations. The suggested association of MIR146A with increased risk of breast 
cancer by Shen et al in 2008 was a result of a study conducted on patients with 
BRCA1/BRCA2 mutations, indicating familial breast cancer where these genes are 
known to play an essential role (Shen et al., 2008). In addition, the study by Pastrello 
et al where BRCA-negative patients were examined supports the data observed by 
Shen et al for the effects of the C allele on age of onset (Pastrello et al., 2010; Shen 
et al., 2008). Similar to the study by Shen et al and Alshatwi et al, the Pastrello et al 
study cohort was a much smaller population when compared to the studies conducted 
by Hu et al and Catucci et al (Catucci et al., 2010; Shen et al., 2008). Finally, a study 
Chapter 6: Association of the microRNA-SNP rs2910164 in MIR146A with sporadic breast cancer susceptibility: 
a case control study. 135 
on 1166 BRCA1 mutation carriers and 560 BRCA2 mutation carriers from France 
and America (no ethnicity specified) by Garcia et al failed to find an association 
between rs2910164 and cancer risk in these patients. MIR146A has thus been 
variably associated with BRCA1/BRCA2 familial BC risk, age of onset and age of 
diagnosis in these studies. Meta-analyses on the BC studies to date indicate that both 
ethnicity and gender is a factor in the effect of rs2910164 on cancer susceptibility 
(Amandine I. Garcia et al., 2011; A. Wang et al., 2012). This would make sense in 
the context of recent results from Omrani et al. who tested the rs2910164 SNP in an 
Iranian breast cancer population and failed to find any association with the alleles 
and breast cancer (Omrani et al., 2014). 
 
The conflicting results of previous studies may arise through differential effects 
of the SNP in the background of a familial impairment of BRCA1 and 2 associated 
pathways compared to non-impairment of these pathways in sporadic breast cancer 
patients. If BRCA associated pathways are poorly functional in familial breast cancer 
patients, then the effect of the increased BRCA1/BRCA2 binding for the C allele of 
rs2910164 may result in greater loss of cell growth regulation. By comparison, in 
sporadic breast cancer the increased binding of the C allele may be compensated for 
by upregulation of the precise BRCA related mechanisms that are impaired in 
familial patients. This would lead to a situation where the control populations used to 
determine association for the familial populations are subject to allelic pressure in the 
same direction, partially masking the effect of the SNP on risk in these patients.  
 
There is also support for differential biological effects for the SNP from data 
gathered in other cancer types. In head and neck cancers, colorectal cancer, acute 
lymphoblastic leukaemia and H. pylori infection related dysplasia, the C allele of 
rs2910164 has been associated with increased risk of development (Chae et al., 2013; 
Hasani et al., 2014; Lian et al., 2012; Ma et al., 2013; Orsós et al., 2013; Song et al., 
2013). By contrast, the G allele has been associated with increased risk of 
hepatocellular carcinoma and prostate cancer, while melanomas showed a more 
complex relationship where heterozygotes had increased risk of cancer development, 
but cells carrying the G allele had increased invasive and proliferative characteristics 
(B. Xu et al., 2010; Yeqiong Xu et al., 2013; Yumin Xu et al., 2013; Yamashita et 
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al., 2013). These differences add weight to the implications from the breast cancer 
studies suggesting that the effect of the polymorphism is modulated by genetic and 
environmental factors, probably due to the relative expression of its target mRNAs 
and factors affecting its own expression. In addition, there may be significant effects 
on the effect of miR146a through the presence or absence of BRCA1 or BRCA2 
mutations, epistatic effects from other SNPs, or specific environmental triggers 
common to closely related individuals compared to more sporadic population 
cohorts. These in turn may influence the overall impact of the rs2910164 SNP on 
breast cancer susceptibility, despite its observed functional effects. 
 
6.7 CONCLUSIONS 
 
Our analysis indicates that the rs2910164 SNP in MIR146A has a significant 
effect on breast cancer susceptibility. Given the interaction with BRCA pathways, the 
potential role of other polymorphisms (inferred from the role of ethnicity) and the 
variable results of research on rs2910164 in breast cancer, further analyses on this 
polymorphism should take into account the potential for familial versus sporadic 
breast cancer effects, and should carefully choose controls to establish the effects of 
the SNP more precisely in the target populations. This latter point may be a 
limitation on our study, as ethnic variation of the SNP differs strongly and may have 
affected our frequency data and obscured the true strength of the polymorphism in 
breast cancer risk. Leading on from this, our relatively low population size may also 
be affecting overall accuracy of the study, especially in the lack of controls available 
for the secondary population. As a result, research using sporadic breast cancer 
populations in larger cohorts of Caucasians and other ethnicities should be 
undertaken to confirm the role of rs2910164 in cancer risk in the general population. 
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7.2 ABSTRACT 
 
MicroRNAs (miRNAs) are important small non-coding RNA molecules that 
regulate gene expression in many important cellular processes related to the 
pathogenesis of cancer. Genetic variation in miRNA genes could impact their 
synthesis and cellular effects and single nucleotide polymorphisms (SNPs) are one 
example of genetic variants previously studied in relation to breast cancer. Studies 
aimed at identifying miRNA SNPs (miR-SNPs) associated with breast malignancies 
could be the initial step towards further understanding of the disease and in 
developing clinical applications for early diagnosis and treatment. In this study we 
genotyped a panel of 24 miR-SNPs using multiplex PCR and chip-based matrix 
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry 
(MS) analysis in our Australian Caucasian breast cancer case control populations. 
Statistical analysis of our genotyping results showed six of these miR-SNPs to be 
non-polymorphic and twelve of our selected miR-SNPs to have no association with 
breast cancer risk. However we were able to show association between rs353291 
(located in MIR145) and the risk of developing breast cancer in two independent case 
control cohorts (p = 0.041 and p=0.023). Our study is the first to report an 
association between a miR-SNP present in MIR145 in individuals of Caucasian 
background and breast cancer risk. This finding requires further validation through 
genotyping of larger cohorts or in individuals of different ethnicities to determine the 
potential significance of this finding as well as studies to determine functional 
significance. 
 
7.3 BACKGROUND 
 
MicroRNAs (miRNAs) are small non-coding single stranded RNA molecules 
of about 21 to 25 nucleotides in length involved in negative regulation of gene 
expression. They account for about 1% of the human genome and they were initially 
identified in Caenorhabditis elegans (R. C. Lee et al., 1993; Reinhart et al., 2000). 
They are transcribed from long microRNA primary transcripts (pri-miRNAs) that 
contain miRNA precursors (pre-miRNA), which are stem-loop molecules of about 55 
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to 70 nucleotides in length. Pre-miRNA are usually generated via the canonical 
pathway, however a small group are produced through splicing/debranching 
machinery in the “miRtron pathway”, or non-canonical pathway (Westholm & Lai, 
2011). In the canonical pathway, pri-miRNA are cleaved by the complex formed by 
the nuclear ribonuclease (RNase) III DROSHA and  the RNA-binding protein 
DCGR8 (DiGeorge syndrome critical region gene 8) (Yoontae Lee et al., 2003). Pre-
miRNAs are transported to the cytoplasm by XPO5 (exportin5) and the nuclear 
protein ran-GTP and they are processed by DICER1, a RNase type III enzyme, and 
double-stranded RNA binding domain (dsRBD) proteins TARBP2 and/or PKRA 
(Chendrimada et al., 2005; Yi et al., 2003).  This process results in the production of 
a duplex molecule that contains both single-stranded mature miRNA sequence and a 
complementary strand named miRNA*. The miRNA* is released and degraded while 
the mature miRNA is loaded into the RNA-induced silencing complex (RISC) , 
where it is merged into the Argonaute/EIFC2C (Ago) proteins to mediate target 
messenger RNA (mRNA) recognition and interaction. The mRNA target is 
recognised by base pairing of the second to eighth nucleotides in the 5’-end of the 
miRNA (Seed region) and the complementary sequence mainly located in the 3’ 
untranslated region (3’-UTR) region of the mRNA, but binding sites may also be 
found in the coding region (Khvorova et al., 2003; Y. Lee et al., 2002).  Each 
miRNA may bind to up to 200 gene targets and each gene could have multiple 
binding sites for different miRNAs, making a highly complex web of interactions 
that may have extensive effects on a variety of biological pathways (Bartel, 2009; 
Rajewsky, 2006).   
 
miRNAs are very likely to play an important role in cancer biology because 
they are involved in regulation of important cellular processes like cell growth, 
differentiation and cell survival (Bartel, 2004; Thalia A. Farazi et al., 2011; Robbins 
et al., 2010; Zuoren Yu et al., 2010; Baohong Zhang, Pan, et al., 2007; Baohong 
Zhang, Wang, & Pan, 2007). Some of the mechanisms that can result in changes in 
miRNA synthesis and expression in relation to cancer include: point mutations in 
miRNA and mRNA sequences, loss or mutation in the promoter regions for specific 
miRNA clusters, epigenetic changes and alterations in pathway related to dsRBD 
proteins (Ha & Kim, 2014; Kim, 2005; Lynam-Lennon et al., 2009). Single 
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nucleotide polymorphisms (SNPs) in miRNA genes (miR-SNPs) are one example of 
point mutation (albeit one occurring in the past) that could affect miRNA function in 
one of three possible ways:  altering transcription of the primary miRNA transcript; 
altering processing of the pri-miRNA and pre-miRNA and; through their effects on 
modulation of miRNA-mRNA interactions(S. Duan, Mi, Zhang, & Dolan, 2009; H.-
C. Lee et al., 2011; Ryan et al., 2010; G. Sun et al., 2009). As a result miR-SNPs 
have been associated with different types of cancer, including chronic lymphocytic 
leukaemia, gastric, lung and thyroid carcinoma (Calin & Croce, 2006; Z. Hu et al., 
2008; Jazdzewski et al., 2008; Q. Sun et al., 2010).  
 
Breast cancer is the second most commonly diagnosed cancer around the world 
(1.67 million new cases, 25%) and the most common type of cancer for women in 
developed countries (793,684 new cases, 28%) according to the International Agency 
for Research on Cancer (IARC) (Ferlay et al., 2013). Breast cancer is also the most 
common cause of cancer-related deaths for women in the world (521,817, 14.7%) 
and it ranks second for women in developed countries amongst all cancers 
deaths(Ferlay et al., 2013). There is evidence of the role that miR-SNPs play in 
relation to breast cancer.  Hu et al. showed that the presence of mutant alleles of 
MIR196A2 rs11614913 and MIR499A rs3746444 significantly increased breast 
cancer susceptibility in Chinese women (Z. Hu et al., 2009). However in the genetic 
association analysis of Caucasian populations and functional studies in breast cancer 
cell lines performed by Hoffman et al. the presence of mutation in MIR196A2 
rs11614913 was significantly associated with reduced risk of breast cancer, as well 
as less efficient processing of MIR196A2 and reduced capacity to regulate target 
genes, indicating additional factors may be at work in this SNP’s effect on breast 
cancer (Hoffman et al., 2009). Kontorovich et al. found 2 SNPs, rs6505162 and 
rs895819 located in MIR423 and MIR27A precursors respectively, to be significantly 
associated with decreased risk of breast cancer in BRCA2 mutation carriers from a 
Jewish population (Kontorovich et al., 2010). rs895819 was also significantly 
associated with reduced risk of developing breast cancer in families with a history of 
non-BRCA related breast cancer in a later study performed by Yang et al (Rongxi 
Yang et al., 2010). Finally rs2910164, a miR-SNP located in the 3p strand of 
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MIR146A, was found to be associated with a younger age of diagnosis in familial 
breast cancer for BRCA1 mutation carriers (Shen et al., 2008).  
 
This study investigated a panel of miR-SNPs present in miRNA genes 
previously identified to be involved in the pathophysiological mechanisms of breast 
cancer. Our initial selection included 24 variants located in 9 miRNA genes or in 
close proximity to them and these were genotyped using multiplex PCR and matrix-
assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF 
MS) analysis. Genotyping results of the 19 miR-SNPS successfully genotyped and 
included in this study identified six previously reported microRNA SNPs as non-
polymorphic. From the remaining polymorphisms twelve miR-SNPS showed no 
significant differences between cases and controls and one variant in MIR145 was 
identified to be associated with breast cancer susceptibility in both of our Australian 
Caucasian breast cancer case-control populations. 
 
7.4 MATERIALS AND METHODS 
 
7.4.1 Study Populations 
 
Two independent Australian Caucasian case control populations were available 
for our study: The Genomics Research Centre Breast Cancer (GRC-BC) population 
and part of the Griffith University-Cancer Council Queensland Breast Cancer 
Biobank (GU-CCQ BB). We conducted single nucleotide polymorphism genotyping 
in the GRC-BC population initially. It consisted of DNA samples from 173 breast 
cancer patients from South East Queensland and DNA samples from 187 healthy age 
and sex matched females with no history of personal or familial cancer collected at 
the Genomics Research Centre Clinic, Southport, with research approved by Griffith 
University’s Human Ethics Committee (Approval: MSC/07/08/HREC and 
PSY/01/11/HREC) and the Queensland University of Technology Human Research 
Ethics Committee (Approval: 1400000104). All participants supplied informed 
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written consent. Average age of test population was 57.52 years and 57 years for 
cases and controls respectively. 
 
Further validation of genotyping results was performed on a subset of the GU-
CCQ BB population. 679 DNA samples from breast cancer patients residing in 
Queensland with a diagnosis of invasive breast cancer confirmed histologically were 
used to validate genotyping of miR-SNPs. Patient samples had been collected by the 
Genomics Research Centre in collaboration with the Cancer Council of Queensland 
as part of a 5-year population-based longitudinal study commenced in January 2010. 
Patients included in this study were between 33 and 80 years of age, with an average 
age of 60.16 years. Control population for the GU-CCQ BB was established from 2 
sources: 107 healthy age and ethnicity matched females with no personal or familial 
history of cancer, recruited since January 2000 at the Genomics Research Centre at 
the Institute of Health and Biomedical Innovation, Queensland University of 
Technology and genotyping result data taken from 201 age, ethnicity and sex 
matched individuals belonging to the phase 1 European population from the 
1000Genomes project (Abecasis et al., 2012). 
 
7.4.2  Genomic DNA sample preparation from whole human blood. 
 
Genomic DNA was extracted from whole blood samples using a modified 
salting out method described previously (Chacon-Cortes et al., 2012; Nasiri et al., 
2005). DNA samples were evaluated by spectrophotometry using the Thermo 
Scientific NanoDropTM 8000 UV-Vis Spectrophotometer (Thermo Fisher Scientific 
Inc., Wilmington, DE. USA) to determine DNA yield and 260/280 ratios (Chacon-
Cortes & Griffiths, 2014; Huberman, 1995; Sahota, Brooks, Tischfield, & King, 
2007). Samples with a reading below 1.7 for their 260/280 ratio were purified using 
an ethanol precipitation protocol to guarantee DNA sample purity (Sambrook & 
Russell, 2001).  
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7.4.3  miRNA SNP selection 
 
Figure 7-1 shows the selection process we followed to determine miRNA SNPs 
(miR-SNPs) that could be included in our study. Two datasets, “The whole miRNA-
disease association data” and “The miRNA function set data” from the human 
miRNA disease database (HMMDD) created by Lu et al (M. Lu et al., 2008) and 
updated in January 2012, were used to select 8 diseases and/or pathological 
characteristics and 24 biological and/or cellular functions related to breast cancer 
(See Table 7-1).  
 
Table 7-1 Selected features from the Human miRNA disease database (HMDD) included in present 
study 
    Selected diseases and/or pathological features related to breast cancer 
miRNA-
disease 
association 
dataset 
Human miRNA 
genes in dataset 
1. Adenocarcinoma  
2. Breast Neoplasms  
3. Carcinoma 
4. Ductal breast 
carcinoma  
5. Squamous Cell Carcinoma 
6. Neoplasms 
7. Germ cell and embryonal 
neoplasm 
8. Squamous cell neoplasms 
503 
Human Diseases in 
dataset 
396 
  Selected biological and/or cellular function in relation to 
Cancer 
miRNA 
function 
dataset 
Human miRNA 
genes in dataset 
1. Activation of 
caspases cascade  
2. AKT pathway  
3. Angiogenesis  
4. Anti-cell proliferation  
5. Apoptosis  
6. Cell cycle related  
7. Cell death  
8. Cell differentiation  
9. Cell division  
10. Cell fate 
determination  
11. Cell motility  
12. Cell proliferation  
13. Chemosensitivity of tumour cells  
14. Chemotaxis 
15. Chromatin remodelling 
16. DNA Repair 
17. Epithelial-mesenchymal 
transition 
18. Human embryonic stem cell 
(hESC) regulation 
19. Immune response 
20. Immune system 
21. Inflammation 
22. miRNA tumour suppressors 
23. Onco-miRNAs 
503 
Biological and 
cellular functions in 
dataset 
43 
 
As shown in Figure 7-1, we picked the 50 miRNA genes from each dataset that 
were present in the majority of selected features for inclusion in the following steps. 
This list was narrowed down to the 25 miRNA genes on each dataset with the 
strongest evidence in order to maximise the potential for identification of 
biologically relevant molecules using two main criteria: miRNAs involved in the 
largest number of selected features from each group followed by a literature search to 
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confirm the number of publications showing significant relationships to cancer 
biology or the possession of known functional effects of polymorphisms within the 
miRNA itself. Following this, we chose 10 miRNA genes from the 25 genes on both 
lists, again prioritising by number of functions and publications, and conducted a 
search to identify SNPs using both dbSNP database from The National Center for 
Biotechnology Information (NCBI) (Sherry et al., 2001) and 1000 Genomes project 
browser (Consortium, 2012). Final selection of SNPs was done using this algorithm: 
All microRNA-SNPs located inside the pre-miRNA gene were automatically 
included in the SNP selection. However, SNPs located outside of the pre-miRNA 
gene were assessed using the following criteria: miR-SNPs located up to 500bp 
upstream or downstream from pre-miRNA were automatically included in the SNP 
selection. On the other hand, SNPs located more than 500bp from the 3’ or 5’ end 
were chosen only if they had a previously reported minor allele frequency higher 
than 5% in Caucasian populations. As a result 56 microRNA SNPs were identified in 
this preliminary selection (Data not shown) (See Figure 7-1).  
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 Figure 7-1 MicroRNA SNP (miR-SNP) selection algorithm using the Human miRNA Disease Database (HMDD). This flow chart shows 
workflow for selection of preliminary miR-SNPs included in genotyping study. 
Abbreviations: dbSNP, single nucleotide polymorphism database; MAF, minor allele frequency; miRNA, microRNA; NCBI National Center for 
Biotechnology Information; SNP, Single nucleotide polymorphisms 
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7.4.4 Primer design 
 
Using the MassARRAY® Assay Design Suite v1.0 software (SEQUENOM 
Inc., San Diego, CA, USA) we were able to create a single multiplex PCR 
genotyping assay containing 24 miR-SNPs from our preliminary selection (See Table 
7-2).  
 
We designed forward and reverse PCR primers and one iPLEX® (extension) 
primer and verified that the mass of extension primers differed by at least 30 Da 
among different SNPs and by 5 Da between alternative alleles of the same marker to 
achieve successful marker and allele identification by mass spectrometry analysis. 
Primers were manufactured by Integrated DNA Technologies (IDT®) Pte. Ltd. 
(Baulkham Hills, NSW 2153, Australia) and primer information is shown in Table 
7-3. 
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Table 7-2 List of the miRNA SNPs included in multiplex primer design using the MassARRAY® Assay Design Suite v1.0 software (SEQUENOM Inc., San Diego, CA, 
USA) 
miRNA Locus Location SNPs in gene region MAF Location 
SNPs near 
3' end MAF Location 
SNPs near 
5' end MAF Location 
MIR210 11p15.5 568,089 - 568,198    rs1062099 0.187 567,627 rs7395206 0.500 568,211 
rs1090217
3 
0.483 570,072 
MIR34A 1p36.22 9,211,727 - 9,211,836 rs35301225 NA 9,211,802 rs77585961 0.024 9,211,468    
MIR155 21q21.3 26,946,292 - 26,946,356    rs2829801 0.470 26,944,305 rs1547354 0.081 26,946,709 
MIR221 Xp11.3 45,605,585 - 45,605,694    rs7050391 0.013 45,605,273 rs2858061 0.435 45,606,132 
rs2858060 0.499 45,607,008 
rs2858059 0.478 45,607,190 
MIR222 Xp11.3 45,606,421 - 45,606,530    rs2858061 0.435 45,606,132 rs2858060 0.499 45,607,008 
rs2858059 0.478 45,607,190 
MIR21 17q23.1 57,918,627 - 57,918,698    rs112394324 0.003 57,918,251 rs1292037 0.244 57918908 
rs3851812 0.037 57,918,370 rs13137 0.244 57919031 
MIRLET7A1 9q22.32 96,938,239 - 96,938,318    rs10761322 0.458 96,937,478    
rs10739971 0.260 96,937,680 
MIRLET7A2 11q24.1 122,017,230 - 
122,017,301 
   rs629367 0.145 122,017,014 rs1143770 0.486 122,017,598 
rs562052 0.326 122,018,550 
rs693120 0.326 122,019,011 
MIR145 5q32 148,810,209 - 
148,810,296 
   rs55945735 0.201 148,809,158 rs353291 0.332 148,810,746 
rs73798217 0.054 148,809,918 
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Table 7-3 Primer sequences for the miRNA SNPs included in genotyping study using multiplex PCR reaction and MALDI-TOF MS 
SNP  Forward primer sequence Reverse primer sequence iPLEX® (Extension) primer sequence 
rs2829801 ACGTTGGATGTTCCCACTCAGGCATATAGC ACGTTGGATGTGGAGTCTATGTCCACTTCC TGGGCTAAGCAACCA 
rs7395206 ACGTTGGATGTCGGACGCCCAAGTTGGAG ACGTTGGATGTCACACGCACAGTGGGTCT GGTGGGCGGGCGGAG 
rs73798217 ACGTTGGATGACTGGAGGTTATCAGAGAGG ACGTTGGATGATGTGTATTCCCCAGTCTCC ACCATTCAGTTCCTAGC 
rs353291 ACGTTGGATGGTAGAGATGCCACAAGAGGG ACGTTGGATGAAACCTTAAGTCTTCGTTCG GGTTGTTCTCTGGCTGC 
rs55945735 ACGTTGGATGGGTCTCAAACTCCTGACTTC ACGTTGGATGCTGCATCTGAGCACTTCAAG TGATGCCTGGCGGGGCG 
rs10902173 ACGTTGGATGTCACAGGCACCTTTTCTCAG ACGTTGGATGGAAGCCTGGGTATTAGGATG ACCTTTTCTCAGCATCTG 
rs112394324 ACGTTGGATGACTGGAGAGAGAAATTACCC ACGTTGGATGGTTGAAACCAGAGTACATGC CAGATACGACAGAGTGTG 
rs1292037 ACGTTGGATGTACAGCTAGAAAAGTCCCTG ACGTTGGATGGGAGGGAGGATTTTATGGAG AACCTTTTCAAAACCCACA 
rs562052 ACGTTGGATGCTCCAGGCTAGTGGAATAAC ACGTTGGATGCTACTGCACTGATCGTGTTC CAGATTCAAATGCCATAGCA 
rs2858059 ACGTTGGATGCAGTAAGTATTTCTGGGGTG ACGTTGGATGCTCCCATGATACAATGAAGG TGGGGTGGATAAATGAATAG 
rs1062099 ACGTTGGATGGACCCGGTCCTGATTTTAAC ACGTTGGATGTGTGTTTCTGCCGCTTCAGT TTTAACAGTAGACTTGAGAAG 
rs10739971 ACGTTGGATGCCTAATAAGACCACTTAGTGT ACGTTGGATGATGCACTAACATACAACGAG CCACCTACTCATTTATCCCATG 
rs2858060 ACGTTGGATGACTGTATTATCCTCAGTTC ACGTTGGATGACTTGGGTAATCTAGCAATG GTATTATCCTCAGTTCGTAACA 
rs2858061 ACGTTGGATGGCTTTCAATACTACAAGGG ACGTTGGATGAATGATACCTTTCATAGGGG GTAAAACAAAAACAGGTAAGAG 
rs35301225 ACGTTGGATGGGCAGTATACTTGCTGATTG ACGTTGGATGGCTGTGAGTGTTTCTTTGGC GGATTATTGCTCACAACAACCAG 
rs1547354 ACGTTGGATGTTGCAGGTTTTGGCTTGTTC ACGTTGGATGGGAGGTTAGTAGTCCTTCTA TTTGATTCAACTGTTAGAAATGTG 
rs13137 ACGTTGGATGAGGTGAAAGAGATGAACCAC ACGTTGGATGAAAGCATTCCCAAAATGCTC TCCCAAAATGCTCTATTTTAGATAG 
rs10761322 ACGTTGGATGGCTTTTGGTTACTAAATCAC ACGTTGGATGCTTCATATTTAGGAGGTAGC GGCATATTTAGGAGGTAGCTACTAC 
rs693120 ACGTTGGATGGTAGATGGCACATATAGAAA ACGTTGGATGCATCCCTTAACTGTAAGTTC GATTGTCAAATGAAAAGAAGAATAT 
rs1143770 ACGTTGGATGCTGAACAATTTAATGCCTTC ACGTTGGATGTTCAGTTTTACCAGAGGAAC CCCCCATGCCTTCTGATATCTGTTGA 
rs77585961 ACGTTGGATGGTTTCCTTCTCTGCAAGACG ACGTTGGATGCACTTACTATGCAGGAAGGC CCTACATGATGTAATACACTTACAATA 
rs7050391 ACGTTGGATGGTAAGGCAGTATGATTAGGC ACGTTGGATGGCCTCAACTGTCAAAGATTG TGTTCATAATTATTATCAGAAGGCATA 
rs3851812 ACGTTGGATGTTTTCCTCCCAAGCAAAAC ACGTTGGATGTTCTTGCCGTTCTGTAAGTG GGTGGAAGTGTTTTATTCTTAGTGTGA 
rs629367 ACGTTGGATGTATGCAGCATTTTTGTGAC ACGTTGGATGATTCTGTTTCCTCGGGTTAG GGGGTCAGCATTTTTGTGACAATGGACA 
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7.4.5 Primary Multiplex PCR 
 
Genotyping was undertaken following the iPLEX™ GOLD genotyping 
protocol using the iPLEX® Gold Reagent Kit (SEQUENOM Inc., San Diego, CA, 
USA). Primer extension reactions were performed according to the instructions for 
the SEQUENOM linear adjustment method included in the iPLEX™ GOLD 
genotyping protocol (SEQUENOM Inc., San Diego, CA, USA). All reactions were 
performed using Applied Biosystems® MicroAmp® EnduraPlate™ Optical 96-Well 
Clear Reaction Plates with Barcode  (Life Technologies Australia Pty Ltd., 
Mulgrave, VIC, Australia) and an Applied Biosystems® Veriti® 96-Well Thermal 
Cycler (Life Technologies Australia Pty Ltd., Mulgrave, VIC, Australia). 
 
7.4.6  MALDI-TOF MS analysis and data analysis 
 
A total of 12-16 nl of each iPLEX® reaction product were transferred onto a 
SpectroCHIP® II G96 (SEQUENOM Inc., San Diego, CA, USA) using 
SEQUENOM® MassARRAY® Nanodispenser (SEQUENOM Inc., San Diego, CA, 
USA). SpectroCHIP® analysis was carried out by SEQUENOM® MassArray® 
Analyzer 4 and the SpectroAcquire software Version 4.0 (SEQUENOM Inc., San 
Diego, CA, USA). Finally data analysis for genotype determination was done using 
the MassARRAY® Typer software version 4.0 (SEQUENOM Inc., San Diego, CA, 
USA). 
 
7.4.7 Statistical analysis 
 
Statistical analysis of genotypes and alleles was conducted using Plink 
software version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 
2007). The α for p-values was set at 0.05 to determine statistically significant 
association with breast cancer. Genotype and allele frequencies for each miRNA 
SNP in our case and control populations were established and we used Hardy-
Weinberg equilibrium (HWE) to evaluate deviation between observed and expected 
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frequencies for identification of unexpected population or genotyping biases (Guo & 
Thompson, 1992; Hardy, 1908). We performed Chi square analysis to evaluate 
differences in genotype and allele frequencies between cases and controls for each 
independent population (Fisher & Yates, 1963). Finally we calculated odds ratio 
(OR) and obtained 95% confidence interval (CI) 95% to assess disease risk.  
 
7.5  RESULTS AND DISCUSSION 
 
MicroRNAs are some of the small non-coding RNA molecules responsible for 
gene regulation at the translational level. They require a very complex series of 
nuclear and cytoplasmic processes for their synthesis and to achieve their functional 
effects on genes involved in key cellular functions like replication and cell 
differentiation (Bartel, 2009; Y. Lee et al., 2002; Baohong Zhang, Wang, et al., 
2007). As a result they are likely to play a role in the development and progression of 
cancer due to the important biological mechanisms they regulate (Thalia A. Farazi et 
al., 2011; Robbins et al., 2010; Baohong Zhang, Pan, et al., 2007). They have been 
shown to have different roles in various types of cancer including breast cancer 
(Calin & Croce, 2006; Lynam-Lennon et al., 2009). Breast cancer is a cause for 
concern since recent reports by the IARC show it has very high incidence and 
mortality rates around the world (Ferlay et al., 2013). Analysis of single nucleotide 
polymorphisms in well-defined case control cohorts has provided information on 
miR-SNPs involved in the pathophysiology of different types of cancer including 
breast cancer (Hoffman et al., 2009; Z. Hu et al., 2008; Z. Hu et al., 2009; 
Jazdzewski et al., 2008; Kontorovich et al., 2010; Shen et al., 2008; Q. Sun et al., 
2010; Rongxi Yang et al., 2010). Therefore we selected a panel of 24 miR-SNPs 
related to 9 miRNA genes previously identified to play a role in breast cancer to 
genotype in our Australian Caucasian breast cancer case control populations.  
Genotyping of our selected miRNA variants in the GRC-BC cohort showed six of 
them to be non-polymorphic (rs73798217, rs112394324, rs35301225, rs1547354, 
rs7050391 and rs3851812) and another five of the chosen miR-SNPs failed to 
successfully deliver genotypes (rs2829801, rs7395206, rs2858059, rs1143770 and 
rs77585961).  
152 Chapter 7: Genetic association analysis of miRNA SNPs implicates MIR145 in breast cancer susceptibility. 
  
On the other hand, genotype and allele frequencies of the remaining 13 miR-
SNPs in the GRC-BC cases and controls showed these to be closely similar to those 
found in Hapmap for Caucasian populations and they were also in Hardy Weinberg 
Equilibrium (HWE) (p > 0.05). Ultimately, however, chi-square analysis of 
genotyping results of 12 SNPs located in relation to seven miRNAs (MIR210, 
MIR221, MIR222, MIR21, MIRLET7A1, MIRLET7A2 and MIR145) showed no 
significant differences for genotype and allele frequencies between cases and 
controls in our GRC-BC population (See Tables 6-4 to 6-9). 
  
In contrast, we were able to determine significant differences at the allelic level 
for rs353291 after chi-square analysis in our GRC-BC cohort (p=0.041) although no 
significant difference in genotype frequencies (p=0.09) (See Table 7-10). We then 
proceeded to genotype this SNP in the GU-CCQ BB population and we also found 
that genotype and allele frequencies closely matched Hapmap frequencies for 
Caucasian populations and that cases and controls were in HWE as well. Statistical 
analysis of genotyping in our replication population showed similar findings to those 
obtained in the GRB-BC cohort shown in Table 7-10. We were able to find 
significant differences in allele frequencies between cases and controls in the GU-
CCQ BB population (p=0.023) and also no statistically significant differences at the 
genotype level (p=0.07). Finally we calculated odds ratios for alleles in the GRC-BC 
and GU-CCQ BB populations to be 1.37(CI 95%: 1.01-1.84) and 1.25 (CI 95%: 
1.03-1.52) respectively, which suggests that the presence of the C allele at this locus 
increases the risk of developing breast cancer. However it should be noted that if we 
consider statistical correction for multiple testing, our finding for the analysis of 
allele frequencies for both populations for this variant is not significant if we 
determine Bonferroni correction of the α for p-value to be 2.08 x 10-3. However these 
results are still potentially interesting, particularly considering the similarity of allelic 
significance in both independent case-control cohorts and point to the need for 
further genotyping in extended populations. 
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Table 7-4 Allele and genotype frequencies for miRNA SNPs in MIR210 obtained from the GRC-BC population 
  rs1062099 rs10902173 
  Allele Genotype Allele Genotype 
  G  
(%) 
C  
(%) 
p-value GG  
(%) 
CG  
(%) 
CC 
(%) 
p-value C  
(%) 
T  
(%) 
p-value CC 
(%) 
TC 
(%) 
TT  
(%) 
p-value 
Control 300 
(83.3) 
60 
(16.7) 
0.36 126 
(70.0) 
48 
(26.7) 
6  
(3.3) 
0.61 216 
(59.3) 
148 
(40.7) 
0.93 63 
(36.6) 
90 
(49.5) 
29 
(15.9) 
0.64 
Cases 263 
(80.7) 
63 
(19.3) 
106 
(65.0) 
51 
(31.3) 
6  
(3.7) 
203 
(59.0) 
141 
(41.0) 
63 
(34.6) 
77 
(44.8) 
32 
(18.6) 
Hapmap (%) 81.7 18.3   66.8 29.8 3.4   60.4 39.6   34.8 51.2 14.0   
 
 
Table 7-5 Allele and genotype frequencies for miRNA SNPs in MIR221 and MIR222 from the GRC-BC Population 
  rs2858061 rs2858060 
  Allele Genotype Allele Genotype 
  G 
(%) 
C  
(%) 
p-value GG 
(%) 
CG 
(%) 
CC 
(%) 
p-value C  
(%) 
G 
(%) 
p-value CC 
(%) 
GC 
(%) 
GG 
(%) 
p-value 
Control 323 
(87.8) 
45 
(12.2) 
0.43 142 
(77.2) 
39 
(21.2) 
3 
(1.6) 
0.38 219 
(69.3) 
97 
(30.7) 
0.75 81 
(51.3) 
57 
(36.1) 
20 
(12.7) 
0.35 
Cases 295 
(85.8) 
49 
(14.2) 
130 
(75.6) 
35 
(20.3) 
7 
(4.1) 
218 
(68.1) 
102 
(31.9) 
74 
(46.3) 
70 
(43.8) 
16 
(10.0) 
Hapmap (%) 86.2 13.8   80.2 12.4 7.4   72.8 27.2   62.3 20.6 17.2   
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Table 7-6 Allele and genotype frequencies for miRNA SNPs in MIR21 obtained from the GRC-BC population 
  rs1292037 rs13137 
  Allele Genotype Allele Genotype 
  A  
(%)  
G  
(%) 
p-
value 
AA  
(%)  
GA  
(%) 
GG 
(%) 
p-
value 
T  
(%) 
A  
(%) 
p-
value 
TT (%) AT (%) AA 
(%) 
p-
value 
Control 300 
(80.6) 
72 
(19.4) 
0.86 122 
(65.6%) 
56 
(30.1) 
8  
(4.3) 
0.95 299 
(80.8) 
71 
(19.2) 
0.85 122 
(65.9) 
55 
(29.7) 
8  
(4.3) 
0.94 
Cases 274 
(80.1) 
68 
(19.9) 
110 (64.3) 54 
(31.6) 
7 
 (4.1) 
276 
(80.2) 
68 
(19.8) 
111 
(64.5) 
54 
(31.4) 
7 
 (4.1) 
Hapmap 
(%) 
81.0 19.0   65.4 31.1 3.4   81.0 19.0   65.4 31.1 3.4   
 
 
Table 7-7 Allele and genotype frequencies for miRNA SNPs in MIRLET7A1 obtained from the GRC-BC cohort 
  rs10761322 rs10739971 
 Allele Genotype Allele Genotype 
  T  
(%) 
C  
(%) 
p-value TT (%) TC 
(%) 
CC  
(%) 
p-value G 
(%) 
A 
(%) 
p-value GG 
(%) 
AG 
(%) 
AA 
(%) 
p-value 
Control 225 
(61.8) 
139 
(38.2) 
0.73 76 
(41.8) 
73 
(40.1) 
33 
(18.1) 
0.08 243 
(67.5) 
117 
(32.5) 
0.39 89 
(49.4)  
65 
(36.1) 
26 
(14.4) 
0.36 
Cases 207 
(60.5) 
135 
(39.5) 
59 
(34.5)  
89 
(52.0) 
23 
(13.5) 
223 
(64.5) 
123 
(35.5) 
74 
(42.8) 
75 
(43.4) 
24 
(13.9) 
Hapmap (%) 61.9 38.1   40.9 42.0 17.2   68.1 31.9   46.4 43.3 10.3   
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Table 7-8 Allele and genotype frequencies for miRNA SNPs in MIRLET7A2 obtained from the GRC-BC population 
  rs629367 rs562052 rs693120 
 
Allele Genotype Allele Genotype Allele Genotype 
  
A  
(%) 
C  
(%) 
p-
value 
AA 
(%) 
CA 
(%) 
CC 
(%) 
p-
value G (%) A (%) 
p-
value 
GG 
(%) 
AG 
(%) 
AA 
(%) 
p-
value 
G  
(%) 
A  
(%) 
p-
value 
GG 
(%) 
AG 
(%) 
AA 
(%) 
p-
value 
Control 302 (82.5) 
64 
(17.5) 0.72 
125 
(68.3) 
52 
(28.4) 
6 
(3.3) 0.88 
242 
(65.4) 
128 
(34.6) 0.76 
81 
(43.8) 
80 
(43.2) 
24 
(13.0) 0.57 
230 
(67.3) 
112 
(32.7) 0.77 
82 
(48.0) 
66 
(38.6) 
23 
(13.5) 0.21 
Cases 289 (83.5) 
57 
(16.5) 
122 
(70.5) 
45 
(26.0) 
6 
(3.5) 
230 
(66.5) 
116 
(33.5) 
74 
(42.8) 
82 
(47.4) 
17 
(9.8) 
225 
(66.2) 
115 
(33.8) 
72 
(42.4) 
81 
(47.6) 
17 
(10.0) 
Hapmap 
(%) 84.6 15.4   75.4 18.5 6.2   68.1 31.9   46.2 43.8 10.0   68.1 31.9   46.2 43.8 10.0   
 
 
Table 7-9 Allele and genotype frequencies for rs55945735 located in MIR145 obtained from the GRC-BC population 
 rs55945735 
 Allele Genotype 
  A (%) G (%) p-value AA (%) GA (%) GG (%) p-value 
Control 193 (59.9) 129 (40.1) 0.29 61 (37.9) 71 (44.1) 29 (18.0) 0.58 
Cases 182 (64.1) 102 (35.9) 60 (42.3) 62 (43.7) 20 (14.1) 
Hapmap (%) 62.8 37.2   38.3 49.1 12.7   
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Table 7-10 Allele and genotype frequencies for SNP rs353291 located in MIR145 obtained from the GRC-BC and GU-CCQ BB cohorts 
  GRC-BC Population GU-CCQ BB Population 
 Allele Genotype Allele Genotype 
  T 
 (%) 
C  
(%) 
p-value TT 
 (%) 
CT 
(%) 
CC 
(%) 
p-value T  
(%) 
C  
(%) 
p-value TT 
(%) 
CT 
(%) 
CC 
(%) 
p-value 
Control 211 
(58.6) 
149 
(41.4) 
0.041 61 
(33.9) 
89 
(49.4) 
30 
(16.7) 
0.09 386 
(62.7) 
230 
(37.3) 
0.023 128 
(41.6) 
130 
(42.2) 
50 
(16.2) 
0.07 
Cases 171 
(50.9) 
165 
(49.1) 
40 
(23.8) 
91 
(54.2) 
37 
(22.0) 
769 
(57.2) 
575 
(42.8) 
229 
(34.1) 
311 
(46.3) 
132 
(19.6) 
Hapmap (%) 62.7 37.3   40.6 44.1 15.3   62.7 37.3   40.6 44.1 15.3   
 
 
Chapter 7: Genetic association analysis of miRNA SNPs implicates MIR145 in breast cancer susceptibility. 157 
miR-SNP rs353291 is located 450 bp upstream from the MIR145 gene, inside the 
MIRNA143HG transcript, in the long arm of chromosome 5 region 32 at position 
148,810,746. To the best of our knowledge there are no previous association studies 
in relation to this miR-SNP and breast cancer risk in Caucasians or any populations 
of other ethnicities. However, MIR145 has been previously reported to play a role in 
cancer biogenesis and progression. Downregulation of MIR145 is a common finding 
previously reported in colorectal (Arndt et al., 2009; Michael et al., 2003), bladder 
(Chiyomaru et al., 2010), lung (Cho et al., 2009, 2011) and oesophageal (Kano et al., 
2010) cancers possibly leading to poor prognosis. Similarly, it has also been found to 
have a tumour suppressor role in breast tissue particularly in the myoepithelial/basal 
cell compartment and it is found to be downregulated in breast cancer tissue samples 
(Iorio et al., 2005; Sempere et al., 2007; Volinia et al., 2006). Research using breast 
cancer cell lines showed it regulates genes involved in modulation of apoptosis 
(Spizzo et al., 2010; S. Wang et al., 2009). Finally downregulation of MIR145 has 
been associated with a more aggressive behaviour of breast malignancies based on 
results performed in both breast cancer cell line and tissue samples (Goette et al., 
2010; Radojicic et al., 2011). However the molecular mechanisms leading to 
decreased expression of MIR145 still remain unknown and our finding could 
potentially help to provide further knowledge on these mechanisms through further 
functional validation on breast cancer cell culture and/or animal/models. It is also 
possible that rs353291 is linked to a different nearby SNP not considered in this 
research that may have direct functional effects on MIR145, so additional 
sequencing/genotyping studies may need to be performed prior to functional 
assessment of the link between rs353291 and breast cancer. 
 
7.6 CONCLUSIONS 
 
This study suggests a role for a mutation in miR-SNP rs353291 in breast 
cancer. To the best of our knowledge, this is the first report on breast cancer risk 
association for this variant. This finding could potentially explain the previously 
described role that MIR145 plays in breast cancer, previously documented in the 
literature, but it requires confirmation via functional studies using cell culture or 
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animal models. It also requires further validation on larger Caucasian population as 
well as in cohorts of individuals with different ethnic backgrounds before it can be 
translated into clinical applications used in breast cancer diagnosis or treatment. 
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8.2 ABSTRACT 
 
Breast cancer incidence and mortality rates are increasing despite our current 
knowledge of the disease. 90-95% of breast cancer cases correspond to sporadic 
forms of the disease and are believed to involve an interaction between 
environmental and genetic determinants. The microRNA 17-92 cluster host gene 
(MIR17HG) has been shown to regulate expression of genes involved in breast 
cancer development and progression. Study of single nucleotide polymorphisms 
(SNPs) located in this cluster gene could help provide a further understanding of its 
role in breast cancer. Therefore, this study investigated 6 SNPs in the MIR17HG 
using two independent Australian Caucasian case-control populations (GRC-BC and 
GU-CCQ BB populations) to investigate association to breast cancer susceptibility. 
Genotyping was undertaken using chip-based matrix assisted laser desorption 
ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). We found 
significant association between rs4284505 and breast cancer at the allelic level in 
both study cohorts (GRC-BC p = 0.01 and GU-CCQ BB p = 0.03). Furthermore 
haplotypic analysis of results from our combined population determined a significant 
association between rs4284505/rs7336610 and breast cancer susceptibility (p = 5x10-
4).  Our study is the first to show that the A allele of rs4284505 and the AC 
haplotype of rs4284505/rs7336610 are associated with risk of breast cancer 
development. However, definitive validation of this finding requires larger cohorts or 
populations in different ethnic backgrounds. Finally, functional studies of these SNPs 
could provide a deeper understanding of the role that MIR17HG plays in the 
pathophysiology of breast cancer. 
 
8.3 INTRODUCTION 
 
In 2012, 14.09 million people in the world were newly diagnosed with cancer 
and about 21% of them corresponded to breast cancer (1,676,633 cases in total) 
according to the International Agency for Research on Cancer (IARC). It is the most 
common type of cancer in women worldwide and is estimated to be developed by 
one in eight women living to the age of 90. Breast cancer is also the fifth cause of 
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cancer-related deaths in the world (6.4%) and accounted for 197,528 of all cancer 
related deaths in developed countries. It has become a cause for concern since both 
incidence and mortality rates have increased by more than 20% and 14% respectively 
from figures reported in 2008 (Ferlay et al., 2013; Robbins et al., 2010; Stewart, 
Wild, International Agency for Research on, & World Health, 2014). Sporadic forms 
of breast cancer account for about 90-95% of all cases and they are most likely the 
result of interaction between genetic and environmental factors (Anderson, 1991; 
Claus, Schildkraut, Thompson, & Risch, 1996; Martin & Weber, 2000; Robbins et 
al., 2010). 
 
MicroRNAs (miRNAs) are small non-coding single stranded RNA molecules 
of about 21 to 25 nucleotides in length involved in gene regulation at the 
translational level. They account to about 1% of the human genome and are very 
likely to be important in cancer biology due to their role in regulating important 
cellular processes like cell growth, differentiation and cell survival (Calin & Croce, 
2006; Thalia A. Farazi et al., 2011; Lynam-Lennon et al., 2009; Robbins et al., 2010; 
Zuoren Yu et al., 2010). miRNAs are usually generated following the canonical 
pathway where they are transcribed from long microRNA primary transcripts (pri-
miRNAs) about 1kb in size that contain up to six miRNA precursors (pre-miRNA). 
Pre-miRNAs are stem-loop molecules of about 55 to 70 nucleotides in length and 
they are produced when pri-miRNA are cleaved by the complex Drosha – DCGR8 
(DiGeorge syndrome critical region gene 8, also known as pasha) within the cellular 
nucleus. Pre-miRNAs are then transported to the cytoplasm by XPO5 (exportin5) 
and the nuclear protein Ran-GTP. In the cytoplasm pre-miRNAs are processed by 
DICER1, a ribonuclease type III enzyme, and double-stranded RNA binding proteins 
(RBP) TARBP2 and/or PKRA producing a duplex molecule that contains both the 
single-stranded mature miRNA sequence and its complementary strand named 
miRNA*. The miRNA:miRNA* molecule is loaded into the RNA-induced silencing 
complex (RISC), where the mature miRNA sequence is merged into the 
Argonaute/EIFC2C (Ago) proteins and the miRNA* is released and degraded. Ago 
proteins bound to mature miRNA mediate target messenger RNA (mRNA) 
recognition and interaction between these three components results in gene 
regulation. The mRNA target is recognised by pairing of the miRNA seed region 
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(nucleotides 2 to 8) located in the 5’-end of the miRNA and the complementary 
sequence mainly located in the 3’-UTR region of the mRNA(Chendrimada et al., 
2005; Yoontae Lee et al., 2003; Y. Lee et al., 2002; Yi et al., 2003).  Each miRNA 
may bind to up to 200 gene targets and each gene could have multiple binding sites 
for different miRNAs (Bartel, 2009; Rajewsky, 2006).  Location of promoter regions 
of microRNA genes, mechanisms that regulate their biogenesis and molecular 
mediators of their functional effects within cells and tissues are still being studied 
and remain unclear for most miRNAs identified  to date (Ha & Kim, 2014; Kim, 
2005). 
 
Around 52% of all miRNA genes are located in different non-random positions 
within the genome, generally in regions of chromosomal instability or cancer-
associated regions (Calin, Sevignani, et al., 2004). Changes in miRNA synthesis, 
expression and effect on target genes in relation to cancer could occur through many 
different mechanisms and some of them include: point mutations in miRNA genes, 
mRNA sequences and surrounding regions, epigenetic changes such as mRNA gene 
methylation, loss or mutation in the promoter regions for specific miRNA clusters 
and/or alterations in pathway related RBP (Ha & Kim, 2014; Lynam-Lennon et al., 
2009).  
 
Approximately one-third of all miRNAs form genomic clusters, about 113 in 
total, which may measure up to 51 kb in length, and they are usually transcribed as a 
single polycistronic transcript (Thalia A. Farazi et al., 2011; Lynam-Lennon et al., 
2009). One such cluster is the microRNA 17-92 cluster host gene (MIR17HG) cluster 
located on chromosome 13q31.3 in the third intron of the c13orf25 gene. It was 
initially identified in relation to B cell lymphoma both in cell lines and tissue sample 
from patients by Ota et al in 2004 (Ota et al., 2004).  The miRNA 17-92 cluster host 
gene transcript is about 800bp in length and contains six miRNAs: MIR17, MIR18A, 
MIR19A, MIR20A, MIR19B1 and MIR92A1, which belong to 4 seed families 
(miRNA 17, miRNA 18, miRNA 19 and miRNA 92). Based on their seed sequences, 
two related paralogues of this cluster have also been identified in the human genome: 
miRNA 106b-25 cluster located on chromosome 7 (7q22.1) in the 13th intron of gene 
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MCM7 and miRNA 106a-363 cluster located on chromosome X (Xq26.2) (Ventura 
et al., 2008).  
 
The MIR17HG was named oncomiR-1 by He et al who found it to promote 
oncogenesis in B-cell lymphoma using a murine model (L. He et al., 2005). Further 
studies have confirmed roles both in cell proliferation and cell death, a feature that 
seems to be dependent on the cell types and tissues in which it is found. Research has 
shown that MIR17HG inhibits tumour growth by targeting important cell cycle 
regulator genes including E2F1, MYC, RB1 and CCND1. In 2005, O’Donnell et al 
observed that MIR17HG down-regulated expression of both E2F1 and MYC genes 
using Burkitt lymphoma cells (P493-6) as a model (O'Donnell, Wentzel, Zeller, 
Dang, & Mendell, 2005). On the other hand, later studies have shown this cluster 
gene region seems to have an oncogenic effect in other types of tumour. 
Experimental models of human B-cell lymphomas overexpressing MIR17HG 
showed evasion of apoptosis due to enhanced activity of MYC. Moreover, studies of 
small-cell lung carcinomas showed negative regulation of the pro-apoptotic gene 
BCL2L11 resulting from overexpression of MIR17HG (Hayashita et al., 2005). This 
finding may suggest that fine regulation of MIR17HG expression is important. 
Research studies indicate that specific processing of miRNAs included in this cluster 
might be the result of largely unknown intricate regulatory mechanisms. There are 34 
transcription factors that regulate MIR17HG transcription identified to date and they 
include MYC, MYCN, MXI, E2F3 and TP53 amongst others, that are specific to 
different cell types and biological contexts (Mogilyansky & Rigoutsos, 2013; Olive, 
Jiang, & He, 2010). 
  
In relation to breast malignancies, a number of studies on the effects of 
MIR17HG in breast cancer cell lines have also been published. In 2006 MIR17 5p, 
one of the miRNAs included in the cluster, was shown to inhibit oestrogen receptor α 
(ESR1) co-activator NCOA3 in different breast cancer cell lines (Hossain et al., 
2006). Following this finding, Yu et al demonstrated a tumour suppressor role for 
MIR17HG inducing cell cycle arrest and decreasing cell proliferation by directly 
inhibiting CCND1 in the MCF-7 breast cancer cell line in 2008 (Z. Yu et al., 2008). 
Similarly in a later study, Leivonen et al showed that MIR17HG reduced cell growth 
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and progression of cell cycle in breast cancer cell lines MCF-7 and BT-474 using 
two mechanisms: translational repression of ESR1 and/or downregulation of ESR1 
responding genes. Additionally, they were able to confirm their in-vitro findings 
through expression studies on breast cancer tumour samples showing significant 
association between high expression levels of miR-18a and ESR1-negative breast 
cancer tumours (Leivonen et al., 2009).  
 
According to the evidence previously presented, MIR17HG seems to play an 
important role in the development of different carcinomas including breast cancer.  
However, there is a lack of knowledge on the molecular mechanisms leading to 
altered expression or regulation of this particular cluster as well as each of the mature 
miRNAs included in it. Genetic variants such as single nucleotide polymorphisms 
(SNPs) could potentially impact biological processes involved in the production or 
functional effects of the microRNA 17-92 cluster host gene and the study of such 
variants in relation to cancer could provide insight into its aetiological mechanisms.  
 
In this study, we genotyped 6 SNPs located in the cluster gene region or in 
close proximity to it. Genotyping of these variants was performed using multiplex 
PCR and Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) analysis in two independent Australian Caucasian 
breast cancer cohorts. Results from our allele and haplotype association analysis 
showed statistical significance for two of the selected SNPs and the risk of breast 
cancer in these Caucasian populations. 
 
8.4 MATERIALS AND METHODS 
 
8.4.1  Study populations 
 
Genotyping was carried out in two independent cohorts of females of 
Caucasian (Northern European) origin: The Genomics Research Centre Breast 
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Cancer (GRC-BC) population and a subset of the Griffith University-Cancer Council 
Queensland Breast Cancer Biobank (GU-CCQ BB). GRC-BC population was 
recruited from the Gold Coast Hospital, Southport and included 244 breast cancer 
patient samples from patients residing in the South East Queensland region. Samples 
from 187 healthy females with no history of personal or familial cancer were used as 
controls and they were also obtained via the Genomics Research Centre Clinic, 
Southport, with the research approved by Griffith University’s Human Ethics 
Committee (Approval: MSC/07/08/HREC and PSY/01/11/HREC) and the 
Queensland University of Technology Human Research Ethics Committee 
(Approval: 1400000104). Mean age of the test populations was 57.52 years and 57 
years, for cases and controls, respectively. 
 
Replication was performed using 679 samples from the GU-CCQ BB 
population. Patient samples were collected by the Genomics Research Centre in 
collaboration with the Cancer Council of Queensland as part of a 5-year population-
based longitudinal study of women newly diagnosed with breast cancer. 929 women 
resident in Queensland with a diagnosis of invasive breast cancer confirmed 
histologically have been recruited by this biobank since January 2010. Age range of 
patient samples included in this study varied from 33 to 80 years, with an average 
age of 60.16. Clinical and demographic information was obtained through the 
Queensland Cancer Registry, Genomics Research Centre General Questionnaire, 
computer assisted telephone interview (CATI) and self-administered questionnaires 
(SAQ) over two main time points: 4 to 6 months post diagnosis and 18 months post 
diagnosis [approximately 12 months after initial interview]. Additionally, using the 
Queensland Cancer Registry and the National Death Index, the study cohort will be 
followed-up for five years post diagnosis to record cancer recurrence and mortality 
(Youl et al., 2011). 308 ethnicity and sex matched control samples for the GU-CCQ 
BB population were obtained from 2 sources: 107 females with no personal or 
familial history of cancer, recruited from January 2000 through the Genomics 
Research Centre at the Institute of Health and Biomedical Innovation Institute, 
Queensland University of Technology and also genotyping data obtained from 201 
individuals belonging to the phase 1 European population from the 1000Genomes 
project (Abecasis et al., 2012). 
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 8.4.2  Genomic DNA sample preparation from whole human blood. 
 
Genomic DNA was obtained from whole blood samples using a modified 
salting out method (Chacon-Cortes et al., 2012; Nasiri et al., 2005). DNA samples 
were checked for quantity and purity using spectrophotometry measurements using 
the Thermo Scientific NanoDropTM 8000 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific Inc., Wilmington, DE. USA) to determine concentration and 260/280 
ratios (Chacon-Cortes & Griffiths, 2014; Huberman, 1995; Sahota, Brooks, 
Tischfield, et al., 2007). To guarantee DNA sample purity, those with a value below 
1.7 for their 260/280 ratio were further purified using an ethanol precipitation 
protocol (Sambrook & Russell, 2001). 
 
8.4.3  miRNA SNP selection 
 
We used the human miRNA disease database (HMDD), developed by Lu et al 
(M. Lu et al., 2008) and updated in January 2012, to identify microRNAs involved in 
development and progression of breast cancer. We selected 24 biological/cellular 
functions and 8 diseases and/or pathological features related to breast cancer from 
two datasets included in the HMDD: “The whole miRNA-disease association data” 
and “The miRNA function set data”. The microRNA 17-92 cluster host gene 
(MIR17HG) was found to be present in most of the features on each dataset and 
therefore we conducted a preliminary literature search to determine its role in cancer 
development and progression and to investigate any SNP genotyping studies for this 
cluster gene. Following this, we searched for previously identified SNPs in the 
MIR17HG using both the dbSNP database from The National Center for 
Biotechnology Information (NCBI) (Sherry et al., 2001) and 1000 Genomes project 
browser (Abecasis et al., 2012). MicroRNA SNPs (miR-SNPs) that were located 
inside the pre-miRNA gene were automatically included in a preliminary selection 
and those located outside of the pre-miRNA gene were selected using either one of 
the following criteria: SNPs located within 500bp to the 3’ or 5’ end of the pre-
miRNA gene region were automatically included in the preliminary selection. 
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Finally, miR-SNPs located at a distance higher than 500bp from either end of the 
pre-miRNA gene were chosen only if they had a minor allele frequency (MAF) 
higher than 0.05 in Caucasian populations. Our preliminary selection identified 13 
miR-SNPs in the MIR17HG cluster or located up to 1.6 kb downstream and two 
variants (rs72631821 and rs9589207) located inside one of the mature miRNA 
sequences (MIR92A1) (See Table 8-1). 
 
8.4.4  Primer design and multiplex PCR genotyping 
 
We were able to design a multiplex PCR assay to include six miR-SNPs: one 
of the variants located inside the MIR92A1 gene (rs9589207) and five miR-SNPs 
located throughout the MIR17HG region using the MassARRAY® Assay Design 
Suite v1.0 software (SEQUENOM Inc., San Diego, CA, USA). Two PCR primers 
(forward and reverse) and one iPLEX® (extension) primer were designed for each 
miR-SNP to achieve successful marker and allele identification by mass 
spectrometry (See Table 8-2). We verified that masses of extension primers differed 
by at least 30 Da among different SNPs and by 5 Da between alternative alleles of 
the same marker and primers were synthesized by Integrated DNA Technologies 
(IDT®) Pte. Ltd. (Baulkham Hills, NSW 2153, Australia). Multiplex PCR reactions 
were performed according to the manufacturer’s protocol for the iPLEX™ GOLD 
genotyping application using iPLEX® GOLD reaction kit reagents (SEQUENOM 
Inc., San Diego, CA, USA). Primer extension reactions were carried out using the 
SEQUENOM linear adjustment method as per manufacturer’s iPLEX® GOLD 
genotyping protocol. All iPLEX® GOLD genotyping reactions were performed using 
Applied Biosystems® MicroAmp® EnduraPlate™ Optical 96-Well Clear Reaction 
Plates with Barcode  (Life Technologies Australia Pty Ltd., Mulgrave, VIC, 
Australia) and a Applied Biosystems® Veriti® 96-Well Thermal Cycler (Life 
Technologies Australia Pty Ltd., Mulgrave, VIC, Australia). 
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Table 8-1 SNPs in the microRNA 17-92 cluster host gene selected for primer design using the MassARRAY® Assay Design Suite v1.0 software (SEQUENOM Inc., San 
Diego, CA, USA) 
miRNA Locus Location miRNA SNPs 
in gene region 
MAF Location SNPs near 3' 
end 
MAF Location Downstream 
distance (bp) 
MIR92A1 13q31.3 92,003,568 - 92,003,645 rs72631821  NA 92,003,588     
rs9589207 0.0211 92,003,589 
MicroRNA 17-92 
cluster host gene 
13q31.3 92,000,074 - 92,006,829 rs4284505 0.4867 92,001,472 rs138514639 0.0517 91,998,497 1577 
rs72640333 0.0939 92,004,927 
rs113242099 0.0504 92,005,118 rs1888138 0.0916 91,999,496 578 
rs111371822  0.1484 92,005,134 
rs7336610  0.4524 92,005,137 
rs7318578 0.3594 92,005,469 rs2351704  0.3539 91,999,716 358 
rs17735387 0.0829 92,006,054 
rs1428 0.463 92,006,770 
 
Table 8-2 Primer sequences for microRNA 17-92 cluster host gene SNPs included in genotyping study using multiplex PCR reaction and MALDI-TOF MS 
SNP  Forward primer sequence Reverse primer sequence iPLEX® (Extension) primer sequence 
rs1888138 ACGTTGGATGGTTTATTACTTTACCGGCCC ACGTTGGATGTACTTCTCTGGTTCCGGTTG TGGGTTTCCGAGGTA 
rs7336610 ACGTTGGATGAAAAAGTTCCGGCTGGACAC ACGTTGGATGACAGCGTTTCACCATGTCGG GACTGACCTCAGGTAATCC 
rs9589207 ACGTTGGATGACTCAAACCCCTTTCTACAC ACGTTGGATGGGACAAGTGCAATACCATAC AAGGAACACAGCATTGCAAC 
rs17735387 ACGTTGGATGAGCCTTAACTATTTGGAGGG ACGTTGGATGGCTTTCTTTCCAAATATAGGC GGGGAGAAAGTTGTACATGCAAA 
rs4284505 ACGTTGGATGCTTTGCAGTCTCGGGTGTTC ACGTTGGATGTGATATTGCAACGACGAGCC TGATCCTGCCTTTTTCAGTTCCTT 
rs1428 ACGTTGGATGTCAATATTCTCGTTCTGGAC ACGTTGGATGACAGTTTGGTCTGGCTGTTT GCATTTAATGTTAATAAATAAAATACTG 
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8.4.5 MALDI-TOF MS analysis and data analysis 
 
We dispensed a total of 12-16 nl of each iPLEX® reaction product onto a 
SpectroCHIP® II G96 (SEQUENOM Inc., San Diego, CA, USA) using 
SEQUENOM® MassARRAY® Nanodispenser (SEQUENOM Inc., San Diego, CA, 
USA) and SpectroCHIP® analysis was performed by SEQUENOM® MassArray® 
Analyzer 4 (SEQUENOM Inc., San Diego, CA, USA). We acquired automated 
spectra after laser desorption/ionisation using the SpectroAcquire software version 
4.0 (SEQUENOM Inc., San Diego, CA, USA) and genotype data analysis was 
performed using the MassARRAY® Typer software version 4.0 (SEQUENOM Inc., 
San Diego, CA, USA). 
 
8.4.6  Statistical analysis 
 
We determined genotype and allele frequencies for each miRNA SNP in our 
case and control populations. Hardy-Weinberg equilibrium (HWE)(Guo & 
Thompson, 1992; Hardy, 1908) was used to evaluate deviation between observed and 
ideal Hardy-Weinberg frequencies. Differences in genotype and allele frequencies 
between cases and controls were evaluated using Chi-square analysis (Fisher & 
Yates, 1963) for each independent population to determine association with breast 
cancer. The α for p-values was set at 0.05 to determine statistical significance. 
Statistical analysis of genotypes and alleles was conducted using Plink software 
version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007). We 
also calculated odds ratio (OR) and a confidence interval (CI) of 95% to assess 
disease risk. Finally, we merged results from both populations and we performed 
linkage disequilibrium (LD) and haplotype block association analysis on the 
combined genotyping data using Haploview software version 4.2 (Daly Lab, Broad 
Institute, Cambridge, MA, USA) (Barrett et al., 2005). 
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8.5  RESULTS 
 
8.5.1  Genotypic Analysis 
 
Table 8-3 shows the 6 SNPs genotyped in our study provided good coverage of 
the MIR17HG cluster. They also included rs9589207 located inside a mature miRNA 
sequence (MIR92A1) and rs1888138 located 578 bp downstream of the cluster gene.  
All SNPs had a MAF greater than 0.05, with the exception of rs9589207 which had a 
MAF of 0.02. We proceeded to include all these SNPs in our multiplex PCR, in 
particular rs9589207 because of their genetic location. However, rs9589207 was 
finally excluded from our association analysis because we were unable to find the 
mutant allele in our initial genotyping of the GRC-BC cohort.  
 
Hence genotyping results of the 5 remaining SNPs obtained from both 
populations are shown in Table 8-4. All control populations were in HWE (p > 0.05) 
for all tested SNPs and allele and genotype frequencies closely matched those found 
in Hapmap for Caucasian populations. As shown in Table 8-4, we were able to 
validate a significant difference in allele frequencies between cases and controls for 
rs4284505 in both the GRC-BC and GU-CCQ BB populations using chi-square 
analysis (p = 0.01 and 0.03 respectively). Statistical analysis of differences between 
allele frequencies in cases and controls in the GRC-BC population for rs7336610 
also showed significance (p=0.03), but we were unable to obtain a similar finding in 
our independent replication population (p=0.10) and all the other remaining SNPs 
showed no significant differences between cases and controls in both populations. 
We observed lower frequencies (38.3% and 35.9% for GRC-BC and GU-CCQ 
cohorts respectively) of the A allele for rs4284505 in cases for both independent 
populations (See Table 8-4) and we calculated an odds ratio of 0.70 (CI 95%: 0.52 – 
0.93) for GRC-BC population and of 0.79 (CI 95%: 0.65 – 0.97) for GU-CCQ 
population. These results indicate that the presence of the A allele in this locus seems 
to have a protective effect on susceptibility to breast cancer. 
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Table 8-3 Chromosomal location and allele information for selected miRNA SNPs in the microRNA 17-92 cluster host gene 
SNP Locus Wild Type allele Mutant allele Chromosomal position MAF 
rs1888138 13q31.3 A T chr13: 91999496 0.0916 
rs4284505 13q31.3 G A chr13: 92001472 0.4867 
rs9589207 13q31.3 G A chr13: 92003589 0.0211 
rs7336610  13q31.3 T C chr13: 92005137 0.4524 
rs17735387 13q31.3 G A chr13: 92006054 0.0829 
rs1428 13q31.3 T G chr13: 92006770 0.4625 
 
Table 8-4 Allele frequencies of SNPs in the microRNA 17-92 cluster host gene obtained from the GRC-BC and GU-CCQ BB cohorts 
    rs1888138 rs4284505 rs7336610  rs17735387 rs1428 
 Alleles                                         
Population  A  
(%) 
T  
(%) 
p-
value 
 G  
(%) 
A  
(%) 
p-
value 
 T  
(%) 
C  
(%) 
p-
value 
 G  
(%) 
A  
(%) 
p-
value 
 T  
(%) 
G  
(%) 
p-
value 
 
GRC-BC 
Population 
Control 361  
(96.5) 
13  
(3.5) 
0.86  189  
(53.1) 
167  
(46.9) 
0.01  185  
(52.6) 
167  
(47.4) 
0.03  360  
(96.3) 
14  
(3.7) 
0.68  182  
(56.2) 
142  
(43.8) 
0.67  
Cases 470  
(96.3) 
18  
(3.7) 
  263  
(61.7) 
163  
(38.3) 
  263  
(60.0) 
175  
(40.0) 
  449  
(96.8) 
15  
(3.2) 
  278  
(57.7) 
204  
(42.3) 
  
GU-CCQ 
BB 
Population 
Control 590  
(95.8) 
26  
(4.2) 
0.87  362  
(58.8) 
254 
(41.2) 
0.03  346  
(56.2) 
270  
(43.8) 
0.10  590  
(95.8) 
26  
(4.2) 
0.66  383  
(62.8) 
227  
(37.2) 
0.36  
Cases 1295  
(95.9) 
55  
(4.1) 
 767  
(64.1) 
429  
(35.9) 
 712  
(60.1) 
472  
(39.9) 
 1287  
(96.2) 
51  
(3.8) 
 655  
(60.5) 
427  
(39.5) 
 
Hapmap (%) 95.9 4.1     57.9 42.1     55.7 44.3     98.2 1.8     65.6 34.4     
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Finally, chi square analysis of genotypes for all selected MIR17HG SNPs 
between cases and controls showed significant differences for rs4284505 and 
rs7336610 (p = 0.01 for both SNPs) in the GRC-BC population. Interestingly, we 
were only able to obtain statistical significance in the analysis at the genotype level 
for rs7336610 in our replication cohort (p = 0.04). 
 
8.5.2   Haplotypic Analysis 
 
Following the basic genotyping association analysis, we combined genotyping 
results from both GRC-BC and GU-CCQ populations to conduct linkage 
disequilibrium (LD) and haplotype block association analysis. As shown in Figure 
8-1, two of our selected SNPs (rs4284505 and rs7336610) were part of a 3kb LD 
block (Block 1) with a D’ score of 0.98.  
 
Table 8-5 Haplotype block association analysis for selected SNPS in the 
microRNA 17-92 cluster host gene in combined GRC-BC/GU-CCQ BB population 
shows frequencies for the different haplotypes in block 1 found in cases and controls, 
as well as results of haplotype association analysis to breast cancer using chi-square 
analysis.  According to our findings, cases had a lower frequency of haplotype AC 
(36.4%) than controls (43.3%) and statistical analysis proved this haplotype to be 
significantly associated with breast cancer risk (p = 5x10-4). Finally, we calculated an 
odds ratio for haplotype AC of 0.75 with a 95% confidence interval of 0.60 to 0.94 (p 
= 0.012). Results from our haplotype analysis validate our finding for the genotyping 
analysis at the allele level in rs7336610. These results also suggest that for the 
individuals that carry the AC haplotype, it appears to confer a protective effect on 
risk of breast cancer in Caucasians reducing the risk of being affected by breast 
cancer to about 25% in comparison to other haplotype carriers. 
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 Figure 8-1 Linkage Disequilibrium (LD) blocks for analysed microRNA 
polymorphisms in the microRNA 17-92 cluster host gene. 
Figure 8-1 shows the haplotype block formed by rs4284505 and rs7336610 found by 
linkage disequilibrium analysis using Haploview software version 4.2 (Daly Lab, 
Broad Institute, Cambridge, MA, USA) for the SNPs in the microRNA 17-92 cluster 
host gene. 
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Table 8-5 Haplotype block association analysis for selected SNPS in the microRNA 17-92 cluster host 
gene in combined GRC-BC/GU-CCQ BB population 
  GT (%) AC (%) GC (%) 
Control 269 (54.3) 214 (43.3) 12 (2.4) 
Cases 544 (58.9) 336 (36.4) 43 (4.7) 
x2 5.05 12.21 6.58 
p-value 0.02 5.0E-04 0.01 
Global Statistics x2 = 9.21   p-value = 0.01 
 
8.6 DISCUSSION 
 
Breast cancer affects a significant number of women and mortality rates seem 
to be increasing, despite substantial research and our current knowledge of the 
disease (Ferlay et al., 2013; Stewart et al., 2014). MicroRNAs are involved in 
molecular pathways leading to cell growth, differentiation and survival and there is 
enough evidence to show they play a significant role in the mechanisms that lead to 
development and progression of different types of cancer. Changes in expression of 
the microRNA 17-92 cluster host gene, also known as oncomiR-1, were initially 
described in haematopoietic and lung cancers where it was shown to play a role in 
tumour growth and apoptosis (Hayashita et al., 2005; L. He et al., 2005; O'Donnell et 
al., 2005; Ota et al., 2004; Ventura et al., 2008). Research has also highlighted 
MIR17HG as an important regulator of genes involved in breast cancer pathways. 
Studies by Hossain et al and Leivonen et al showed it plays a role in regulation of 
oestrogen receptor α (ESR1) in different breast cancer cell lines and tumour tissues 
through transcriptional downregulation of this receptor and genes that interact or co-
activate ESR1 (Hossain et al., 2006; Leivonen et al., 2009). Yu et al found the 
microRNA 17-92 cluster host gene to have a tumour suppressor role through CCND1 
inhibition in the MCF-7 cell line (Z. Yu et al., 2008). However, we currently lack 
understanding of the specific features that result in altered biogenesis and functional 
effects of this particular miRNA cluster gene in breast malignancies. Therefore the 
study of single nucleotide polymorphisms located inside the MIR17HG cluster gene 
using well defined breast cancer cohorts may help to assess whether they have a role 
on the molecular events leading to the development of this disease.  
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Selection of 6 miRNA SNPs found 0.6 kb downstream and inside the 
microRNA 17-92 cluster host gene region provided a thorough coverage of the gene 
and we were able to successfully genotype all of these variants in the two available 
cohorts, even rs9589207 located inside the MIR92A1 transcript. Unfortunately this 
particular SNP was not included in our association analysis because we could not 
identify the presence of the mutant allele in any of our populations.  However two of 
the five remaining SNPs, rs4248505 located about 1.4 kb downstream from MIR17A 
and rs7336610 found about 1.4 kb upstream from MIR92A1, showed some 
interesting results on our association analysis of breast cancer risk. Moreover, there 
does not appear to be any previous genotyping studies on these variants in relation to 
breast cancer or other diseases in Caucasian or any other ethnic populations. 
Statistical analysis of our results for rs4284505 showed a significantly higher 
presence of the A allele in healthy individuals for both GRC-BC and GU-CCQ BB 
populations (p = 0.01 and 0.03 respectively) and a reduction in breast cancer risk of 
up to 30%. We also found higher frequencies for the C allele of rs7336610 in 
controls in our GRC-BC cohort but failed to establish a similar finding in our 
replication population.  Analysis of the haplotypes present in the LD block 
rs4284505/rs7336610 showed results consistent to our previous finding in the 
individual SNP analysis, with the presence of the AC haplotype found to have 
significantly higher frequencies in controls (p = 5x10-4) decreasing the risk of 
developing breast cancer by about 25%.  
 
In conclusion, via analysis of SNPs from MIR17HG, we were able to identify 
significant association between rs4248505 at the allele level and 
rs4248505/rs7336610 at the haplotype level with susceptibility to breast cancer. To 
the best of our knowledge this is the first study investigating SNPs in this cluster 
gene in breast cancer populations and the first to determine that the presence of the 
AC haplotype significantly affects the risk of developing breast cancer. However our 
findings require further validation in larger populations and/or population of different 
ethnicities, as well as functional studies to further define the role of this haplotype in 
miRNA expression or molecular pathways leading to the development of breast 
cancer. 
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 Chapter 9: General Discussion 
 
9.1 INTRODUCTION 
 
Cancer affects a large number of individuals worldwide. Increase in incidence 
and mortality rates is a concerning fact and it is a trend also observed in Australian 
population (AIHW & AACR, 2010, 2012; Ferlay et al., 2010; Ferlay et al., 2013). 
Breast cancer is the most common type of cancer in women and it ranks first as a 
cancer-related cause of death worldwide and second in Australia (AIHW, 2009, 
2012). 
 
Breast cancer is a malignant neoplasm characterised by uncontrolled cellular 
growth within breast tissue with the potential to invade distant tissues and organ 
within the human body. It is a complex disease that results from innate and/or 
acquired genetic predisposition from somatic mutations in breast tissues and their 
interaction with hormonal exposure and other risk factors (Robbins et al., 2010; 
Strachan & Read, 2011; Weinberg, 2007). Hereditary or familial forms of the disease 
that can be primarily attributed to germline mutation are only a small fraction of the 
total of cases currently diagnosed accounting for about 10% of all reported cases 
(Anderson, 1991). On the other hand sporadic breast cancer requires very complex 
signalling networks created by the interaction of many molecular pathways that have 
been identified up to date. Therefore several genes and mediators may play a role in 
the development of the sporadic disease, including input from the environment 
(Robbins et al., 2010; Weinberg, 2007; Ben Zhang et al., 2011).  Genes involved in 
the inherited or familial types of the disease have helped our understanding of the 
molecular mechanisms and have shown the molecular pathways involved in the 
pathogenesis but we still lack knowledge on the detailed molecular mechanisms 
involved in those pathways. Better understanding of the mediators and molecular 
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regulator involved in those pathways will give us a better understanding of the 
pathophysiology of the disease, as well as help in the development of diagnostic or 
treatment approaches that would have a substantial impact for breast cancer patients. 
 
9.2 BREAST CANCER AND MICRORNAS 
 
MicroRNAs have been described as important epigenetic regulators of gene 
expression present in all the molecular pathways involved in cell growth, 
differentiation and survival. Therefore, they might be important for the pathogenesis 
of breast cancer because they are known to regulate about 60% of the genes in the 
human genome (Thalia A. Farazi et al., 2011; Robbins et al., 2010; Zuoren Yu et al., 
2010). Research studies aimed at a better understanding of the molecular 
mechanisms and mediators involved in miRNA biogenesis and function in relation to 
cancer are fundamental. Scientific research to elucidate the role of microRNAs in 
cancer biology is increasing and differential patterns of expression for miRNAs  have 
been identified in many types of cancer including breast cancer (Calin & Croce, 
2006; Iorio et al., 2005; J. Lu et al., 2005; Volinia et al., 2006). The molecular 
mechanisms leading to miRNA expression deregulation that results in cancer 
development are still not fully understood. However it has been recognised that 
mutations present in the miRNA sequences could result in the changes in miRNA 
synthesis and function seen in cancer biology.  
 
Single nucleotide polymorphisms (SNPS) are the most common type of 
variation present in miRNA genes (T. A. Farazi et al., 2011; H.-C. Lee et al., 2011; 
Ryan et al., 2010). Therefore the study of miRNA SNPs (miR-SNPs) has the 
potential to explain the mechanisms behind miRNA changes in biogenesis and 
function. They can also be used as markers to identify cancer predisposition, predict 
cancer behaviour and prognosis and as targets for cancer therapy (Budhu et al., 2010; 
Heneghan et al., 2010; Roth et al., 2010; Q. Wu et al., 2011). There is not currently a 
lot of evidence for involvement of miR-SNPs in cancer but it is a field of research 
that seems to be growing (Gong et al., 2012; H.-C. Lee et al., 2011; Mishra & 
Bertino, 2009). The lack of data arises primarily because only a small fraction of the 
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total of miR-SNPs identified to date have been studied in relation to cancer and 
breast cancer more specifically (Z. Hu et al., 2008; Z. Hu et al., 2009; Jazdzewski et 
al., 2009; Jazdzewski et al., 2008; B. Xu et al., 2010; T. Xu et al., 2008; Yeqiong Xu 
et al., 2013; Yamashita et al., 2013; Ye et al., 2008).  
 
miR-SNPs located in MIR27A, MIR423, MIR146A, MIR196A2 and MIR499 
have been associated with breast cancer, but findings are still somewhat controversial 
(Alshatwi et al., 2012; Bansal et al., 2014; Catucci et al., 2012; Catucci et al., 2010; 
Esteban Cardenosa et al., 2012; Gao et al., 2011; Amandine I. Garcia et al., 2011; 
Hoffman et al., 2009; Jedlinski et al., 2011; Kontorovich et al., 2010; S. J. Lee et al., 
2014; Lian et al., 2012; Linhares et al., 2012; Pastrello et al., 2010; Shen et al., 2008; 
R. A. Smith et al., 2012; P. Y. Wang et al., 2013; R. Yang & Burwinkel, 2012; 
Rongxi Yang et al., 2010; M. Zhang et al., 2012; N. Zhang et al., 2013; Zhong et al., 
2013).  Conflicting results in regards to miR-SNPs and breast cancer are probably the 
result of limitations in terms of the populations examined, experimental design and 
methods used for analysis. Therefore all of these need to be carefully considered and 
addressed in the study of the remaining miR-SNPs that need to be analysed in 
relation to breast cancer or to validate previous findings. More research is required to 
address a larger number or miR-SNPs, in particular those related to genes previously 
identified to be involved in breast cancer development and progression as this would 
allow better understanding of the mechanisms involved and it might result in the 
development of new and/or improved diagnostic and therapeutic approaches.    
 
This study aimed to contribute to the understanding of microRNA 
polymorphisms and their potential association with breast cancer risk as an initial 
step in the identification of those miR-SNPs that may have a substantial role in the 
biology of cancer. In order to successfully identify those miRNA variants that are 
significantly associated with breast cancer we established some specific aims: i) the 
establishment of a large sized and well characterised prospective DNA biobank to be 
used as a replication cohort to the one previously available in our facility. ii) to 
determine the most appropriate protocol to use in the establishment of our new breast 
cancer case-control cohort in a time-efficient and cost-effective manner. iii) to 
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identify miR-SNPs associated with breast cancer risk in both Australian Caucasian 
populations using genotype association analysis.   
9.3 POPULATION RESOURCES DEVELOPMENT 
 
We aimed to establish a significant sized and well-characterised prospective 
genomic DNA (gDNA) biobank extracted from whole blood samples obtained from 
breast cancer patients in Queensland recruited in collaboration with the Cancer 
Council Queensland. A well-characterised biobank would contain comprehensive 
information from volunteers regarding ethnic origin, age, sex, biometric data and 
complete clinical information to allow selection of candidates with very specific 
phenotypes to be included in genetic studies in relation to a condition, which would 
minimise bias from experimental findings. This goal was achieved through the very 
thorough process of recruitment and follow-up described in Section 3.1.2, resulting 
in a very comprehensive database containing the information required for appropriate 
characterisation of volunteers. However, for this study, we were limited in our access 
to some of the information, due to the fact that both the biobank and the database are 
still under development and data is still being collated and finalised. This limited 
information in turn prevented us from including important features like type of breast 
cancer, stage at diagnosis and characteristics of the tumours into our analysis and 
results. This could have an impact on our findings that is yet to be determined.   
Therefore, once such information is available it could be included as part of the 
future work needed to further validate and interpret our findings. 
 
 About 3000 samples were expected to be collected during the 5 year period of 
patient recruitment and 929 breast cancer patients had been recruited by this biobank 
since January 2010. We were able to successfully perform DNA extraction of all the 
929 samples collected to date with the resources available to the study. This was the 
result of careful planning and assessment of the DNA extraction technique that we 
used which allowed us to progress the construction of the population most 
efficiently. As previously mentioned in Section 3.2.3, we were also able to establish 
significant sized populations because both GRC-BC and CCQ-GU BB populations 
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has a sufficient size to achieve ~80% or greater power to detect an allelic association 
at the 0.05 level. 
 
9.3.1 DNA extraction methods 
 
In order to determine the best possible method to perform DNA extraction 
from the ones available at our facility, we decided to review current knowledge of 
genomic DNA extraction from whole blood methods to determine the most suitable 
one to successfully achieve the establishment of our biobank population. Chapter 
Five reviews the history of DNA extraction techniques and the main categories of the 
methods used in DNA extraction from whole blood samples most commonly used in 
facilities around the world. Finally, we reviewed available literature on evaluation 
studies previously published comparing different extraction techniques to highlight 
their strengths and weaknesses.  This review evidenced the limited scientific 
evidence available in regards to the best choice for gDNA extraction, since to the 
best of our knowledge there is no publication that comprehensively evaluates all 
approaches in terms of all possible features. It also highlighted the need to conduct 
our own validation study to determine the most appropriate technique to be used 
from the ones currently available at our facility to determine the one to be used in the 
establishment of our new case control cohort.  
  
9.3.2 Comparison of DNA Extraction methods 
 
Chapter Four presents our in-house evaluation study conducted to determine 
the most appropriate method in terms of cost effectiveness and time efficiency to 
perform genomic DNA (gDNA) extraction from whole blood samples. We 
conducted a study that compared the modified salting-out protocol described by 
Nasiri et al (Nasiri et al., 2005), against a traditional salting out method (Miller et al., 
1988) and a commercially available DNA extraction kit. We performed gDNA 
extraction in eleven whole blood samples obtained from breast cancer patients and 
evaluated the performance of each method in terms of the quality and quantity of 
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DNA obtained, as well as time requirements and costs for each technique.  Our 
results showed that any of these three techniques perform similarly in terms of 
quantity and quality of final DNA product, but it highlighted the modified salting out 
method to be the most cost-effective and time-efficient technique to isolate gDNA 
from whole blood samples achieving similar results to the ones obtained with the 
commercial DNA extraction kit.  Unfortunately, costs associated with the collection, 
handling and storage of the sample were not taken into account. However they are 
important because  this could potentially impact on the integrity of the initial sample, 
as well as the performance and success of any DNA extraction technique chosen. 
They are also a significant factor to consider, since it is very important to carefully 
obtain and preserve initial samples, especially for future extraction of DNA samples 
from those which are exhausted from the biobank.  
 
Some of the limitations of this study included the small number of samples 
used to test our chosen DNA extraction methods and we also failed to include a more 
comprehensive range of techniques like magnetic bead-based extraction methods or 
automated method unavailable at our facility. Spectrophotometry can potentially 
overestimate the amount of double stranded DNA resulting from the chosen 
extraction method up to 35% compared to other methods such as PicoGreen, because 
there are different amounts of double and single stranded DNA and RNA remaining 
as a result of differences in chemistry between different methods. Moreover, using 
qPCR to evidence differences in quantification cycle (Cq) would potentially improve 
our data in regards to the quality of DNA yield. 
 
 Nonetheless, the modified salting out method has consistently proved to be an 
appropriate technique based on the quality and quantity of DNA obtained from blood 
samples extracted for the GU-CCQ biobank population. DNA samples extracted with 
this technique have also showed to perform well in downstream application, as 
evidenced by the genotyping results obtained in the genotyping analysis included in 
this study, as well as other studies performed at our facility not included here because 
they escaped the scope of this manuscript.  
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9.4 ASSOCIATION STUDIES 
 
9.4.1 MIR146A results 
 
Chapter Six was our pilot genotyping study to determine whether our newly 
established population extracted with the modified salting out technique performed 
well in downstream applications. It also provided us with the opportunity to validate 
previous findings in relation to a miR-SNP that has shown conflicting results in 
studies previously conducted by other research groups. We selected the miR-SNP 
rs2910164 present in MIR146A because it had not been properly analysed in purely 
sporadic or purely Caucasian breast cancer populations to validate previous findings. 
We genotyped this variant using high resolution melt (HRM) analysis and were able 
to determine that presence of the mutant allele in this locus to be significantly 
associated with breast cancer risk in both our primary and replicate populations. One 
limitation of this study was the small number of samples included in our replication 
population (GU-CCQ BB population), as this was still under development. However 
we were able to successfully conduct our assay and to achieve statistically significant 
results. Our study showed that the presence of the mutant allele in rs2910164 was 
significantly associated with sporadic breast cancer risk in both of our cohorts (p = 
0.03 and p = 0.00013). To the best of our knowledge this is the first study to identify 
an association between this variant and breast cancer risk in a purely sporadic breast 
cancer bearing Caucasian population. 
 
9.4.2 miRNA selection and analysis 
 
Chapter Seven presents the results of a large scale genotyping study using both 
of our previously established cohorts. In this study, we developed a selection 
algorithm to choose miR-SNPs to be included shown in Figure 7-1 of this chapter. 
This allowed the selection of a large panel of miR-SNPs (24 miR-SNPs in total 
present in 9 miRNA genes) to be evaluated using multiplex PCR and chip-based 
matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
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spectrometry (MS) analysis. Results from our study showed 6 of the miR-SNPs 
(rs73798217, rs112394324, rs35301225, rs1547354, rs7050391 and rs3851812) not 
to be polymorphic in our populations.  As mentioned in Section 2.5.1.1, there are 
around 10 million SNPs in the human genome and only about 56% of SNPs have 
been successfully typed. Many of these SNPs have been tested using small 
populations and therefore it is very likely that a large number of those will turn out to 
be non-polymorphic, or have altered minor allele frequencies when genotyping larger 
cohorts, or cohorts from different ethnicities. Therefore, it is not surprising that up to 
21% of our selected miR-SNPs were shown not to be polymorphic. Our results 
provide initial validation of the rarity of these variants in Caucasian populations.  
 
From the remaining polymorphisms analysed, we were able to show significant 
association to breast cancer risk for one of our selected variants. We determined that 
miR-SNP rs353291, occurring in relation to MIR145 had significant differences in 
allele frequencies between cases and controls in both populations (p = 0.041 and p = 
0.023). To the best of our knowledge this is the first report of an association to breast 
cancer risk for this variant in Caucasian populations. Although we provided initial 
validation of our findings using two independent populations, further validation of 
this results in larger cohorts or populations of both similar and different ethnic 
background is required to strengthen their significance. If we take into account 
multiple testing correction of our results, however, our findings are no longer 
significant, yet still interesting and worthy of further research based on the similarity 
of significance found in both populations. Functional studies to help refine the likely 
mechanism by which the miR-SNP may interact with breast cancer influencing 
pathways may also help in properly identifying populations who may be affected by 
it. 
 
9.4.3 MicroRNA 17-92 cluster host gene analysis 
 
Chapter Eight presents the results of our genotype and haplotype analysis of 6 
miR-SNPs present in the microRNA 17-92 cluster host gene (MIR17HG) conducted 
in our two Australian Caucasian breast cancer cohorts. We decided to study 
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polymorphisms in MIR17HG because it has been previously shown in the literature 
to be associated with cancer development. It was the first cluster host gene to be 
found to play a role in cancer biology for hematopoietic malignancies and other types 
of cancer (Hayashita et al., 2005; L. He et al., 2005; Mogilyansky & Rigoutsos, 
2013; O'Donnell et al., 2005; Olive et al., 2010). It has also been linked to the 
pathogenesis of breast cancer. It has been shown to target important genes in breast 
biology, such as NCOA3, CCDN1 and ESR1 (Hossain et al., 2006; Leivonen et al., 
2009; Z. Yu et al., 2008). The molecular mechanisms that lead to deregulation of 
MIR17HG may be influenced by SNPs and to the best of our knowledge there are no 
previous studies evaluating the role of miR-SNPs for this particular cluster host gene, 
making it an ideal candidate for study. We selected 6 miR-SNPs located in the 
cluster gene region or in close proximity to it providing good coverage for this 
miRNA cluster, and they included a polymorphism located inside the mature 
sequence for MIR92A1 (rs9589207), a variant almost certain to be functional in some 
respect. We genotyped these SNPs using multiplex PCR and chip-based MALDI-
TOF MS analysis in our two independent Australian Caucasian breast cancer case-
control cohorts. Genotypic analysis of our results showed significant differences 
between cases and control for miR-SNP rs4284505 in both of our populations (p = 
0.01 and p = 0.03) and for rs7336610 only in our initial population (p = 0.03). We 
then performed haplotypic analysis on the combined results from both populations 
and we identified these two miR-SNPs (rs4284505/rs7336610) to be in linkage 
disequilibrium and part of a haplotype block (D’ score = 0.98). Chi-square analysis 
of the haplotypes contained in that block showed a lower frequency for haplotype 
AC in cases compared to controls and our analysis showed it to be significantly 
associated with breast cancer (p = 5x10-4). Odds ratio for this haplotype was 
calculated to be 0.75 with a 95% confidence interval of 0.60 to 0.94 (p = 0.012) 
suggesting that individuals that carry the AC haplotype had a reduced risk of 
developing breast cancer (about 25%) in comparison to other haplotype carriers. To 
the best of our knowledge this is the first report of a significant association between 
these polymorphisms and breast cancer risk in Caucasian populations.  
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9.4.4 Comparison to GWAS results and miRNA functional implications. 
 
As mentioned before and to the best of our knowledge the genotype association 
studies included in this thesis are the first to report an association between the risk of 
sporadic breast cancer in purely Caucasian populations and the presence of mutation 
in these loci (MIR146A (rs2910164), MIR145 (rs353291) and MIR17HG 
(rs4284505)).  These miR-SNPs are located in intergenic regions at a large distance 
from any implicated genomic regions previously identified in GWAS for breast 
cancer (Easton et al., 2007; Fletcher et al., 2011; Hunter et al., 2007; Khan et al., 
2014; Li et al., 2011; Michailidou et al., 2013; Stacey et al., 2007; G. Thomas et al., 
2009; Turnbull et al., 2010) with none of these GWAS implicating regions near these 
miRNA genes.  
 
Our findings are supported by the functional implications of these miRNA 
genes for breast cancer development and progression previously identified by other 
studies. For instance, MIR146A has been found to downregulate expression of 
BRCA1 and BRCA2 genes (A. I. Garcia et al., 2011; Shen et al., 2008) and to inhibit 
breast cancer cell invasion and metastasis (Bhaumik et al., 2008; Hurst et al., 2009). 
Moreover, some of the predicted targets for MIR146A include IRAK1, CARD10, 
MMP16, MNAT1, GTF2H4 and TRAF6 which are found in diverse cancer related 
pathways (Z. Hu et al., 2009). MIR145 has been found to play a tumour suppressor 
role in breast cancer through activation of TP53 and reduced expression of ESR1 
which reduces proliferation and induces apoptosis of breast cancer cells (Spizzo et 
al., 2010). Furthermore, it has been found to reduce expression of RTKN which 
confers breast cancer cell resistance to apoptosis (S. Wang et al., 2009).  Finally 
MIR17HG has been also described to have a tumour suppressor role through 
regulation of expression of important genes for breast cancer development including 
ESR1 and CCND1 (Hossain et al., 2006; Leivonen et al., 2009; Z. Yu et al., 2008). 
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9.5 LIMITATIONS AND FUTURE DIRECTIONS. 
 
There are some limitations to the studies presented in this thesis and they 
include: Size and ethnicity of the study populations, failing to include other variables 
like age and type of breast cancer in the analysis and lack of studies to establish the 
functional effects of the miR-SNPs positively associated to breast cancer risk. 
 
We acknowledge that the size of the populations used in some of our studies 
may limit their power to detect association for the rare variants that were included. 
We may also be able to strengthen the significance of our findings by testing the 
miR-SNPs found to be positively associated with breast cancer risk in larger 
populations. This would be particularly important for those association studies were 
multiple testing was performed. Another alternative to increase the power for our 
populations would be to increase the number of individuals present in the control 
populations to obtain a case-control ratio of 1:4 (Hong & Park, 2012; Schork, 2002). 
However, some of these populations are still recruiting volunteers for both cases and 
controls which could address this issue of population size for future studies. 
 
Our populations only included women of Caucasian (Northern European) 
origin due to the importance of using well-characterised population to conduct 
genetic association studies but this also limits the strength of our findings. Therefore, 
it would be important to test our findings using population of other ethnic 
backgrounds as this changes the distribution of genotypes and alleles for miR-SNPs. 
Findings in regard to other ethnicities may also indicate the role these miR-SNPs 
play in the development of the disease, therefore they should be the focus of future 
genotyping studies. 
 
The studies included in this thesis focused on the association between the 
presence of mutation in miRNAs and the risk of developing breast cancer. However 
it would be also important to determine their association to some other important 
characteristics like type of breast cancer, age of onset, response to treatment options 
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and recurrence of cancer. Unfortunately, information on these features was 
unavailable to us because some of the cohorts were still under development but they 
could be the focus of future studies as they could provide information on the role 
they may play in the development and progression of breast cancer. 
 
Finally it is important to conduct functional studies using cell culture and/or 
animal models to establish the effects of these SNPs in the synthesis and expression 
of the miRNA genes where they are present, as well as their effect on the genes these 
miRNAs target and the molecular pathways where they are present. This is a 
fundamental step towards the translation of these findings into diagnostic or 
therapeutic approaches that could impact prognosis of breast cancer sufferers.   
 
9.6 CONCLUSIONS 
    
This study has implicated a number of miR-SNPs in breast cancer. More 
specifically, we were able to identify significant association with the presence of 
mutation and breast cancer risk for three miR-SNPs and one haplotype (rs2910164 in 
MIR146A, rs353291 in MIR145, rs4284505 in MIR17HG and rs4284505/rs7336610 
in MIR17HG) in both of our tested populations. 
 
Results presented in Chapters Six to Eight of this document are only the initial 
step required to determine whether the studied microRNA SNPs have an effect in 
breast cancer development. Further research that includes functional assays will be 
required for these findings to be able to translate into strategies that impact breast 
cancer diagnosis, treatment and prognosis. The next immediate step would be 
validation of our positive findings through genotyping of larger populations or 
populations of different ethnic backgrounds to ascertain our findings. Following this, 
functional validation using cell culture or animal models would allow a better 
understanding of the detailed mechanisms behind their involvement in breast cancer 
biology, which is also fundamental to proceed with future translational studies.   
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Appendices 
Appendix A 
Modified salting out protocol for DNA extraction from whole blood samples. 
Adapted from Nasiri et al., 2005.  
 
1. Thaw blood by placing in 4°C fridge for a few hours or quick-thawing at 
room temperature (RT) on bench.  
 
2. Transfer contents of blood vial by pipetting blood carefully into a 15ml 
falcon tube.  
 
3. Add 8ml of lysis buffer (0.3 M sucrose, 0.01 M TrisHCl, pH 7.5, 5mM 
MgCl2, 1% Triton X100) to each sample and mix by inversion. 
 
4. Centrifuge the tubes at 2500rcf for 30mins at 4°C. Prepare a beaker with 
diluted (5-10%) Decon90® for blood waste disposal. 
  
5. Discard the supernatant by pouring carefully into beaker containing 
Decon90® without disturbing pellet on the bottom. Alternatively, remove 
supernatant by using a transfer pipette, without disturbing pellet.  
 
6. Add 300µl of 10mM TrisHCl, pH 8.0 to the falcon tube and break up the 
pellet using a transfer pipette. Ensure pellet is completely broken 
up/resuspended.  
 
7. Transfer to fresh microfuge tubes and resuspend by vortexing vigorously.  
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8. Centrifuge at 2500rcf for 20 mins at 4°C temperature.  
 
9. Discard supernatant, and add 330µl of 10mM TrisHCl, pH 8.0; 330 µl of 
laundry powder (30mg/ml) and a glass bead. Vortex the samples for 1 min 
and add 250 µl of 6M NaCl and vortex again for 20 seconds. 
 
10. Transfer sample to a fresh 2ml microfuge tube and centrifuge tube at 
15000rcf for 10 min.  
 
11. Transfer supernatant to fresh microfuge tubes (about 900µl) and precipitate 
by addition of 900µl of chilled 100% ethanol. Gently swirl and observe the 
DNA strands precipitate. 
 
12. Using an inoculating loop, washed twice in 70% ethanol, transfer the DNA 
into one labelled 2ml tube containing 1ml 1X TE buffer (10 mM Tris pH 8.0, 
1 mM EDTA).  
 
13. Parafilm the 2ml tube and allow the DNA to dissolve by incubating at 70°C 
for 5 minutes or at 37 °C overnight. 
 
14. Discard the blood waste into the beaker containing Decon90®, cover with 
aluminium foil and let sit overnight. It can be poured down the sink with 
copious amounts of water the next day. 
 
15. Vortex and quantitate using the Thermo Scientific NanoDropTM 8000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE. USA) or 
other methods (picogreen, fluorometer) and keep a record of concentrations. 
Store DNA tubes in appropriate boxes in -20°C freezer. 
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16.  Prepare DNA to a concentration of 20 ng/µl dilution from 1X TE stock DNA 
using sterilised deionised water and use in PCRs (store this at 4°C).  
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Appendix B 
Protocol for genotyping using multiplex PCR and matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) 
analysis.  
 
Primary Multiplex PCR  
 
1. Set up multiplex PCR reactions to a final volume of 5 µl using 10 ng of 
genomic DNA, 0.1 µM of PCR Primers mix (IDT® Pte. Ltd., Baulkham Hills, 
NSW, Australia), 1 U PCR enzyme (Roche®, Indianapolis, IN, USA), 1X  
SEQUENOM PCR Buffer (SEQUENOM Inc., San Diego, CA, USA),  2 mM 
SEQUENOM MgCl2 (SEQUENOM Inc., San Diego, CA, USA) and 500 µM 
SEQUENOM 2´-deoxynucleoside- 5´-triphosphate (dNTP) mix 
(SEQUENOM Inc., San Diego, CA, USA) in an Applied Biosystems® 
MicroAmp® EnduraPlate™ Optical 96-Well Clear Reaction Plates with 
Barcode  (Life Technologies Australia Pty Ltd., Mulgrave, VIC, Australia). 
   
2. Place reaction plate in Applied Biosystems® Veriti® 96-Well Thermal Cycler 
(Life Technologies Australia Pty Ltd., Mulgrave, VIC, Australia) and 
perform primary PCR using the following conditions: initial denaturation at 
95°C for 2 min; 45 cycles at 95°C for 30 s, 56°C for 30 s, 72°C for 1 min; 
and final extension at 72°C for 5 min. 
 
Shrimp Alkaline Phosphatase (SAP) dephosphorylation  
 
3. Remove plate from thermal cycler and add 0.5 U of shrimp alkaline 
phosphatase (SAP) (iPLEX® GOLD reaction kit, SEQUENOM Inc., San 
Diego, CA, USA).  
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4. To neutralize unincorporated dNTPs run dephosphorylation reaction using 
the following cycling conditions: 37°C for 40 min and 85°C for 5 min. 
 
iPLEX® primer extension reactions  
 
5. Remove reaction plate from thermal cycler and perform primer extension 
reactions using the iPLEX® Gold Reagent Kit according to the SEQUENOM 
linear adjustment method described in iPLEX™ GOLD genotyping 
application guide.  
 
6. Prepare the iPLEX® reaction cocktail using: 0.222X iPLEX® Buffer Plus 
(SEQUENOM Inc., San Diego, CA, USA), 1X iPLEX® Termination Mix 
(SEQUENOM Inc., San Diego, CA, USA), 1X iPLEX® Enzyme 
(SEQUENOM Inc., San Diego, CA, USA) and an extend primer mixture 
made according to the manufacturer’s linear adjustment method. 
 
7. Add iPLEX® reaction cocktail to the amplification products and place 
reaction plate in the thermal cycler. Run iPLEX® primer extension reactions 
using the following conditions: initial denaturation at 94°C for 30s; 40 cycles 
of 94°C for 5s, annealing at 52°C for 5s and extension 80°C for 5s. Annealing 
and extension procedure repeats five-times (to give a total of 200 short 
cycles), followed by a 5 s denaturation step, and a final extension step of 3 
min at 72°C.  
 
8. Remove reaction plate and add 41 µl of sterile water and 15 mg of Clean 
Resin (SEQUENOM Inc., San Diego, CA, USA) to each iPLEX® reaction. 
Seal reaction plate and mix continuously by rotation for at least 15 minutes.  
 
9. Centrifuge reaction plate at 3200g for 5 minutes.  
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MALDI-TOF MS analysis and data analysis 
 
10. Transfer reaction plate to the SEQUENOM® MassARRAY® Nanodispenser 
(SEQUENOM Inc., San Diego, CA, USA) and dispense a total of 12-16 nl of 
each iPLEX® reaction product onto a SpectroCHIP® II G96 (SEQUENOM 
Inc., San Diego, CA, USA).  
 
11. Run SpectroCHIP® analysis using SEQUENOM® MassArray® Analyzer 4 
and laser desorption/ionisation, automated spectra acquisition using 
SpectroAcquire Version 4.0 (SEQUENOM Inc., San Diego, CA, USA).  
 
12. Perform genotype data analysis with the MassARRAY® Typer software 
version 4.0 (SEQUENOM Inc., San Diego, CA, USA). 
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Appendix C 
Protocol for genotyping using automated Sanger sequencing  
 
1. Prepare a 10 µl Exo-SAP-IT Clean-up reaction using 5ul of HRM product, 4 
µl of Reverse Osmosis water and 1µl of Exo-SAP-IT. Mix reaction and 
incubate in Applied Biosystems® Veriti® 96-Well Thermal Cycler (Life 
Technologies Australia Pty Ltd., Mulgrave, VIC, Australia) using the 
following cycling conditions: 37°C for 15 min and 80°C for 15 min.  
 
2. Subsequently, prepare a 20 µl reaction mixing 15 ng/µl of the Exo-SAP-IT 
product, 650nM of each primer (separate reactions for forward and reverse 
primer), 3.5ul of BDT v3.1 Ready Reaction Mix (100RR) and 1x Sequencing 
Buffer. Incubate in Applied Biosystems® Veriti® 96-Well Thermal Cycler 
(Life Technologies Australia Pty Ltd., Mulgrave, VIC, Australia) using the 
following cycling conditions: 1 cycle of 96°C for 1 min, 30 cycles of 96°C 
for 10 s, 50°C for 5 s. and 60°C for 4 min, 1 cycle of 4°C for 5 min and 1 
cycle of 10°C for 5 min.  
 
3. Perform standard ethanol precipitation on the products and load them onto the 
ABI-3130 Genetic Analyzer (Life Technologies Australia Pty Ltd., Mulgrave, 
VIC, Australia) to perform automated Sanger sequencing. 
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